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A bstract
The interactions between proteins and peptides in aqueous solution have been 
investigated using a classical molecular dynamics procedure with a molecular me­
chanical representation of the potential energy surface. During post-processing of 
the trajectory an implicit solvation method has been applied in order to calculate 
the free energy of each of the complex, protein and peptide structures in solution, 
allowing the binding free energy of the protein-peptide complex to be evaluated. 
Entropic contributions have been estimated using classical ideal gas thermody­
namics. A program has also been developed that systematically mutates each 
of the peptide residues to alanine and determines the effect on the binding free 
energy. The method has been applied to the interaction between the oncopro­
tein Mdm2 and the tumour suppressor peptide p53 and reasonable agreement 
has been found with previous theoretical and experimental studies. The method 
has also been extended to the interactions between IQN17, an engineered pro­
tein that represents a potential drug target in the HIV-1 gp41-mediated cellular 
fusion process, and several peptides that have been shown to inhibit cellular fu­
sion. The key residues in the binding of each protein-peptide system have been 
identified and quantitative information regarding the factors influencing binding 
obtained and compared with available experimental data, demonstrating encour­
aging agreement with analogous alanine scanning experiments.
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Introduction
1
Chapter 1
Biom olecular System s
1.1 Proteins and Polypeptides
1.1.1 Structure and Function
Proteins are biologically important molecules that consist of one or more 
polypeptide chains, which are linear heteropolymers of monomeric units called 
amino acids.1 There are 20 amino acids that occur naturally and the codes used 
to identify each amino acid in a polypeptide chain conveniently are given in Ap­
pendix A. Proteins found in nature only contain amino acids with L-chirality 
and a schematic diagram of an amino acid is given in Figure 1.1. In aqueous 
solution, the amine group becomes protonated, N H j, and the carboxylic acid 
group is deprotonated, COO- , resulting in a zwitterionic amino acid form. The 
central carbon atom of an amino acid, illustrated in green in Figure 1.1, is called 
the a-carbon and the carbon atoms of the side chain are referred to as the j3~, 7-,
2
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Figure 1.1: Schematic diagram of an amino acid. The amino group is shown in blue, 
the carboxylic acid group is shown in red and the a-carbon is shown in green.
(5-carbon and so on. Amino acids are distinguished by their side chain groups, 
which can range from a hydrogen atom, as in the achiral amino acid glycine, to 
much bulkier side chains such as the indole ring of tryptophan. For a chain of 
N  amino ac ids there are 20N possible amino acid sequences and although only 
a relatively small percentage of these are viable polypeptides, there is a great 
diversity in observed protein structure and function.
Two amino acids can join together, as shown in Figure 1.2, by the elimination 
of a water molecule. The carbon-nitrogen bond formed during this process is 
called a peptide bond and a chain of amino acids joined together in this way is 
called a polypeptide. The polypeptide chain has an am ino or N-terminus at one 
end of the chain carrying the -NHj group, and a carboxy- or C-terminus at the 
other end of the chain carrying the -COO-  group. By convention, polypeptide 
chains and amino acid sequences are given with the N-terminus to the left and
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Figure 1.2: Schematic diagram of peptide bond formation. The C-N bond formed is 
termed the peptide bond.
the C-terminus to the right.
The primary structure of a polypeptide chain refers to the sequence of amino 
acids in the chain. The local folding of a polypeptide chain is referred to as 
its secondary' structure and the way that these elements of secondary structure 
are arranged in space is described as the tertiary structure. The quaternary 
structure describes how several subunits (connected or unconnected polypeptide 
chains) fold and join together to form the complete functional protein. The 
secondary structure can be described in terms of the torsional angles along the 
peptide backbone, where torsions about the N-CQ bond are described in terms of
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the dihedral angle 0 , torsions about the Ca-C  bond are described in terms of the 
dihedral angle 0  and torsions about the C-N peptide bond are defined in terms of 
the dihedral angle jj. Common elements of secondary structure such as a-helices 
and 0-sheets correspond to particular values of these torsional angles. Typical 
torsional angles for right-handed a-helices are 0 =  —60° and 0  =  —60°. For 
antiparallel 0-sheets, typical torsional angles are 0 =  —120° and 0  =  120°. The 
peptide bond is typically planar and found in the trans conformation resulting 
in a torsional angle u> = 180°. One notable exception to this is proline, where a 
cis conformation about the peptide bond is observed and the typical value for 
the torsional angle is a; =  0°. Some polypeptide chains are random coils and 
have little or no identifiable secondary structure. The torsional angles of each 
side chain are \ i .  \2 and so on.1
Protein structures can be determined in atomic detail using techniques such 
as X-ray and neutron diffraction for crystallised protein structures. Proteins can 
also be studied in solution using nuclear magnetic resonance (NMR) spectroscopy. 
The atomic structures of a vast number of proteins, approximately 29000 at 
present, are available from resources such as the Protein Data Bank (PDB).2
The biological activity of vital proteins is intrinsically related to their structure. 
Enzymes are catalysts that control chemical reactions taking place in biological 
environments. These reactions can be simple processes such as the hydration of 
carbon dioxide or more complex transformations of large molecules. Proteins such 
as haemoglobin, which stores oxygen in red blood cells, also have a key function in 
storing ions and small molecules within the body and transporting them from one 
place to another. Hormones such as insulin, which regulates the concentration of
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sugars in the blood, play vital roles in coordinating biological processes between 
different tissues and organs. Antibodies are proteins that bind to foreign bodies, 
including viruses and bacteria, serving a vital biological function.
The non-covalent interactions between biologically important macromolceules 
such as proteins, polypeptides and nucleic acids provide the key to understand­
ing many physiological processes including enzyme catalysis, protein and nucleic 
acid folding, immune response processes and complexation of biologically active 
molecules. These interactions are of particular importance in the biomolecular 
systems considered in this work, which are discussed in more detail in the re­
mainder of this chapter.
1.2 Suppression o f Tumour Growth
The interaction between the tumour suppressor protein p53 and the cancer- 
causing protein or oncoprotein Mdm2 is of vital importance in cancer research.3 
The role of p53 in the cell cycle is to preserve the DNA from alterations caused 
by infrared (IR), ultraviolet (UV) and y radiation, as well as other stress stimuli. 
The response of p53 to these various stimuli is to arrest cellular growth, allowing 
time for damaged DNA to be repaired.4 The Mdm2 oncoprotein precludes this 
vital regulatory function by forming tightly bound complexes with p53, thus 
preventing p53 from binding to DNA. It has been found that p53 is missing or 
altered in approximately half of all human tumours and Mdm2 is often found in 
increased amounts in a variety of cancers.3
The crystal structures of human and African clawed frog, Xenopus Laevis (X.
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Laevis), Mdm2 in complex with a stretch of p53 have been determined previ­
ously.5 Experiments carried out on these complexes identified three residues in 
p53 that are vital to the binding of the complex. These residues, Phe-19, Trp- 
23 and Leu-26, could not be replaced by any other amino acid without at least 
a threefold increase in IC50, defined as the inhibitory concentration required to 
reduce activity by 50 per cent.6 The residue Leu-22 was also found to be highly 
selective.6 These residues extend into the hydrophobic binding site of Mdm2.5 
Theoretical studies have been carried out on the human and X. Laevis Mdm2-p53 
complexes using a methodology similar to that used in this work.3 The findings 
were in agreement with the replacement experiments and are discussed in more 
detail in Chapter 5. This system was chosen to test the methodology imple­
mented in this work because of its biophysical significance and the availability of 
experimental and theoretical results for comparison. The amino acid sequences 
and structure of the Mdm2-p53 complexes used in this work are discussed in 
more detail in Chapter 4.
1.3 Inhibition of HIV-1 A ctiv ity
1.3.1 Introduction
It was estimated that 40 million people would have been infected with the 
human immunodeficiency virus (HIV) by the end of the twentieth century7 and 
there is strong evidence that type 1 HIV (HIV-1) is the cause of acquired im­
munodeficiency syndrome (AIDS).8' 10 Clearly, it is essential to understand the
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processes by which HIV infection takes place in order to allow the production of 
effective anti-HIV drugs and to suggest possible new targets for such drugs.
The HIV viral cell is approximately spherical, with a diameter of roughly 
1000 A, and has complexes of two proteins, g p l20 and gp41, protruding from the 
surface. These protrusions are the envelope glycoproteins that are involved in the 
process of viral entry into the cells. The active parts of the virus are contained 
within the core of the spherical cell and can only act upon the target cell once 
viral entry has been achieved. Within the viral envelope is a matrix protein, pl7, 
and the viral core or capsid, p24, containing the viral machinery such as the viral 
RNA and the enzymes protease (PR), reverse transcriptase (RT) and integrase. 
HIV is a retrovirus, meaning that it uses the RNA in its viral core as a template 
to make DNA within the host cell. The enzyme PR within the viral core is used 
to break proteins down into smaller units. The role of RT is to convert RNA 
into viral DNA, which is then transported into the nucleus of the cell, where the 
enzyme integrase facilitates the insertion of the viral DNA into the host cell’s 
DNA. The HIV DNA is then known as a provirus and is replicated by the host 
cell. A schematic diagram of HIV illustrating these elements is given in Figure 
1.3.
There are a large number of drugs that have been approved by the United 
States Food and Drug Administration (FDA) that target the RT and PR en­
zymes of HIV.7,12-13 These are two of the key parts of the viral core of HIV 
and these drugs are designed to reduce the rate of viral replication significantly. 
The mortality rate for people infected with the virus has also been significantly 
improved as a result of treatment with these drugs.11,15
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Figure 1.3: Schematic diagram of the HIV cell11 showing the envelope glycoproteins, 
gpl20 and gp41, as well as the RNA in the core that brings about viral replication.
However, one of the major difficulties in dealing with HIV, and, indeed, one 
of the reasons that it is such a dangerous pathogen, lies in its ability to mutate 
rapidly and develop strains that are resistant to treatment with RT- and PR- 
inhibiting drugs. The rapid emergence of such drug-resistant strains of HIV has 
become a widespread and growing problem,16 meaning that new drugs, possibly 
targeting different aspects of HIV-1 activity, must be developed. Another diffi­
culty in this approach is that these drugs can only ever treat HIV infection rather 
than preventing it. Furthermore, since these anti-RT and anti-PR drugs are not 
effective until the virus has fused with the human cell, they must penetrate the 
human cell, which can lead to debilitating side effects.
gpl20
gp41
pl?
p24
RNA
HIV - Structure
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Native Pre-Hairpin Fusion Post-Fusion
Cell membrane
Viral membrane
Figure 1.4: Viral entry mechanism for HIV-1.19 The N- and C-peptides of gp41 are 
shown in grey and blue, respectively. The conformational change from the pre-hairpin 
intermediate to the fusion-active form of gp41 brings the two cells together and allows 
fusion to take place.
1.4 Inhibition of HIV-1 Viral Entry
1.4.1 M echanism of Viral Entry
HIV-1 is an enveloped virus and its entry into human cells is controlled by the 
envelope glycoproteins gpl20 and gp41, found in a complex on the surface of the 
viral cell. The mechanism for viral entry involves several steps,17-19 providing 
several potential targets for inhibitory drugs,19-24 and is shown in Figure 1.4. 
The function of gpl20 is to bind to receptors on the target human cell while gp41 
mediates the fusion of the viral and target cells. In this work, the main focus is 
on the function of gp41 and inhibiting the essential conformational change that 
allows gp4l-mediated fusion to take place.
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The structure of gp41 is vital to its function in the HIV-1 fusion process 
and its main features are illustrated in Figure 1.5. Each monomeric unit of 
gp41 is a heterodimer consisting of two a-helical components; the N-terminal 
region denoted N36 and the C-terminal region denoted C34.12,17 The native 
conformation of gp41 is non-fusogenic but when gpl20 binds to the receptors 
on the target cell membrane a conformational change to the fusogenic form of 
gp41 takes place. This fusion-active conformation of gp41 consists of a trimer 
of heterodimers. The three N-peptide helices come together to form a parallel 
trimeric core with the C-peptide helices bound in an anti-parallel fashion along 
hydrophobic grooves on the surface of this core. Each of these grooves has a deep 
hydrophobic pocket at one end.
Once the human and viral cells are attached an intermediate of gp41, termed 
the pre-hairpin intermediate, is transiently exposed, providing the target for many 
of the fusion inhibitors discussed here. It is possible to inhibit gp41-mediated fu­
sion by binding molecules to the N-peptide or C-peptide regions of the transiently- 
exposed intermediate, preventing the essential conformational change. Once the 
six-helical bundle is formed it is very stable and inhibitors are not effective in 
the same manner. In the pre-hairpin intermediate species the glycine-rich fusion 
peptide (denoted fp in Figure 1.5) is exposed and interacts with the target cell 
membrane. The intermediate then gradually gives way to the fusogenic confor­
mation, bringing the human and viral cells into close proximity and allowing 
membrane fusion to take place.12,17,19,25-28
Many other enveloped viruses undergo similar membrane fusion processes. It 
is therefore likely that breakthroughs in understanding and inhibiting the HIV-1
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fusion process could lead to advances in the treatment of such viruses, including 
influenza,29 Ebola,30 Visna,31 human respiratory syncytial virus (HRSV)32 and 
the Moloney murine leukaemia virus (MMLV).33
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Figure 1.5: The structure of gp41. (A) Schematic showing the N-peptide and C- 
peptide regions, including the fusion peptide (fp), transmembrane segment (tm) and 
cytoplasmic region (cyto). The amino acid sequences representing some HIV-1 fusion 
inhibitors are also illustrated. The location of key pocket-binding residues Trp-628, 
Trp-631 and Ile-635 are indicated by red bars. (B,C) Helical representations of the 
packing of the N-peptides (grey) and C-peptides (blue) in the fusogenic conformation. 
(D) Dlustration of the hydrophobic grooves and pockets on the surface of the N-peptide 
trimeric core. The pocket-binding residues of C34 are shown in red. Taken from Chan 
and Kim . 1 7
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1.4.2 Inhibition  o f Cellular R eceptors
During the early stages of HIV-1 infection the glycoprotein gpl20 on the sur­
face of the viral cell interacts with CD4 and co-receptors, such as CXCR4 or 
CCR5, on the surface of the target cell. This is a vital stage in the fusion pro­
cess, shown in Figure 1.4, as it effectively attaches the two cells together, allowing 
gp41-niediated fusion to take place. Experiments have been conducted using sol­
uble forms of the CD4 receptors found on the target cell that suggested that they 
bound preferentially to gpl20. This was successful for laboratory strains of HIV-1 
but not for viral cells taken from other sources. More recently, variants of the 
co-receptors themselves showed antiviral activity by binding to gpl20. They also 
reduced the number of points for potential viral entry by suppressing the activity 
of the receptors on the target cell. Small molecules have also been identified that 
bind directly to the cellular receptors, blocking their binding to g p l20 and hence 
inhibiting viral entry.34
1.4.3 Viral Entry Inhibitors
1.4.3.1 C -Peptides
It has been shown that peptides derived from the C-terminal helix of gp41 can 
inhibit gp41-mediated fusion by binding to the transiently-exposed pre-hairpin 
intermediate, preventing the C-peptide region of the bound gp41 from interacting 
with the N-terminal core.26-28,35-37 This type of binding is described as dominant- 
negative and prevents the essential conformational change to the fusogenic form 
of gp41.
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Several C-peptides have been investigated for inhibitory activity, such as C34, 
T649 and DP-178 (T20) and these are illustrated schematically in Figure 1.5. 
Of these, C34 and T649 contain residues that bind to the hydrophobic groove 
and the pocket on the surface of the core, while DP-178 (T20) does not bind 
to the pocket but still exhibits inhibitory activity. However, the measured IC5o 
for C34 is 2-5 nM compared to 50-60 nM for T20, strongly suggesting that the 
interactions between the pocket-binding residues and the pockets on the surface of 
the N-peptide core play a vital role in determining the potency of the HIV-1 entry 
inhibitor.20 Furthermore, since the residues forming the hydrophobic pockets are 
essentially conserved in the vast majority of strains of HIV-1, the virus is less 
likely to develop strains that are resistant to inhibitors that bind specifically to 
the pockets, rather than binding solely to the hydrophobic grooves.21 It also 
suggests that the pocket itself could be a valid target for HIV entry inhibitors.36
Shorter C-peptides have also been investigated for inhibitory activity. C- 
peptides of 19 residues in length were found to have poor inhibitory activity38 
while C-peptides consisting of fourteen residues showed no inhibitory activity 
at fiM concentrations.39 In general, C-peptides are only a-helical when bind­
ing to the trimeric core but are found as random coils in solution.37,40 Thus, a 
large entropic penalty is incurred upon complexation as the C-peptide can no 
longer occupy such a large number of possible non-helical conformations but is 
restricted to the a-helical structure.40 This effect is particularly significant for 
short C-peptides as they only bind through a relatively small interface with the 
N-peptide core, resulting in a smaller change in enthalpy upon complexation.
The inhibitory activity of short C-peptides was investigated by using tech­
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niques to restrain the C-peptides using cross-linking bridges between two residues 
and substituting for non-natural amino acids that have a higher propensity for 
forming regular helical structures in solution.40 It wras shown that by reducing 
the entropic cost of association, peptides such as C14 could be modified to inhibit 
cellular fusion.40 The modified peptide that showed the best inhibitory activity 
was called Cl41inkmid (Cl41m) and this peptide is used as the basis for the cal­
culations on C-peptide inhibitors in this work. Cl41inkmid has a diaminoalkane 
bridge linking two amino acids separated by seven residues and a 12-residue ver­
sion of the peptide, C12, is described in more detail in Chapter 4. When the 
linker was broken to form Cl4unlinkmid (Cl4unlm), the inhibitory activity wras 
reduced significantly.40
1.4.3.2 D -P eptides
The importance of binding to the hydrophobic pocket for inhibitory activity 
makes it a target for small molecules that can disrupt the conformational change 
to the fusogenic form of gp41. Small, mirror-image D-peptides have been identi­
fied that bind exclusively to the pocket and inhibit gp41-mediated fusion.21,41
Eckert et al.21 began bv designing a peptide to represent the trimeric N- 
peptide core of gp41. This was achieved by fusing a soluble trimeric coiled-coil 
from a peptide called GCN4-pIqI42 to the portion of N36 that comprises the 
hydrophobic pocket. This species formed aggregates of order greater than the 
desired three but a small number of mutations were made to improve solubility 
and the resulting species formed fully a-helical trimers similar to the N-peptide 
trimeric core of gp41. This peptide was designated IQN17 and its mirror-image
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D-IQN17 was used in a mirror-image phage display screening43 to find L-peptides 
that bound exclusively to the pocket. The peptides that bound to D-IQN17 were 
also tested against control peptides that lacked the hydrophobic pocket residues, 
in some cases exhibiting one thousand times stronger binding to the peptide 
containing the pocket residues.21
Nine L-peptides were identified and their mirror-image D-peptides were syn­
thesised and tested for inhibitory activity. Eight of the nine peptides shared a 
common sequence pattern that included a disulphide bridge between two cysteine 
residues, making the peptides roughly circular in shape. These eight D-peptides 
inhibited HIV cellular fusion and infection at nM concentrations, while the ninth 
D-peptide exhibited no inhibitory activity.21 The amino acid sequences of the 
eight inhibitory D-peptides are given in Table 1.1.
These D-peptide inhibitors are 16 or 18 residues in length compared to 30 
or more for the C-peptide inhibitors discussed previously. In order for drugs 
to be orally bioavailable they must be able to cross cell membranes readily and 
must therefore be below a certain size and although these D-peptides are still too 
large, they could act as a starting place in the search for smaller and more potent 
HIV-1 inhibitors. Only six of the residues make contact with the hydrophobic 
cavity and mutations could be possible to reduce the size of the peptides. As 
suggested previously, the conserved nature of the hydrophobic pocket residues in 
almost all of the reported strains of HIV-1 means that there would be a reduced 
risk of the virus mutating rapidly to become resistant to drugs based on these 
D-peptides.21 Furthermore, due to their mirror-image nature, these D-peptides 
would be expected to be resistant to degradation by natural L-chirality enzymes
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D-peptide Am ino Acid Sequence Total
Charge
Syncytia
ICso/ mM
Entry
IC5o/ a*M
GACxxxxxEVxVLCAA
DIO-pl CACEARHREVAVLCAA 0 29
D lO -pl-2K KKGACEARHREVAVLCAA + 2 46 85
D l0-p3 GACGLGQEEVFVLCAA -2
DlO-p3-2K KKGACGLGQEEWFWLCAA 0 16 39
DlO-p-1 GACDLKAKEVFVLCAA 0 64
DlO-p-l-2K KKGACDLKAKEVFVLCAA + 2 83 160
D l0-p5 GACELLGVEWAWLCAA -2
DlO-p5-2K KKGACELLGWEVAWLCAA 0 3.6 11
D l0-p6 GACSRSQPEWEVLCAA -1 53 94
D10-p6-2K KKGACSRSQPEVEVLCAA +  1 113 210
D l0-p7 GACLLRAPEVGVLCAA 0
D10-p7-2K KKGACLLRAPEWGVLCAA + 2 41
DlO-plO GACMRGEVEWSWLCAA -1
DlO-plO-2K KKGACMRGEVEWSWLCAA +  1 48 96
D l0 -p l2 GACPPLNKEVAWLCAA -2
D 10-pl2-2K KKGACPPLNKEVAWLCAA 0 130 270
Table 1.1: Amino acid sequences, total charges and IC5 0  values of inhibitory D-peptides 
for syncytia formation and viral entry . 2 1  The D-peptides were also synthesised with 
two additional lysine residues to improve solubility.
within the body.21
1.4.3.3 N -P eptides
In the same way that C-peptides can inhibit HIV fusion by binding to the pre­
hairpin intermediate and preventing the conformational change to the fusogenic
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form of gp41, peptides derived from the N-terminal region of the protein might 
be expected to inhibit fusion by binding to the exposed C-peptide. However, 
N-peptides in aqueous solution tend to form high-order aggregates, reducing the 
possibility of binding to the transiently-exposed intermediate.19 The high-order 
aggregation of N-peptides has been investigated and shown to be the cause of 
the lack of inhibitory activity.44 When the N-peptides are fused to other proteins 
that limit the aggregation to trimeric species, as was done in the design of IQN17, 
similar inhibitory activity to that exhibited by C-peptides is observed.
A small protein, designated 5-Helix, has also been designed,19 consisting of 
three C-peptide (C38) helices and two N-peptide (N40) helices. These are joined 
together by linkers to form a single protein that resembles the six-helical bundle of 
the fusogenic conformation of gp41 but with one of the C-peptide helices removed, 
as shown in Figure 1.6. This provides a potential binding site for the exposed 
C-peptide of the pre-hairpin intermediate and 5-helix has been found to inhibit 
HIV fusion at similar concentrations to the C-peptides discussed previously. A 
similar protein, 6-Helix, was also engineered that did not contain the potential 
binding site for the C-peptide helix. This protein did not inhibit cellular fusion.19 
This is further evidence that the proposed mechanism for viral fusion is correct, 
again confirming the pre-hairpin intermediate as a potential target for anti-HIV 
drugs.
Peptides derived from the N-terminal region with point mutations have also 
been shown to inhibit gp41-mediated fusion. By making substitutions designed to 
block formation of the trimeric coiled-coil core while preserving the interactions 
with the C-terminal region, it was shown that the formation of the trimeric coiled-
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Figure 1.6: Schematic diagram of the structure of 5-Helix showing the C-peptide 
binding site and C-peptide-N-peptide linkers. 1 9
coil was essential for binding to the C-terminal region. However, when mutations 
were made that allowed the formation of the core but decreased the interactions 
with the C-terminal region, inhibitory activity was still seen.45 This was ascribed 
to the ability of the mutant N-peptide to disrupt the formation of the N-terminal 
trimeric core in the native gp41.45
1.4.3.4 Non-Peptide Inhibitors
Many of the HIV-1 entry inhibitors described previously are too large to be 
orally bioavailable. Furthermore, peptides are often susceptible to enzymatic 
degradation in the body, making them difficult to use as potential drugs. Several
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studies have been carried out in order to find non-peptide ligands that could form 
hybrid molecules with elements derived from the C-terminal region of gp41 that 
act as inhibitors.22-24 These studies used biased combinatorial libraries to screen 
large numbers of potential anti-viral compounds that could bind to the trimeric 
N-terminal core of gp41, in particular the hydrophobic pocket region, in order 
to prevent gp41-mediated cellular fusion. In some cases, the non-peptide moiety 
could bind in more than one fashion to the target region. This could lead to 
new ligands that are capable of utilising both modes of binding and improving 
the activity of the inhibitor.24 Small organic molecules that bind to the gp41 
core and inhibit cellular fusion have also been designed using a computational 
docking scheme. Some of these molecules were found to inhibit cellular fusion at 
//M concentrations.46
Chapter 2
Biom olecular Sim ulation
2.1 Introduction
As discussed in the previous chapter, a vast number of physiological processes 
are governed by interactions between biological molecules such as proteins and 
nucleic acids. Theoretical methods of studying the behaviour of such molecules 
have become increasingly common as computational resources have increased 
in recent times, allowing more and more complex biomolecular systems to be 
studied.1,47-58 Different aspects of biological activity require the use of different 
theoretical methods, requiring that a range of techniques be used to probe the 
behaviour of these macromolecules. For example, quantum mechanical techniques 
are necessary when studying any process where chemical bonds are formed or 
broken59 61 but classical techniques have been shown to perform well for processes 
involving non-covalent aggregation of proteins and nucleic acids.1,62 66 These 
classical techniques and their application to free energy calculations are discussed
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in some detail in this chapter.
One of the key assumptions used in almost all biomolecular simulations is the 
Born-Oppenheimer approximation, which states that the electrons and nuclei 
move in different time scales, allowing the nuclei to be treated as essentially fixed 
when considering the motion of the electrons.67 The simulation can then be 
considered in two stages: determining the electronic potential energy surface and 
simulating the dynamical behaviour of the nuclei.
One of the most important objectives of quantum chemistry is to solve the 
non-relativistic, time-independent Schrodinger equation, in order to determine 
the electronic structure of a molecular system. The two main approaches to 
this are ab initio techniques, in which a model wavefunction is chosen and the 
Schrodinger equation is solved without recourse to empirical parameters, and 
semi-empirical techniques, which make use of simplified forms of the Hamiltonian 
and use some adjustable empirical parameters to reduce the computational cost 
of the calculation.60,67,68
Another technique that has been particularly successful for large, biologically 
significant molecules such as proteins and nucleic acids does not involve solving 
the Schrodinger equation at all, but uses a classical molecular mechanical force 
field to represent the potential energy surface. The potential energy has contri­
butions due to bond stretching, bending and twisting, as well as van der Waals 
and electrostatic interactions between atoms. Other terms can be included, de­
pendent on the individual force field and molecular system studied. Each force 
field has many empirical parameters that are obtained from comparison with ex­
periments and high level ab initio calculations, meaning that care must be taken
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when selecting a force field for a given molecular system.1,63,64,68
Each technique has advantages, such as the computational efficiency of the 
force field methods compared to ab initio and semi-empirical techniques, and 
disadvantages, including the simplifications and assumptions present in the force 
fields and their inability to treat bond formation or cleavage. In practice, many 
techniques have been developed that combine one or more of the above approaches 
to form a hybrid method, which treat the important part of a system, such as 
the active site of an enzyme, quantum mechanically and the rest of the system 
using a force field or similar technique.69,70
Two of the most widely used approaches to sampling the configurational phase 
space of large molecules are Monte Carlo (MC) and molecular dynamics (MD) 
techniques. MC techniques vary widely in their formulation and application but 
generally involve sampling a number of the possible accessible states of a system 
to obtain accurate statistical information.68,71,72 MD techniques investigate the 
time-dependent behaviour of a system by solving Newton’s equations of motion 
for the atoms, normally using a classical force field to determine the force on each 
atom .1,63,64-68
2.2 Representing the Potential Energy Surface
2.2.1 M olecular M echanics Force Fields
Despite progress in electronic structure methods for biologically significant 
molecules, they are still very computationally expensive. It is common, therefore,
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to use an entirely empirical molecular mechanical (MM) force field to model the 
potential energy surface of a molecular system.1163,64,68 One particular advantage 
of MM techniques is that they allow rapid evaluation of the potential energy 
function. However, they are incapable of simulating processes where chemical 
bonds are broken or formed, or where charge transfer takes place. Furthermore, 
great care must be taken in selecting a force field to use as each one is empirically 
parametrised for specific types of molecules.
In general, the potential energy is defined as having contributions from defor­
mation of bond lengths, bond angles and torsional angles, as well as non-bonded 
interactions such as charge-charge and van der Waals interactions.1,53 The func­
tional forms of these energy terms are described in the Theory section of this 
work. This leads to a large number of empirical paramaters such as force con­
stants, equilibrium bond lengths, equilibrium bond angles, equilibrium torsional 
angles, atomic partial charges and van der Waals radii. These parameters can be 
determined by experiment or by fitting to high-level ab initio calculations.53
Many force fields have been developed for simulation of proteins, includ­
ing A M B E R ,73,74 C H A R M M ,75 C V F F ,76 G R O M O S96,77 O PL S-A A 78 and 
M M 3 P R 0 .79 Some of these force fields also have implementations for the simu­
lation of nucleic acids.80 Force fields are also being developed that do not have an 
additive form for the potential energy, although the extra computational cost of 
these more accurate models could cause problems in biomolecular simulations.53 
MM force fields representing water, including T IP 3 P ,81 have been developed, 
allowing simulations in an explicitly modelled solvent environment. Methods 
combining MM with implicit solvent models are discussed later. The detailed
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theory of MM methods are given in Chapter 3.
Evaluating the single-point potential energy of a molecular system, even a 
large, biologically significant one, is not very computationally expensive using 
empirical force fields. This means that large numbers of such evaluations can 
be performed in a short time, which is of particular importance when sampling 
large amounts of conformational phase space, for example during Monte Carlo 
(MC) or molecular dynamics (MD) simulations that can lead to an improved 
understanding of dynamical properties of biomolecules.1,63,64 68
2.2.2 Treatm ent o f Solvation
Proteins and nucleic acids are not generally found in vacuum conditions and 
it is therefore necessary to consider the effect of the environment, usually aque­
ous solution, on the interactions within and between biomolecules. Several ap­
proaches to solvation are possible, ranging from treating both solute and sol­
vent explicitly and atomistically to treating the solvent as an implicit continuous 
medium, with the same average properties as water, and even treating some of 
the solute degrees of freedom implicitly.82
The solvation free energy of a solute is usually divided into contributions due 
to electrostatic and non-polar solvation. The two most common methods used 
for evaluating the electrostatic or polar contribution are the Poisson-Boltzmann 
(PB)82~84 and Generalised Born (GB)85,86 methods, with the non-polar contri­
bution usually treated as being proportional to the solvent accessible surface 
area (SASA).82 These methods are discussed in more detail in Chapter 3. These 
methods have been used with MM force fields and MD simulations using explicit
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water to evaluate free energies of binding and solvation, and these applications 
are discussed below in Section 2.4.2
The solvent can also be modelled explicitly using force fields such as T IP 3 P  
and T IP 4 P .81 The parameters in these models are empirically determined to re­
produce the enthalpy of vapourisation and density of water. The model T IP 5 P 87 
has also been developed to reproduce the temperature dependence of the density 
of water. For most applications of explicit solvation to biomolecules, T IP 3 P  is 
sufficient and is the force field used throughout this work.
2.3 Dynam ical M ethods
2.3.1 M onte Carlo M ethods
Monte Carlo (MC) methods provide a way of sampling the conformational 
phase space of molecular systems. This is of particular importance in biologically 
significant systems as they are not stationary and the dynamical behaviour must 
be understood in order to gain insights into biological function.
An initial configuration is chosen for the system and its potential energy is 
evaluated, using one of the techniques described previously. A new configuration 
of the system is then generated, for example using the Metropolis method,88 
and the potential energy of the new state evaluated. If the new state has lower 
potential energy than the old one, i.e. A V  < 0 then the new state is accepted 
automatically. If the new state has higher potential energy than the initial state, 
i.e. A V  > 0, then it might still be accepted. A random number between zero
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and unity is chosen and if this number is less than exp then the new
configuration is accepted and the process is repeated. Average values of molecular 
properties can then be generated from the sample configurations using as many 
steps as desired.68
Monte Carlo techniques have the advantage that only the potential energy for 
a configuration needs to be known. It is not necessary to evaluate gradients of the 
potential energy surface to generate the next configuration, as is the case for the 
molecular dynamics (MD) methods described below. It is also easy to constrain 
certain degrees of freedom w'hen newr configurations are generated. Structures 
that are far apart in configurational space can also be sampled rapidly using 
MC techniques, whereas MD methods tend to generate configurations that are 
close together, meaning that lengthy MD simulations are necessary for studying 
biomolecular processes. However, this also means that the methods for generating 
new configurations can be complicated, particularly for atomistic models of large 
molecules such as proteins and nucleic acids.68
MC techniques, in some cases combined with path integral (PI) theory, have 
been used to investigate the importance of quantum dynamical effects in pro­
teins such as gelsolin, enkephalin and HIV-gp41.89,90 These studies restricted the 
proteins to torsional motions and investigated the behaviour of the proteins at 
non-zero temperatures, finding that quantum dynamical effects could be signifi­
cant for these types of molecules. A quantum thermal annealing technique using 
PIMC has been described for locating global minima of proteins.91,92 Monte Carlo 
methods have also been applied to determining binding affinities for proteins, as 
discussed in further detail below.53,93
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2.3.2 M olecular D ynam ics M ethods
Molecular dynamics (MD) methods also allow sampling of the conformational 
phase space of a system. The force on each particle is determined from the gra­
dient of the potential energy surface, traditionally described using a molecular 
mechanical (MM) force field, and Newton’s equations of motion are integrated 
numerically for each particle. Therefore, the time-dependent behaviour of a sys­
tem can be simulated, with the only requirements being a starting structure 
and a suitable MM force field.1,63,64,68 The details of the method are described 
in Chapter 3 and the simulation conditions used in this wrork are described in 
Chapter 4. The focus here is on the applications of MD techniques to systems of 
biological interest.
Early MD simulations of biomolecules were performed in vacuum,94 providing 
insights into the importance of protein flexibility for biological function. How­
ever, it is now common to consider the influence of solvent, either explicitly or 
implicitly.1,50 Counterions can also be added to the simulation, in order to make 
the system electronically neutral, and their effect on the trajectory considered.95 
MD simulations are computationally expensive, particularly when explicit solvent 
molecules are considered, meaning that a great deal of effort is put into devel­
oping new algorithms, for example to allow efficient treatment of electrostatic 
effects.50,96-98
Many biomolecules have been studied using MD, from the smallest alanine 
dipeptide in solution99 to large systems such as the calcium-sensing protein calmod­
ulin100 in aqueous solution with sodium and chloride ions present. The calmod­
ulin system had a total of over thirty thousand atoms and lasted for 3.0 ns,
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requiring significant computational resources and illustrating the need for devel­
opment of more efficient algorithms.52 Calmodulin is a relatively small protein, 
consisting of 148 amino acid residues, and a large amount of the computational 
resources are spent determining detailed trajectories for the explicitly-modelled 
water molecules, which are not necessarily the most interesting parts of the sim­
ulation.
2.4 Statistical M echanics
2.4.1 Ensem ble A verages
MD simulations aim to give information on a macroscopic scale by simulating 
the microscopic behaviour of the atoms within molecules. Statistical techniques 
are used to provide the link between the microscopic and macroscopic levels.101,102
The thermodynamic or macroscopic state of a system is described in terms 
of a small number of parameters such as the temperature, pressure and number 
of atoms in the system. The mechanical or microscopic state of the system is 
defined in terms of the atomic positions and momenta, which can be considered as 
coordinates in 6iV-dimensional phase space. The state of the system is described 
by a single point in phase space and an ensemble is defined as a collection of 
points in phase space that all satisfy the same thermodynamic conditions. An 
MD simulation generates a series of points in phase space as a function of time. 
These points all belong to the same ensemble.101
In statistical mechanics, averages corresponding to experimentally observable
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properties are defined in terms of ensemble averages. The ensemble average is 
represented by the notation ( )  and is given by:
( E n s e m b l e  =  J J  d p N d r N A ( p N , TN ) p ( p N , TN ) , (2 . 1)
where A, the observable of interest, is a function of the momenta, p, and the 
positions, r, of the N  atoms and p is the probability density of the ensemble, 
given by:
p ( p \ r v) =  l e x p ( ~ ^ f r / r  (2.2)
where is the Hamiltonian, T  is the temperature, R  is the molar gas constant 
and Z  is the total partition function, given by:
Z = j j dp'V exp . (2.3)
This integral is generally extremely difficult to calculate as all possible states of 
the system must be included. In order to calculate an ensemble average using MD, 
the simulation, which calculates points in the ensemble sequentially in time, must 
pass through all possible states corresponding to the thermodynamic conditions. 
It is easier to calculate a time average for the observable A , given by:
1 f T 1
( - T ) t i m e  =  lim -  /  A (p N(t), rN(t ) )d t&  —  ^ 2  A (plV, O , (2.4)
T ~ >oc T  J t=0 M  “
where r  is the simulation time and M  is the number of time steps.
If a system could be allowed to evolve indefinitely over time it would eventually 
sample all possible states. This leads to the so-called ergodic hypothesis, namely 
that the time average is the same as the ensemble average:101
( - ^ ) e n s e m b l e  — ( - T )  t im e  • ( ^ - 5 )
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This assumption is fundamental to the use of MD simulations to generate ensem­
ble averages. It also follows that averages determined by MC simulations can be 
treated in the same way, provided that sufficient phase space sampling is ensured. 
For example, the average potential energy, V, for a system can be calculated as 
follows:
where M  is the number of configurations or points sampled in phase space and Vt 
is the potential energy of configuration i. Another example is the average kinetic 
energy, K,  given by:
where m, is the mass of particle i and i\ is the velocity of particle i.
Clearly, it is vital for the MD simulation to be sufficiently long that enough pos­
sible configurations of the system are sampled in order that the ergodic hypothesis 
be valid. This represents one of the most significant problems in simulations of 
large biological systems.
2.4.2 Free Energy C alculations
2.4.2.1 Therm odynam ic Cycle
Free energy is a state function, meaning that free energy differences can be 
calculated from a thermodynamic cycle similar to the one shown in Figure 2.1. 
The relative binding free energies, AAG, of two similar ligands, LI and L2, bound
(2 .6 )
1=1
(2.7)
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to the same protein, P, can be calculated:
AAG =  AGi -  AG2 =  AG3 -  AG4, (2.8)
where AG\  and AG 2  are the binding free energies of LI and L2, respectively, and 
A G 3 and AG 4 are the free energy changes upon transforming LI to L2 in the 
free and bound states.53,103,104 For the case where LI and L2 are similar, it is 
normally easier to calculate these transformation free energies than the physical 
binding free energies.
AG
AG AG,
AG
C2
Figure 2.1: Thermodynamic cycle used for calculating differences in binding free en­
ergies for two similar ligands, LI and L2, bound to the same protein, P.53,103,104
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2.4.3 Free Energy P erturbation  M ethods
2.4.3.1 Theory
In the canonical ensemble, N, V  and T  are all constant, where N  is the number 
of particles, V  is the volume and T  is the temperature. The Helmholtz free energy, 
.4, of a system is given by:101,102
A = - R T \ n Z  (2.9)
where Z  is the canonical partition function, as in equation 2.3. The evaluation 
of Z  requires an integration over 3N  degrees of freedom and is therefore not 
practical for most systems.54 However, the difference in Helmholtz free energy of 
twro related systems, denoted system A and system B, described by Hamiltonians 
J4?a and J4?b , is given by:54,103
A A  = A B - A A = - B T \ n ( ^ \ .  (2.10)
Furthermore, it can be shown that this is equivalent to :103
A A  =  - f l r i n  ^exp (2.11)
where ( )a indicates an ensemble average over system A. Equation 2.11 is the
basis of free energy perturbation (FEP) approaches but will only give a reasonable
value for the free energy difference if the systems A and B differ only in a small 
way from one another. This problem is avoided by the introduction of a coupling 
parameter, A, which can take values from zero to unity. The Hamiltonian, J f ( A), 
is written as:54
J f  (A) =  \J ? B +  (1 -  A) j r A, (2.12)
2.4 Statistical M echanics 35
where A =  0 gives Jif(X) = J t% and A =  1 gives A) =  M b- This allows 
the calculation to be broken into smaller parts as A is varied from zero to unity. 
The interval in A is chosen to be small enough that the free energy difference 
can be evaluated accurately at each stage. This is referred to as the free energy 
perturbation (FEP) method and equation 2.11 can be generalised to give:
A similar method to FEP calculations is thermodynamic integration (TI), 
which involves calculating derivatives of the Hamiltonian at each value of A and 
using numerical integration techniques to find the free energy difference:
Both FEP and TI are rigorous methods that depend on the accuracy of the 
Hamiltonians used to represent the different systems. It is normal to neglect the 
kinetic energy contribution to the Hamiltonian and use «  V, wrhere V  is the 
potential energy, usually represented by a MM force field. As mentioned previ­
ously, it is essential that enough conformational space is sampled that the ergodic 
hypothesis is valid. Therefore, these methods are computationally expensive.
The MM topologies can be handled in twro distinct ways in free energy cal­
culations.54 In the first approach, the energy terms of the force field change 
the molecular topology as A changes. In the second approach, two independent 
topologies are kept: for example, one topology for methanol and one for ethane 
in the calculation of the relative solvation free energy.54,105 Both the methanol 
-OH group and the ethane -CH 3  group exist in the simulation but do not interact 
with one another. The interactions of these groups with their environments are
(2.13)
r '  / d j f ( \ ) \  
Jo \  d \  /
(2.14)
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calculated using a variation of equation 2.12:
JT  (A) -  A" +  (1 -  A)n J?A, (2.15)
where the exponent n allows different pathways to be used in determining the 
free energies.54 Within the single topology method, the A-dependence is included 
more directly through the individual terms of the potential energy. It is also some­
times necessary to change the electrostatic part of the potential energy function 
on its own before changing the remainder of the Hamiltonian.106,107 This is called 
electrostatic decoupling and is necessary when some atoms, particularly hydro­
gen, end up with small van der Waals repulsions but have some residual charge, 
giving an unrealistically high free energy change upon the approach of a solvent 
molecule.54
One potential disadvantage of FEP compared with TI is that the calculated 
free energy cannot be rigorously decomposed into its components,108 since the 
logarithm of an exponential containing several terms is not the same as the sum 
of the logarithms of the individual components.54 Once again, however, the main 
issues are the quality of the Hamiltonians and the degree of sampling rather than 
the choice of FEP or TI.
2.4.3.2 A pplications
The concepts used in FEP calculations existed for some time before they were 
applied explicitly to chemical and biochemical systems.109-111 Early applications 
to such systems included studies of solvation of noble gases112 and solvation free 
energy contributions to a simple electron transfer reaction.113 The potential of
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FEP approaches was shown for model systems by Tembe and McCammon,114 who 
first used the calculation of the non-physical legs of the thermodynamic cycle to 
evaluate A AG. Jorgensen and Ravimohan105 used Monte Carlo (MC) and FEP 
techniques to calculate the relative solvation free energy of methanol and ethane, 
finding good agreement with experiments.
Early work on applying these methods to biologically significant systems by 
Bash et al. 1 0 6 , 1 0 7  studied the relative solvation free energy of a number of organic 
molecules, including amino acid side chains and nucleic acid bases, as well as 
the relative binding free energy of two ligands in complex with the enzyme ther- 
molysin. Further work using FEP methods to investigate thermolysin inhibitors 
has been carried out by Merz and Kollman.115 Warshel et al. 1 16 used MD and 
FEP to calculate the relative free energy of acid dissociation for key Asp and Glu 
residues in bovine pancreatic trypsin inhibitor (BPTI). An early application of 
FEP to protein-ligand association was carried out by Wong and McCammon,117 
who investigated the interactions between substituted benzamidines and trypsin. 
Simulations combining MC and FEP have also been utilised by Essex et al.us to 
predict the strongest of four trypsin inhibitors by studying trypsin-benzamidine 
complexes. These simulations also provided insights into the factors affecting the 
calculated relative binding free energies.
Free energy perturbation approaches have also been extensively applied to the 
inhibition of HIV protease (HIV-PR).lig~128 Reddy et al. 1 20 calculated the rela­
tive binding free energy of two peptide inhibitors, comprising seven and six amino 
acid residues, respectively. The large mutation from a seven-residue inhibitor to 
a six-residue inhibitor, involving the elimination of a valine residue, led to a re­
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duction in the calculated binding free energy that was in excellent quantitative 
agreement with experiment. Rao et a/.123 studied two inhibitors of HIV-PR and 
found that constraining the active site of the enzyme to maintain its structure 
gave better agreement with experiments for the hydroxyethylene inhibitor (HEI). 
Another tight-binding hydroxyethylene inhibitor of HIV-PR, JG365, has been ex­
tensively investigated using FEP and MD, writh several mutations being proposed 
that are predicted to improve the strength of the binding.119,121,122 Cieplak128 
investigated the replacement of each peptide bond in JG365 with trans-ethylene 
or fluorethylene groups. Rick et al. 1 26 performed TI calculations to calculate 
relative binding free energies between a drug-resistant mutant of HIV-PR and 
the unmutated enzyme bound to several potent inhibitors. McCarrick and Koll- 
man127 used FEP calculations involving haloperidol thioketal (THK) and three 
of its derivatives bound to HIV-PR to predict further derivatives of THK with 
tighter binding.
Many other biological systems have been studied using FEP. Rastelli et al. 129  
studied an inhibitor of aldose reductase and several analogous inhibitors involv­
ing point substitutions at the protein surface. The calculated relative binding 
free energies agreed qualitatively with experiments. Several M D/FEP stud­
ies of protein-carbohydrate complexes have been reported.130-132 Zacharias et 
al. 1 32 compared the binding of arabinose and fucose to arabinose binding protein 
(ABP). Liang et al. 130 examined the relative binding of mannose and galactose 
to mannose binding protein (MBP). Pathiaseril and Woods131 also found relative 
binding free energies in good agreement with available experimental data in their 
calculations 011 an anti-Salmonella antibody bound to variants of a trisaccharide
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from Salmonella serotype B.
Fox et a/.133 used TI to calculate the relative binding free energy of two 
similar substrates with the antibody 17E8. Substitution of a -CH2- group with a 
-S- reduced the calculated binding free energy by about 1 kcal mol-1 . Analysis of 
the components of the free energy indicated that the main factor in the preference 
for -CH2- was the loss, upon complexation, of favourable solvation free energy for 
the more polar -S- side chain.
Simonson et al,134 performed a detailed M D/TI study of the binding of 
aspartyl-tRNA synthetase (AspRS) to Asp and Asn residues. The specificity 
of binding to Asp over Asn is essential to maintaining the integrity of the genetic 
code. The calculated binding free energy was 15 kcal mol-1 more favourable for 
Asp binding to AspRS than Asn, largely due to the loss of electrostatic interac­
tions with the carboxvlate of the Asp side chain in the transformation to Asn. 
Lau and Karplus135 had previously used TI in conjunction with MD to calculate 
the relative binding free energy of the Tyr substrate to wild type tyrosyl-tRNA 
synthetase (TyrRS) and a mutant of TyrRS, where a key Tyr residue had been 
replaced with Phe. The calculated free energy difference was attributed to in­
teractions of the hydroxyl group of the wild type TyrRS and was found to be in 
good agreement with experimental values.
As well as calculating the relative binding free energy of similar ligands, FEP 
and TI have also been used to calculate absolute binding free energies for protein- 
ligand and DNA-ligand complexes. Helms and Wade136 used MD with TI to 
calculate the absolute binding free energy of camphor with cytochrome P450cam 
from Pseudonomas putida to within 1 kcal mol-1 of the experimental value. This
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was achieved by mutating the camphor, consisting of 11 non-hydrogen atoms, to 
six water molecules within the binding site.
Park and Lee137 used MD and FEP to rationalise the relative binding strengths 
of several known histone deacetylase (HDAC) inhibitors. These inhibitors may 
provide a new approach to the treatment of cancer by preventing inappropriate 
uptake of HDACs by histone proteins complexed with DNA, which has been 
shown to affect gene transcription.138 The results illustrated that any increase 
in favourable interactions between the enzyme and inhibitor, for example due to 
structural improvements in the inhibitor, must overcome the additional stability 
of the free modified inhibitor in solution to increase the binding free energy.
Saito and Sarai139 calculated the effect on the binding free energy of DNA 
bound to A-repressor of substituting thymine (T) with deoxyuracil (U) using 
FEP and MD simulations. The calculated relative binding free energy was in 
good agreement with available experimental data. Although T and U only differ 
in a small way, with a -CH group in T replaced by a hydrogen atom in U, the 
significant reduct ion in binding free energy was rationalised in terms of two effects: 
the lowering of the free energy of the unbound DNA as a result of a reduction in 
solvation free energy and the raising of the free energy of the bound state due to 
the loss of favourable van der Waals interactions in the binding site.
Setny and Geller140 used MD simulations with the thermodynamic cycle ap­
proach to calculate binding free energy differences for adenosine triphosphate 
(ATP) and guanine triphosphate (GTP) to the protein casein kinase 2 (CK2). 
They obtained good agreement with experimental data and illustrated the im­
portance of individual water molecules in the vicinity of the binding site.
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2.4 .4  M ultip le M olecule M ethods
2.4.4.1 Theory
FEP and TI are computationally expensive methods for calculating the free en­
ergy difference between two states or molecules. Methods such as the A-dynamics 
of Kong and Brooks141,142 and the adaptive chemical Monte Carlo/molecular 
dynamics (CMC/MD) method of Pitera and Kollman143 have been developed 
in order to obtain the free energy differences between several similar states or 
molecules from a single simulation.
The A-dynamics approach141 treats A as a set of variables, Aj, where j  can take 
values from 1 to n. Each of the n molecules is assigned a A j. As before, A j = 0 and 
A j = 1 correspond to initial and final states. An extended Hamiltonian is defined 
for the whole system, combining the Hamiltonians of the n molecules or states, a 
kinetic energy term for a set of fictitious masses and a potential function used for 
umbrella sampling. Umbrella sampling involves modifying the potential function 
to ensure that all states, even the most unfavourable ones, are sufficiently sampled 
during a simulation.66,72 When the simulation reaches equilibrium, each of the n 
molecules has a different value of A associated with it. The weighted histogram 
analysis method144,145 (WHAM) can then be used to generate free energy profiles. 
A-dynamics has the advantage over conventional FEP methods that rather than 
proceeding along a fixed path in A-space, the approach dynamically searches for 
the optimal path in A-space, allowing the simulations to converge more rapidly.141
The adaptive CMC/AID approach143 uses the MD approach to sample the 
configurational space of each ligand and MC to sample the chemical space cor­
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responding to the whole set of ligands being studied. The complex of one ligand 
and receptor provides the starting point for the MD simulation. After a certain 
amount of simulation time, a mutation to another of the set of ligands can occur, 
with the acceptance of any mutation determined by the usual MC criteria. At 
the end of the simulation, the ligands that bind most strongly to the receptor 
will have been sampled most often by the MC approach, allowing free energy 
differences between ligands to be obtained from an analysis of the sampling of 
each ligand.
2.4.4.2 Applications
The A-dynamics approach was initially implemented in determining free en­
ergies of hydration for small organic molecules as a representative example to 
demonstrate the potential of the method.141 Guo et al.146 applied the method to 
a trypsin-inhibiitor system, obtaining results that were consistent with other free 
energy methods and experimental data. More recently, the method has been ap­
plied to determining the relative binding free energies of several inhibitors bound 
to the hepatitis C virus (HCV).147 A single A-dynamics simulation correctly iden­
tified strongly and weakly bound inhibitors. Multiple simulations were used and 
these gave accurate rankings for the potency of each of the inhibitors, with five of 
the seven inhibitors’ calculated binding free energies found to be within 0.6 kcal 
mol-1 of the experimental value. Furthermore, the method was tested against 
conventional FEP calculations for six pairs of the ligands, with the free energy 
differences determined by A-dynamics fitting better to experimental data for four 
of the six ligand pairs. The total cost of all the A-dynamics simulations was
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significantly less than the cost of the FEP calculations but obtained results that 
were comparable in accuracy.
Eriksson et al.148 used the adaptive CMC/MD method to calculate the relative 
binding free energies for a series of HIV reverse transcriptase (HIV-RT) inhibitors. 
Again, the results were validated against conventional FE P/T I methods.
Pitera and Kollman149 used the CMC/MD approach to calculate the relative 
free energies of several different amino acid side chains. The technique was used 
to calculate the relative solvation free energies of N-methylated and acetylated 
alanine, valine and serine. The calculations were in good agreement with TI cal­
culations for these systems and illustrated the need to consider the flexibility of 
biological molecules and to include all of the signifcant conformations. They also 
used CMC/MD to investigate free energy changes due to several mutations at po­
sition 133 of T4 lysozyme from a single trajectory, again finding good agreement 
with previous free energy calculations150 and experiment.
2.4.5 P ictorial M ethods: PR O FEC  and O W FEG
2.4.5.1 Theory
Two methods have been proposed that use pictorial representations of the free 
energy surface around a potential inhibitor to suggest possible enhancements that 
would be expected to improve binding: pictorial representation of free energy 
components151 (PROFEC) and the one window free energy grid152 (OWFEG) 
method. Both methods involve mapping the system of interest onto a grid and 
approximately evaluating the free energy at each grid point.
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In PROFEC, a neutral probe is placed at each grid point and a single window 
FEP calculation is performed. The free energies of the grid points are then shown 
as contours around the inhibitor, suggesting promising regions of the inhibitor 
for alterations to be made to improve the strength of binding.
OWFEG is similar to PROFEC but flexible regions of the ligand are explored 
by translating and rotating each grid point and its nearest atom. Furthermore, 
positively and negatively charged probes are used, as well as neutral ones, to 
determine the effect of adding charged groups at the various points of the grid.
2.4.5.2 A pplications
Radmer and Kollman151 used PROFEC in studying trypsin and its inhibition 
by benzamidine, finding it useful in ranking the strength of nine inhibitors. Lee 
and Kollman153 combined PROFEC with FEP to predict more potent inhibitors 
of thymidylate synthase (TS), an enzyme whose inhibition could provide another 
way to treat cancer since it is involved in DNA synthesis. They predicted new, 
more potent TS inhibitors, modified from existing inhibitors, and validated their 
predictions using TI.
Pearlman152 tested OWFEG on a protein-ligand complex, FKBP-12-FK506, 
and found excellent qualitative agreement with TI calculations. Pearlman and 
Charifson154 introduced an OWFEG scoring grid, related to the free energy grid 
by a linear translation function with three fitted parameters. They then compared 
the ability of OWFEG with TI and several rapid scoring functions, designed for 
screening vast numbers of potential compounds, to predict the relative binding 
free energies of 16 inhibitors of a p38 kinase protein.155 They defined a predictive
2.4 Statistical M echanics 45
index (PI) that measures the reliability of a prediction method, with a PI of 
+  1.0 being perfect correct prediction, 0.0 being random prediction and —1.0 
being perfect incorrect prediction. The PI for TI was found to be 0.84 for the 
16 p38 inhibitors, with OWFEG scoring 0.56. The rapid scoring functions had 
much lower PI values, even doing worse than random predictions in some cases. 
They concluded that precise free energy calculations such as FEP and TI allow 
accurate and reliable predictions that agree with experimental observations but 
much less computationally expensive methods such as OWFEG can give less 
reliable, but still qualitatively correct, predictions of relative binding free energies. 
Rapid scoring functions, designed as they are to be used in the rapid screening 
of large libraries of compounds, were not accurate enough to accurately predict 
the relative strengths of the inhibitors.
Eriksson et a/.148 used PROFEC in conjunction with the adaptive CMC/MD 
method and conventional FE P/T I methods. They used the technique to pre­
dict a new derivative of an inhibitor of HIV-RT that should bind more strongly 
and confirmed that its calculated binding free energy was 1-2 kcal mol-1 more 
favourable than the original inhibitor.
2.4.6 Linear Interaction Energy M ethod
2.4.6.1 Theory
The linear interaction energy (LIE) method for estimating absolute binding 
free energies was proposed by Aqvist et a/.156 The LIE method is based on 
linear response assumptions: in other words, the change in the polarisation of the
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solvent caused by changes in the electrostatic field due to the solute is linear and 
characterised by a single dielectric constant. The absolute binding free energy, 
AGbinding, for a protein-ligand complex is written as:
a /n» _ a /^ electrostatic , a /^ rvdW /<-> -i^t^binding 7^ '-zbinding ■ ^ '-Tbinding>
where A G J ^ ir“ tatlc and AGbfnding are contributions due to electrostatic and 
van der Waals interactions, respectively. These components are estimated from 
ensemble averages, again denoted by ( ) , taken from MD or MC simulations, as:
a / o  ^  /  zpelectrostatic  /^ e le c tro s ta t ic \  i f t  /  ZT’vdW  r-iv d W \ (c \ i 7 \
A D b in d in g  ~  Q  A b o u n d  “  ^ f r e e  /  +  P  A b o u n d  “  ^ f r e e  /  > ( A -1 7 )
where and are the electrostatic and van der Waals interaction
energies, respectively, taken from a simulation of the bound protein-ligand com­
plex; £gj^tr°static and £vd\v are electrostatic and van der Waals interaction 
energies, respectively, between the ligand and water, taken from simulations of 
the free ligand in water; and a  and j3 are empirical parameters. A third pa­
rameter, 7 , sometimes presented as being dependent on the solvent accessible 
surface area (SASA) change upon complexation, A(SASA), has also been used 
to improve the fitting of binding free energies to experiment.157-161
2.4.6.2 A pplications
Aqvist156 applied the LIE method to calculating absolute and relative binding 
free energies of several inhibitors bound to endothiapepsin. For a calibration set 
of four inhibitors, a = 0.50 and >3 — 0.16 gave a mean unsigned error of 0.4 kcal 
mol-1 for absolute binding free energies and 0.6 kcal mol-1 for relative binding 
free energies. These parameters were used to predict the binding free energy of
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a fifth endothiapepsin inhibitor. The predicted value of —9.70 kcal mol-1 was 
found to be in good agreement with the experimental value of —9.84 kcal mol-1. 
This method, using the same values of a  and (3 and a correction term for the 
effects of long-range electrostatic contributions to the binding free energy, was 
also applied to HIV protease (HIV-PR) inhibitors162 and benzamidine inhibitors 
of trypsin,163 again finding good agreement with experimental studies. Hansson 
et al.164 further refined the parameters using FEP calculations to determine the 
electrostatic coefficient, a. They found that a model where a  took one of four 
values from 0.33 to 0.50, depending on the charged or dipolar groups in the ligand, 
(3 = 0.18 and 7 =  0 gave optimal fitting to experiment.
Paulsen and Ornstein165 found that a different value of the van der Waals pa­
rameter, [3 = 1.043, gave good agreement with experiment for 11 ligands bound 
to cytochrome P450cam. Wang et al.166 found that (3 =  1.0 gave good agreement 
with experiment for 14 analogues of biotin bound to avidin, prompting Wang et 
al.167 to investigate what factors determine the value of (3 in the LIE method. 
They examined several different protein-ligand complexes using MD simulations 
and defined a weighted non-polar desolvation ratio (WNDR), related to the hy- 
drophobicity of the ligand and the binding site, that exhibited a linear correla­
tion with (3. The greater the proportion of non-polar groups that are buried in 
the binding site, the smaller the WNDR and hence the larger the value of ft. 
Conversely, burying polar groups in the binding interface increases the WNDR, 
thereby reducing {3. They found that using the WNDR, easily calculated for any 
protein-ligand system, generally predicted values of (3 that gave better estimates 
of the binding free energy for twelve neutral ligands bound to avidin than using
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a fixed value, (3 = 0.87, taken from the best estimate of the binding free energy 
for the biotin-avidin system.
Jorgensen’s group used the LIE method with MC to calculate hydration and 
binding free energies, adding a term, proportional to the change in solvent acces­
sible surface area (SASA) upon complexation, to equation 2.17. Once again, the 
coefficients a  and $  were calibrated in a test set and used to calculate binding 
free energies of inhibitors of human thrombin168 and FKBP12 inhibitors.158
Wall et al.157 applied the LIE method with MC simulations to the binding 
of 15 inhibitors to the enzyme neuraminidase. They found that application of 
equation 2.17 led to root mean square (RMS) errors of 1.5 kcal mol-1, compared 
to experiment, in the binding free energies. A detailed statistical analysis showed 
that the addition of the surface area-dependent parameter 7 significantly im­
proved the fit to experimental data. Ljungberg et al.159 found that a constant 7 
was also necessary in their studies of the absolute binding energies of inhibitors 
binding to thrombin.
Almlof et al.161 recently investigated the dependence of the parameters a, 
and 7 in the LIE method on the force field used. They used three different 
force fields to investigate the binding of nine ligands to P450cam and found that 
the same parameters given by Hansson et al.164 produced relative binding free 
energies in good agreement with experiment. However, for the absolute binding 
free energies, all three force fields predict values that are too positive. A value of 
7 =  —4.4 kcal mol-1 brought the absolute binding free energies predicted by each 
of the three force fields to within 0.4 kcal mol-1 , suggesting that the parameters 
were not dependent on the choice of force field.
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Chen et al.169 used MD simulations with the LIE approach to calculate binding 
free energires for steroids binding to antibodies and predicted the binding free 
energy for an untested steroid. The LIE method was also used by van Lipzig et 
al.170 to predict the binding affinites of ligands to the estrogen receptor (ER), also 
taking into account every possible orientation of the ligands within the binding 
site. Ersmark et al.171 applied the method to the haemoglobin-degrading aspartic 
proteases, plasmepsin I and plasmepsin II, of the malaria parasite, to a series of 
potential inhibitors, reproducing the experimental binding data well. Asi et a l172 
applied the method using MD simulations to calculate binding free energies for 
wild type and mutant forms of the C-terminal domain of Escherichia coli (E. 
coli.) arginine repressor (ArgRc) bound to L-arginine and L-citrulline. Svab et 
al.173 calculated binding free energies for sulfonamide inhibitors bound to matrix 
metalloproteinases, predicting which of two possible binding modes was favoured 
for the inhibitors.
2.4 .7  M M -P B S A  and M M -G B S A  M ethods
2.4.7.1 Theory
The theory of combining molecular mechanics (MM) and continuum solvation 
techniques, such as Poisson Boltzmann Surface Area (PBSA) and Generalised 
Born Surface Area (GBSA), is described in the Theory chapter of this thesis as 
it is directly used in the research reported here.
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2.4.7.2 A pplications
The approach of combining a force field with a continuum solvation model was 
introduced by Srinivasan et a/.174 to study the relative free energies of alterna­
tive forms of DNA in aqeuous solution. The MM-PBSA method has been used 
extensively due to its much lower computational cost compared with free energy 
perturbation methods. In particular, the work of Massova and Kollman3 on the 
binding of the oncoprotein Mdm2 with the tumour suppressor peptide p53, in 
which they introduced the computational alanine scanning technique used in this 
work, has been discussed previously in Chapter 1.
Huo et al.175 extended the method to investigate the binding of human growth 
hormone (HGH) and its receptoor, for wdiich experimental alanine scanning data 
were available. The calculations were in good agreement with experiment for the 
12 mutations, wfith the exception of two arginine mutations, for which a significant 
conformational change would take place upon replacement with alanine.
Chong et al.176 illustrated the usefulness of the method for calculating relative 
binding free energies for germ line and mature forms of an antibody fragment to 
an anionic hapten. Reasonable agreement wras also found for the absolute binding 
free energies. The stronger binding of the mature antibody was attributed to the 
optimisation of the binding site geometry and the resulting gain in favourable 
electrostatic interactions overcoming the loss of solvation free energy upon com- 
plexation.
Kuhn and Kollman177 used MM-PBSA to study derivatives of biotin bind­
ing to avidin and streptavidin, reproducing relative binding free energies of 9- 
methylbiotin compounds. They used computational fluorine scanning, a tech­
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nique similar to the computational alanine scanning described earlier, to replace 
hydrogen atoms in the MD trajectory with fluorine. This is a much cheaper 
alternative to traditional free energy perturbation methods as several potential 
mutations can be investigated from the same trajectory. Of the nine fluoro- 
substitutions investigated, only one was predicted to increase the binding free 
energy. The relative binding free energies were also in agreement with TI calcu­
lations.177
Kuhn and Kollman178 also compared the MM-PBSA and LIE methods for 
calculating binding free energies for a number of diverse avidin and streptavidin 
ligands. They found that MM-PBSA performed better than LIE for a fixed value 
of f3 =  1. Although the LIE method allows for the empirical adjustment of /3, the 
MM-PBSA approach introduces no empirical parameters that are not intrinsic 
to the force field.03
Wang and Kollman179 studied the stability of HIV-PR dimers. Different dimers 
were ranked in order of binding free energy in good agreement with experiment. 
They introduced the method of virtual mutagenesis to suggest cavities near the 
binding interface of the dimer that could potentially be filled by a larger side 
chain in a mutated PR, which could then bind in a dominant-negative manner 
and inhibit dimer formation.
Santa et al.180 have used MM-PBSA to investigate different conformations of 
tetrapeptides in order to gain insights into which types of turns are preferred in 
aqueous solution. Nordman et al.181 have studied the binding of testosterone and 
several of its analogues to an anti-testosterone antibody. The method produced 
relative binding free energies in reasonable agreement with experiment for both
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neutral and charged steroids. Computational mutagenesis techniques were used 
to rationalise the lower binding affinities of some ligands than testosterone in 
terms of the contributions from specific residues.
Several applications of the generalised Born surface area (GBSA) method, 
which is the method used in this work, have also been reported. Rizzo et al.182 
used the GBSA method, rather than explicit water molecules, for the MD simu­
lation of six thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A, two 
homologous matrix metalloproteases (MMPs) that have been implicated in breast 
cancer. They also used MM-GBSA in post-proessing the trajectories and found 
a strong correlation between the calculated binding free energies and experiment, 
correctly predicting the preference in binding stromelysin-1 over gelatinase-A and 
rationalising this selectivity in terms of stronger van der Waals interactions and 
a smaller net desolvation penalty upon complexation.
Lepsik et a/.183 have also used MM-GBSA to study an inhibitor of wild- 
type and drug-resist ant HIV-PR, designated QF34. Its binding to HIV-PR was 
compared with two clinically used drugs, saquinavir (SQV) and indinavir (IDV), 
and it was shown that its greater flexibility allowed QF34 to form more stable 
hydrogen bonds than either SQV or IDV. The MM-GBSA analysis showed that 
the van der Waals and electrostatic interactions favoured binding and that more 
residues of HIV-PR were involved in binding to the inhibitor than was the case 
for SQV or IDV.
Rinaldo et a/.184 have investigated several potential strontium-binding pro­
teins, of interest in the area of nuclear waste management, using MM-GBSA. 
They analysed the dynamical and binding properties of seven mutants of a se­
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quence from the calcium-binding protein calmodulin and identified factors that 
could contribute to a stronger specificty for strontium.
2.5 This Research
The aim of the research presented in this thesis is to investigate the non- 
covalent interactions between Mdm2 and p53, with particular emphasis on the 
contribution of each amino acid residue of the peptide to the overall binding free 
energy. The same approach is applied to the interactions of IQN17 wfith DIO-pl, 
and IQN17 with two C-peptides, Cl21m and C12unlm. Identification of the key 
peptide residues for binding to the protein could potentially lead to suggestions of 
changes in the HIV inhibitors that would improve the binding and hence reduce 
the concentration needed to successfully inhibit cellular fusion.
In this work, protein-peptide interactions are probed using MD simulations 
with explicitly modelled water. The A M B E R 74 force field is used for the protein 
and peptide and the water molecules are represented using the T IP 3 P 81 model. 
The GBSA implicit solvation method is used in post-processing the MD trajectory 
to obtain solvation free energies for the complex, protein and peptide for each 
of the molecular systems studied. Each residue of the peptide is systematically 
mutated to alanine using a computer program developed in this laboratory and 
the effect on the binding free energy is evaluated. This allows the identification 
of the key residues in the binding between the protein and peptide. It also gives 
insights into the factors influencing binding, including whether electrostatic or 
van der Waals interactions are the main contribution to the binding energy from
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a given peptide residue, or whether solvation effects dominate. The theory and 
methods used in this work are described in more detail in Chapters 3 and 4, 
respectively.
Part II 
Theory and M ethods
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Chapter 3
Theory
3.1 M olecular M echanics
3.1.1 Introduction
The time-independent behaviour of a molecule is described by the Schrodinger 
equation:185,186
=  (3.1)
where ^  is the wavefunction of the system, E  is the energy of the state and J ?  
is the Hamiltonian operator. The electrons in the system are much smaller and 
lighter than the nuclei. Thus, we can invoke the Born-Oppenheimer approxima­
tion and treat the motions of the electrons and the nuclei as separate. On the 
timescale of electronic motion, the nuclei can be treated as fixed, allowing the 
nuclear kinetic energy and internuclear repulsion terms to be neglected. Thus,
56
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the Schrodinger equation can be expressed as:
^electronic — E electroTiiC1p  i ('^ •^ )
where ip is the electronic wavefunction and J feiectronic, the electronic Hamiltonian 
operator, is given by:
(3.3)
where V is the differential operator, N  is the number of nuclei, n is the number 
of electrons, m e is the mass of an electron, ^  is the charge on particle i, eo is the 
permittivity of free space, h is Planck’s constant divided by 27t, is the position 
of electron i and R j is the position of nucleus j .
These three terms in the Hamiltonian represent the kinetic energy of the elec­
trons, the attraction between the electrons and the fixed nuclei and the repul­
sion between the electrons, respectively. Despite progress in electronic structure 
theory, it is still not possible to solve the Schrodinger equation accurately and 
efficiently for large molecules. Therefore, it is often necessary to use simplified 
models such as molecular mechanics (MM) to study the interactions within pro­
teins and polypeptides.
Molecular Mechanics63-65,68 (MM) is an atomistic model that considers the 
interactions between individual atoms using classical mechanics. These interac­
tions can be broadly divided into bonded or internal interactions and non-bonded 
interactions. Many molecular mechanical force fields have been developed such 
as C H A R M M ,75 M M 2,187 M M 3,188 M M 3 P R 0 79 and O PL SA A .78 The AM ­
B E R 73,189 force field has been used throughout this work and its functional form
■ h  o A A  2,e2 AA AA e2
• ^ e le c tro n ic  ~  E  „ V? E E  J „ ,  I _  R  , I +  E  E2m  ' f - f  “  47re0 r, -  | •f-f L- ‘ 4ire0 rf -  r
1 = 1  1 = 1  7 = 1  1 J  ' 1 = 1  J  =  l + 1  1
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is described below.
3.1.2 Internal Interactions
There are three main types of internal motion that must be considered: bonds 
stretching and compressing, bond angles deforming and torsional motions. The 
potential energy due to deformation of bond lengths, Ebonds, and bond angles, 
Wangles, away from their equilibrium values are modelled within the A M B E R 73,189 
force field by harmonic terms as shown in equations 3.4 and 3.5:
where K r and K q are force constants, r and 0 are bond lengths and angles, 
respectively, and rgq and 0^  are equilibrium values of the bond lengths and angles, 
respectively. K r , K q, and #eq are parameters that are established within the
force field by fitting to experimental data.
The potential energy due to torsional motions, Etorsions, 1S giyen
where 0 are the dihedral angles, Vn is a force constant and 7 is a phase term.
The sum of the energies due to these internal motions is the internal energy, 
^ in te r n a l, given by:
bonds
(3.4)
angles
angles
(3.5)
torsions (3.6)
torsions
•^internal -^bonds torsions • (3.7)
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3.1.3 N on-bonded Interactions
The A M B E R 74 force field assigns partial charges to each type of atom and
the energy due to electrostatic interactions between atoms, Electrostatic, is given 
by a Coulombic term:
where qi is the charge on atom z, e is the permittivity or dielectric constant and 
rij is the distance between atoms i and j .
The energy due to van der Waals interactions, Ev&w, is modelled by a Lennard- 
Jones potential:
where Aij and Bij are parameters that characterise the interaction between two 
given types of atom.
Energies due to non-bonded interactions are only evaluated for atoms sepa­
rated by at least three bonds. Interactions between atoms separated by exactly 
three bonds, i.e. 1-4 interactions, are evaluated but a scaling factor is applied to 
the energy terms. For electrostatic interactions, the calculated energy is divided 
by a factor of 2.0. For van der Waals interactions the scaling factor is 1.2.
3.1.4 Gas P hase Energy
The gas phase energy, Egas, of a molecule is defined in terms of internal and 
non-bonded energies as shown in equation 3.10.
E l e c t r o . , . t i c  =  £ (3.8)
(3.9)
-^internal T  ^ elec tro sta tic  +  Ey  dVV (3.10)
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3.2 Implicit Solvent Treatment
3.2.1 Introduction
Proteins are usually found in aqueous solution and it is therefore essential to 
consider the effect of solvent when studying protein interactions. It is possible 
to model the solvent atoms explicitly using a potential energy surface such as 
T IP 3 P ,81 as has been done during the molecular dynamics simulations in this 
work. However, this is computationally expensive as large amounts of time are 
spent calculating the behaviour of individual solvent atoms when it is actually 
the effect of these atoms on the solute that are of primary interest. Furthermore, 
simulations with explicit solvent molecules have inherent assumptions involving 
the treatment of long range electrostatic interactions.82 Therefore, it is becoming 
increasingly common to treat the solvent as an implicit continuous medium with 
the same average properties as the real solvent.3’56,82’85,86’99’174,175,190-199 The free 
energy of solvation of a molecular species in this solvent continuum is defined in 
terms of a solvent-solvent cavity term, Gcav, a solute-solvent van der Waals term, 
Gvdvv, and a solute-solvent electrostatic polarisation term, G poiar, as follows:
^ so lv a tio n  =  Gc&y +  Gv dW  +  G polar • ( 3 - 1 1 )
Solvating a molecule in such a continuous solvent medium can be thought of 
as a three-stage process. First, a cavity is made in the solvent and the solute 
is inserted but does not interact with the solvent. Next, van der Waals inter­
actions between the solute and solvent are switched on and, finally, the solute 
and solvent are allowed to interact electrostatically.68’82’85’86,198 Normally, the
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first two stages of this process are considered simultaneously and the solute is
are switched on. Hence, it is normal to define G soivation in terms of polar and 
non-polar contributions:
3.2.2 Surface A rea M ethods
The free energy of aqueous solvation for non-polar solutes such as saturated 
hydrocarbons is approximately proportional to their solvent accessible surface 
area (SASA).200-202 Hence, it is normal to estimate the non-polar contribution to 
the solvation free energy203,204 using an expression such as:
where SASA* is the total solvent accessible surface area of all atoms of type k, 
which can be calculated numerically205,206 and cr*. is an empirically determined 
atomic solvation parameter. Clearly, for saturated hydrocarbons, since G poiar ~  
0, this is sufficient to obtain good estimates for the free energy of solvation. 
However, for molecules such as proteins, it is also necessary to determine the 
polar contributions to the solvation energy.
3.2.3 P oisson-B oltzm ann M ethod
The classical treatment of electrostatic interactions in solution is based on the 
Poisson-Boltzmann equation:56,82,83
essentially inserted into the solvent with no partial charges and then the charges
C 'non—polar “I” G polarivation (3.12)
^ n o n -p o la r  — /  J (JfcSASAfc 
k
(3.13)
V • [e (r) V4> (r)] — k2 (r) sinh (4> (r)) 4- 4np (r) =  0, (3.14)
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where $  (r) is the electrostatic potential, e (r) is the dielectric constant, p (r) is 
the charge density, k (r) is the Debye-Hiickel parameter and V is the differential 
operator. Note that all of these terms depend on position. The second term in 
equation 3.14 accounts for salt effects due to mobile ions in solution. If $> (r) is 
small, the sinh term can be expanded as a Taylor series207 and truncated at the 
first term to yield the linear Poisson-Boltzmann equation. Furthermore, when 
such salt effects are absent, i.e. when «(r) =  0, equation 3.14 reduces to the 
Poisson equation:68,83,84
V • [e (r) V $ (r)] -  -4 ttp  (r ) . (3.15)
It should also be noted that this in turn reduces to Coulomb’s law if the dielectric 
constant is the same throughout all space.83 The charge density, p (r), is deter­
mined by the spatial distribution of partial atomic charges within the solute. The 
most difficult term to describe accurately is the dielectric constant, e(r). Due 
to the inhomogeneous nature of proteins, there is no one such constant that can 
describe the dielectric response of an entire protein to an applied electric field. 
For example, in the protein interior where hydrophobic residues are most com­
mon and the response to any electric field is small, a dielectric constant of 2-4 
is appropriate. However, at the protein surface where polar or charged residues 
can produce a significant dielectric response to the presence of an applied electric 
field, a value for the dieletric constant of 10-30 is more appropriate.56 Hence, 
it is necessary to consider the dielectric constant as an empirical parameter that 
attempts to describe the overall dielectric behaviour.56
The Poisson-Boltzmann equation is generally solved numerically due to the
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complicated shapes of protein surfaces. The most common methods involve plac­
ing the protein at the centre of a cubic grid and solving the equation iteratively 
until a preset level of tolerance is met at all grid points. This can be done using 
programs such as DelPhi,208 which can be used with common molecular mechan­
ical force fields. Solving the Poisson-Boltzmann equation yields the electrostatic 
potential, <E> (r), throughout the space in and around the macromolecule of inter­
est. For the case of the linear Poisson-Boltzmann equation, the total electrostatic 
free energy of the system, Ges, is simply given by:
where is the electrostatic potential at the position of charge i.56
The polar contribution to the solvation free energy, Gpoiar> is thus the difference 
between the electrostatic free energy in solution, given by equation 3.16, and the 
electrostatic free energy in vacuo, given by Coulomb’s law, as shown in equation
expensive and the method is therefore best used for evaluating Gpoiar for single 
structures and a faster method for evaluating Gpoiar is required for calculations in­
volving large numbers of structures. Simple models involving distance-dependent 
dielectric constants, e (r) oc r, have been employed but are of dubious accuracy 
and more precise models based on the Born expression are commonly used.
(3.16)
3.8.
Solving the Poisson-Boltzmann equation in this fashion is computationally
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3.2.4 G eneralised Born M ethod
The Born expression209 for a spherical ion is given by:
Gbor„ <X ( i  -  i )  £ ,  (3 .17)
where q is the charge on the ion, a  is the effective Born radius and e is the 
dielectric constant of the medium.
The total electrostatic free energy of a system of n widely separated particles 
with separations r, in solution, Ges, can be written as:
n n / 1 \ n 2
Gm<x' £ ' £
■y ^  r O€ V 6 /  - y  ai1 = 1  J  \  s  1 = 1
(3.18)
where the first term in this equation is Coulomb’s law in a dielectric medium. 
This can be expanded into two terms: Coulomb’s law in a vacuum and a term 
that resembles the Born expression. This gives the following expression:
n n / 1> . n n  /  i \ n 2
C e s O c V  T  —  ~  ( l - - ) E  E  —  -  f l - - ) E - -
h . k t x Tii ^ e ' h t i t r + i T'i v
(3.19)
Therefore, Gpoiar can be written in terms of some function / g b  in the Generalised 
Born (GB) equation:
rpolar CX [ 1 ~  -  j  ^  ^  (3 .20)
where /gb is a function of and ai and is not defined uniquely but is chosen to 
make equation 3.20 mimic the equations of classical electrostatics.86 One effective 
expression for / g b  is:
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where =  yJaicTj. As becomes larger than aij the exponential term becomes 
very small. In other words, the exponential term forces the expression for G poiar 
to approximate the dielectric part of Coulomb’s law as the two atoms i and j  
move beyond the contact distance of their Born radii.86
The Generalised Born equation, equation 3.20, requires a Born radius a* for 
each atom, which depends on the positions and sizes of all the other atoms in 
the solute as they displace the dielectric medium. The Born radius for an atom 
is more like an average distance from the partial charge to the boundary of the 
dielectric medium.86 These atomic Born radii can be evaluated accurately using 
numerical techniques85 but this is time consuming. A fast analytical approach 
to calculating Born radii has been introduced by Qiu et a/.86 and this method 
is used throughout this work for calculating polar contributions to the solvation 
free energy.
The general method for computing Born radii starts with the Born expression, 
equation 3.17, and considers a polyatomic solute with no partial charges. For this 
system G poiar is zero but the dielectric medium is displaced by the solute atoms. 
A charge can then be introduced on atom i and the Born equation can be 
used to calculate an average effective Born radius, a*, provided that G poiar can 
be evaluated for the hypothetical system. Qiu et al.86 developed an analytical 
function for calculating G poiar that estimated the effect of the presence of each 
of the other atoms in the solute and their displacement of the dielectric medium. 
Their effect on G poiar is based on a V/rfj  relationship between the volume of 
dielectric medium displaced by atom j  and the separation of atoms i and j .  This 
represents the loss of the interaction between the atomic partial charge, ^ , and
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the induced dipole in the volume of dielectric medium displaced by atom j .  In 
this model it is assumed that the solute atoms only displace the dielectric medium 
within their van der Waals radii and therefore does not include cavities within 
the solute that are too small for solvent molecules. This process is carried out 
for each atom and although the model is conceptually simple it provides a fast 
and fairly accurate method for calculating a* and hence Gpoiar-
3.3 Free Energy of Binding
3.3.1 D efinition
The free energy of each of the molecular species in aqueous solution is defined
as:
^G^aq — -figas +  G'solvation ~ TS,  (3-21)
where T  is the temperature, 5  is the entropy, Egas is defined in equation 3.10 and 
^solvation is defined in equation 3.12.
For a complex between a protein and a peptide the free energy of binding, 
AG^ binding, is defined as:
^G^ binding ^ G^aqcompiex (^G^aq^rotein "b ^ G^aq,peptide)• (3.22)
The equilibrium constant, K , for the non-covalent association of two species,
A and B:
A +  B ^ A B ,  (3.23)
is given by:
*• ■ S -  »■*>
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This can be related to the free energy of binding using the expression:
AGbinding =  — R T \ n K , (3.25)
which allows the concentrations of products and reactants, in particular the IC50, 
to be explicitly related to changes in free energy.
3.4 Entropy
3.4.1 Introduction
The entropy of a molecule can be estimated, in terms of contributions from 
translational, rotational and vibrational motions, using classical ideal gas ther­
modynamics. One of the main ideal gas assumptions is that the particles are 
not interacting with one another, which is clearly not the case for biomolecular 
systems. This will introduce errors in the determination of the partition func­
tions. However, it is important to consider the entropic cost of protein-protein 
association and this method allows quantitative estimates to be made.
3.4.2 Classical Partition  Functions and Entropy
Using classical ideal gas thermodynamics, the contribution to the total entropy 
of a molecule due to any individual component is related to the partition function 
for that component. The translational contribution to the entropy, SVrans, is given
by:101
Stmns =  * ( +  ln(e) + T  ( — 13 = =). (3.26)
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where 2trans is the translational partition function, k is the Boltzmann constant, T  
is the temperature, the subscript V  implies constant volume and molar quantites 
are used. The factor of e arises from the derivation of the expression using 
Stirling’s approximation for the logarithm of a large number.207 The translational 
partition function is given by:101
(2 i rm k T \ 3 ' 2 k T  
t^rans =  ( ---- -------  ) “p .  (3-27)
where m  is the mass of the molecule, P  is the pressure and h is the Planck con­
stant. Since, at constant volume, the ratio is constant, the partial derivative
is:
/  d ln(ztrans)\  =  _3_
v dT  ) v ~ 2  T
and the translational contribution to the entropy, T 5 tran s, is given by:
(3.28)
T  StrpLns — ln(^trans) T ^ kT. (3.29)
The rotational contribution to the entropy, S rot, is given by:101
5 rot = k ^ln(irot) +  T  (^ N A ol))  \  t (3 .30)
wrhere zrot is the rotational partition function. For the general case of a non-linear 
polyatomic molecule, the rotational partition function is given by:101
 ^ _  1 /87T2f c T \ 3/2 1/2
-°rot — ( ^ 2  ) (7r/a/ b / c) , (3 .31)
where 7a, lb and Ic are the moments of inertia of the molecule about its three 
principal axes and a is the symmetry number, which is equal to one for non- 
symmetrical biomolecules. As for the translational partition function, the partial
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derivative at constant volume is:
( dln(z[ot) \  _  3
V d T  ) v 27” 3^ '32^
and the rotational contribution to the entropy, T S rot, is given by:
T S r n t  — lft (^rot) +  2 kT. (3.33)
The vibrational contributions to the entropy, T S VI\>, can be obtained from the 
normal mode frequencies, Vj, as follows:101
3 N - 6  ,riv
T S '*> = E  - kTln (J - e_wtr) ■ (3-34)
j =i
3.5 Energy M inim isation
3.5.1 M inim isation Techniques
There are several techniques for finding the minimum energy geometries of 
large molecules.63-65,210 Line searching is a simple method that involves calculat­
ing the gradient of the potential energy surface and performing a one-dimensional 
minimisation in the direction of the line of steepest negative slope. This can be 
achieved in the T IN K E R 211 package using the M INIM IZE program, which 
stores information from previous line searches in order to make the calculations 
more efficient. This type of minimisation technique is efficient for structures that 
are far from the minimum but becomes less useful near the minimum. Truncated 
Newton techniques such as those used in the N EW TO N  program in T IN K E R 211 
use the gradient and the curvature of the potential energy surface. Approxima­
tions are made for the curvature in order to reduce the computational cost of the
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calculations. Consequently, these techniques, when used together, are useful for 
finding minimum energy geometries of large molecules such as proteins or nucleic 
acids.
3.5.2 The H essian M atrix
The potential energy of a system, V, depends on p variables such that:
V = V  ( x i , x 2, ■ ■ . , x p) , (3.35)
where the variables x { . . .  xp could be bond lengths, bond angles or the carte­
sian coordinates of the atoms in the molecule. A vector x can be defined in 
p-dimensional space as:
( \Xi
X  = (3.36)
\ x p J
Therefore the Taylor expansion207 of V  about the point xo can be written as:64 
V ( x )  =  V(x6) +  g ( g ) ^ ( i f - x ? )  +
(3.37)
1 1 \  /  u  ut=l j = l x J xi xj
It is then possible to define the gradient vector g of the function V  as in equation 
3.38. When evaluated at an atomic position the gradient of V  gives the negative
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of the force acting on the atom.
g =
(  av \
dx\
d V  
8 x2
d V
\  9 x p J
(3.38)
Furthermore, the Hessian or force constant matrix can be defined as follows:
H =
/  d 2V  
d x 2
d2v
di2dx\
d 2V
dx\di2
d 2V
d x \
d 2V
dxidif
d 2V
di2dxf
\
d2v d2v m d2v
\  d i p d x i  d x pd i 2 d x £ /
(3.39)
At the stationary points of the potential energy function the gradient vector, g, is 
zero. The nature of the stationary point is determined by the eigenvalues of the 
Hessian matrix, H. If all of the Hessian eigenvalues are positive or zero then it is 
a local minimum and if all of the eigenvalues are negative it is a local maximum. 
If n eigenvalues are negative then it is described as an nth order saddle point.
3.5.3 Norm al M odes
For a system of N  atoms with masses m, and position vectors ri, 1*2, . . . ,  r^r, 
where the atoms each vibrate about their equilibrium positions, r®, r^,. . . ,  reN, 
the mass-weighted displacement coordinates, Qi, are defined as follows:
Q* =  s / f n t (rt -  r -q) . (3.40)
A set of 3N  mass-weighted displacement coordinates qi, <72, • • •, q^N can be defined 
such that <71, <72 and <73 are the components of Qi and so on. As before, the
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potential energy, V, of the system can be expressed as a Taylor expansion about 
the equilibrium position, as follows:
§ ( & ) . « + - ■  ,3 -411
If the vibrations are small the harmonic approximation can be made and higher
order terms in the expansion can be neglected. Since the gradient is zero at 
equilibrium, the potential energy can be written as follows:
14- K~ + 5 <” 21
As stated previously the negative of the gradient evaluated at an atomic posi­
tion gives the force, F*, acting on atom i. This can be expressed as:
d2r  •
- W  = F t =  mt^ ,  (3.43)
where t is time and the second derivative of position with respect to time is
the acceleration on atom i. Hence, each coordinate q must satisfy the following
expression:
d 2 q{ dV
+  (3-44)
If we write qi =  Ai sin (u>t -I- (fit) then these terms can be written as in equations 
3.45 and 3.46:
£ - § ( & ) . •  —  ™
-u j 2 qt. (3.46)
d 2 qt 2
d*2
The sum of the terms in equations 3.45 and 3.46 is zero and this can be written
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in matrix form as:
/  d2v
~dq[
d2v
<9<72<9<71
d 2V  
dq\ dq2
d2v
dql
d2v
d2v  d2v\  dq3Ndqi dq3 tfdq2
dqi9q3N
d 2V
dq2&q3s
Q2V
‘
92
\  93  N  J
=  UJ
f  \
9i
92
\  Q3N /
(3-47)
The matrix on the left is the mass-weighted Hessian matrix and its eigenvalues 
give the vibrational frequencies of the normal modes of vibration. For a non-linear 
molecule there are six zero eigenvalues, corresponding to three translational and 
three rotational normal modes. The eigenvalues, e, are found by solving the 
following determinant:
k ii — € k \ 2  • • • k 137V
2^1 2^2 — e • • • &237V
= 0, (3.48)
k 3 N l  k $ N 2  ' ' • ^ 3 N 3 N  ~  £
where kij = . These eigenvalues can then be used to determine the eigen­
functions, which give the relationship between the normal coordinates and the 
original Cartesian coordinates.
3.6 M olecular Dynam ics
3.6.1 Introduction
Molecular dynamics (MD) simulations are among the principal tools used in 
the study of biomolecules as they allow the time-dependent behaviour of a molec­
ular system to be determined.72 The trajectory describing the motion of each
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particle within a system can be determined by integrating Newton’s second law, 
also called the equation of motion. The force acting on each atom is calculated 
from the potential energy surface. The trajectory can then be studied using sta­
tistical techniques to calculate average values of a wide range of properties. MD 
simulations are deterministic in the sense that once the positions and velocities of 
the atoms are known, the positions and velocities can be calculated, in principle, 
for any value of time.
3.6.2 N ew to n ’s Equations of M otion
Newton’s equation of motion can be expressed as:
Fi =  rrii&i =  —ViV, (3.49)
where F* is the force on particle i, m* is the mass of particle z, a; is the acceleration 
of particle z and V  is the potential energy. This relation can also be expressed 
as:
dV  d2r
=  (3.50)
allowing the gradient of the potential energy of the system to be related to the
changes of atomic positions, r^, as a function of time.
For the one-dimensional case where acceleration is constant and position is 
given by x:
a  =  ^ ,  (3.51)
integration gives:
v — at +  u0, (3.52)
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and since:
(3.53)
it also follows by integration that:
X  =  v t  + X q . (3.54)
Thus, the value of x at time t  is given by:
X  =  a  t 2 +  Vot +  Xo (3.55)
where v0 is the initial velocity and x 0 is the initial position.
Therefore, all that is needed to calculate a trajectory are the initial atomic 
positions, a distribution of initial velocities and the acceleration, which is deter­
mined by the gradient of the potential energy function. This allows the position, 
velocity and acceleration for each atom within a system to be determined at any 
given value of time, t.
The initial positions can be taken from experimental data and the initial dis­
tribution of velocities is usually determined randomly from a Maxwell-Boltzmann 
or Gaussian distribution. The velocity distribution is chosen to correspond to the 
required system temperature, T , and such that there is no overall momentum.
3.6.3 Integration A lgorithm s
The potential energy is a function of 3N  variables for N  atoms. Due to 
its complicated nature, there is no analytical solution and the equations must 
be solved numerically. Taylor expansions207 can be used to approximate the
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positions, velocities and accelerations of the atoms:
r  (t +  St) = r  (t ) +  v (t) St -f ^ a  (t ) 8 t 2 + • • ■ (3.56)
v  (t +  St) = v (t ) +  a  (t) St +  (t) St2 +  • • • (3.57)
a  (t 4- St) = a  (t) +  b (t) St +  • • • , (3.58)
where r  is the position, v is the velocity, a  is the acceleration and b  is the third 
derivative of r  with respect to t.
Some of the commonly used integration algorithms are given below.72 All 
of the algorithms described here are essentially equivalent and generate identical 
position trajectories. Their main differences occur in the treatment of the velocity 
propagation and how many variables need to be stored to calculate a trajectory. 
Other methods, such as the predictor-corrector method of Gear,212,213 can also 
be used to propagate MD trajectories but are not described further here.
3.6.3.1 V erle t A lgo rithm
The Verlet algorithm214 is one of the simplest methods of solving the equations 
of motion. It is based on the positions and accelerations at time t and the 
positions at time t — St. The Taylor expansion for the positions at time t +  St is 
given in equation 3.56. The Taylor expansion for the positions at time t — St is 
given by:
r  (t -  St) — r  (t) — v (t))St +  i a  (t) St2 +  • • • , (3.59)
and adding these two expressions together gives the expression for the propaga­
tion of the positions:
r  (t +  St) = 2r (t) -  r  (t — St) +  St2a  ( t ) . (3.60)
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This expression does not explicitly contain the velocities but they can be calcu­
lated from:
although this expression is not exact. More accurate expressions for v (t) re­
quire the storage of more variables and increase the computational cost of the 
calculations, as well as requiring the positions r  (t +  5t) to be known.
3.6.3.2 L eap-Frog  A lgo rithm
The leap-frog algorithm215 treats the velocities explicitly by calculating them 
at half-step intervals. The velocities are calculated at time t 4- \ 8 t and used to 
calculate the positions in the following scheme:
Equation 3.63 is implemented first and the velocities are said to leap over the 
positions to the next half-step velocities. The velocities at time t can be evaluated 
during this stage using:
giving the positions and velocities at the same instant. Equation 3.62 is then 
used to propagate the positions, which again leap over the velocities, before the 
accelerations are determined for the next step.
(3.63)
(3.62)
(3.64)
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3.6.3.3 V elocity  V erlet A lgorithm
The velocity Verlet algorithm216 is equivalent to the Verlet algorithm214 but 
treats the velocities explicitly. The algorithm takes the form:
r (t + 8 t) = r  (t ) +  v  (t) St +  ^ a  (t ) St2 (3.65)
v (t +  St) = v (t ) +  i  [a (t) +  a  (t +  (5t)] St. (3.66)
The positions at time t +  St are calculated first and half-step velocities are
determined using:
v ^t  +  7 ^ ^  — v (t) -I- ^ a  (t ) St. (3.67)
The forces and, hence, the accelerations at time t +  St are evaluated and the
velocity propagation is completed:
v (t -f St) = v  ^  (3.68)
This method also requires the storage of just three variables: the positions, ve­
locities and accelerations at time t.
3.6.3.4 B eem an A lgorithm
The Beeman algorithm217 is similar to the velocity Verlet algorithm216 but uses 
the following expressions for the positions and velocities:
r  (t +  St) =  r  (t) +  v (t ) St +  ^ a  (t ) St2 — ^ a  (t — St) St2 (3.69)
3 6
1 5v (t +  St) = v (t) +  v (t ) St +  - a  (t +  St) St +  - a  (t) St -f
3 6
- - a  ( t - S t ) S t .  (3.70)
6
This is the integration algorithm used in the molecular dynamics simulations 
described in this thesis. This method requires the storage of four variables: the
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positions, velocities and accelerations at time as for velocity Verlet, as well 
as the accelerations at time t — St. However, the treatment of the velocities is 
improved over the standard Verlet method.72
3 .6 .4  Long R an ge In teraction s
3.6.4.1 Periodic B oundary  C onditions
(-1,1) (0,1) (1,1)
(-1,0) (0,0) (1,0)
(-1,-1) (0,-1) (1,-1)
Figure 3.1: (Left) The unit cell and its coordinates, x and y, for a square box of length 
L in 2D. (Right) A 3x3 periodic lattice built from unit cells. Each cell’s coordinate 
vector is given, with the original cell located at (0,0). Figure adapted from Toukmaji 
and Board. 2 1 8
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In the periodic boundary conditions (PBC) approach, the simulation box is 
infinitely replicated in each direction to form a lattice of identical boxes. The 
simulation box can take any shape that will fill space as it is periodically repli­
cated, although the case of a cubic box of length L will be considered here. The 
origin cell and the first layer of replicas for a 2-dimensional system are shown in 
figure 3.1. The array of boxes in 3-dimensional space is conceptually built up 
in approximately spherical layers starting from the initial simulation box. The 
location of a box within the infinite lattice is described in terms of a coordinate 
vector, defined as:
n  =  (m, n2, n3) =  riiLx +  n2Ly  +  n3Lz, (3-71)
where x, y and z are the cartesian unit vectors. The origin cell is located at 
n  =  (0,0,0) and the image cells are located at Ln  intervals as n  goes to infinity. 
The distance between a particle in the origin cell and another in an image cell is 
given by:
Tij,n = kjn — r*| =  |r* — Tj +  L n |. (3.72)
Calculating the non-bonded interactions within a molecular system involves 
determining interactions between all pairs of atoms. For a large system, for 
example a protein in solution, this can be a huge number of interactions and 
this significantly increases the computational cost of a simulation. Consequently, 
it is common to use more approximate methods such as cutoff approaches and 
Ewald summation to deal with the van der Waals and electrostatic interactions. 
The treatment of these interactions is particularly important for the electrostatic 
terms as these are effective over a much longer range, varying as the recriprocal of
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the interatomic separation. In particular, the use of PBC introduces the problem 
of determining interactions between a molecule and the infinite replicas of itself.
3.6.4.2 C utoff M ethods
Cutoff approaches can be used for any non-bonded interactions but are more 
commonly used for shorter range van der Waals interactions. The approach is to 
set all interactions involving atoms separated by more than some cutoff distance, 
c^utoff, to zero. The simplest way to achieve this is by the use of a truncation 
function such as:68
S  (r) =  <
1 t < rc
(3.73)
0 r > rc
which is multiplied by each term of the non-bonded interaction energy. This 
achieves the desired result in terms of reducing the cost of the energy calculation 
but has the drawback that the energy is no longer a continuous function and its 
derivatives, from which the forces on atoms are determined, also become discon­
tinuous. This can cause problems in energy minimisations or MD simulations 
as atoms pass in and out of each other’s cutoff distance. There are two general 
approaches to avoiding this problem: switch functions and shift functions. A 
switch function such as:68
1 r  < r,on
s  (r) =  I ron < r < r cutoff , (3.74)
V cutoff **on/
0 v > rcutoff
does not modify the non-bonded interactions for separations less than an inner
cutoff, ron, and smoothly reduces the interactions to zero between r on and rcutoff.
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The energy and its first derivative are both continuous throughout the whole 
range of r. A shift function such as:68
uses only one cutoff distance and modifies the interaction for all interatomic 
separations. Once again, the energy and its first derivative are both continuous 
throughout the whole range of r. Both switch and shift approaches are therefore 
suitable for dynamics calculations.
The simplest way to apply these methods is to calculate each interaction and 
apply the truncation function. However, this does not reduce the cost of the 
calculation as all of the interactions must still be evaluated. This is avoided by 
keeping a list of all the non-bonded interactions that involve interatomic sep­
arations less than the list cutoff, riist, which is larger than r cutoff. This means 
that more interactions are calculated than are within the cutoff but significantly 
reduces the number of interactions that must be evaluated. The list is updated 
when the current list becomes invalid,68 i.e. the atoms have moved by a similar 
amount to the difference between the list and interaction cutoffs, rnst — rcutoff.
Within the PBC approach, it is common to restrict the cutoff distance to 
half the length of the simulation box. This has the effect of ensuring that each 
particle in the box only interacts with particles in the nearest layer of replicated 
cells. This is known as the minimum-image convention.68 Although this method 
is easy to implement and appropriate for van der Waals interactions, its use for 
treatment of electrostatic interactions has been shown to introduce errors and 
artificial behaviour into simulations, meaning that another approach must be
( —!—) 2
y rcutoff J T — ^cutoff (3.75)
0 T ^cutoff
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used.218-221
3.6.4.3 Particle M esh Ewald Sum m ation
Ewald summation222 provides an efficient method for calculating the long- 
range electrostatic interactions between the particles and all of their infinite peri­
odic images. Particle mesh Ewald (PME) summation223 is an improvement over 
standard Ewald techniques but follows the same basic recipe. The total elec­
trostatic energy of a system of N  particles in a cubic box of length L and their 
infinite replicas within PBC is given by:218
■^electrostatic 'ey E 'E E  ( 3 . 7 6 )
„ - 1 1 ^  0»n n i=l j  =  \  J
where qi is the charge on particle i and n is the cell coordinate vector, defined 
previously. The prime on the first sum indicates that terms are omitted when 
n =  0.
In order to decompose this sum, consider that each point charge in the sum is 
surrounded by a Gaussian charge distribution of equal magnitude and opposite 
sign. This has the effect of screening the charges from one another, effectively 
making the interactions short-ranged, which causes the sum in real space to con­
verge rapidly. In order to counteract the induced charges, a second Gaussian 
distribution is added with the same magnitude and sign as the original point 
charges. The sum is then performed in reciprocal space using fast Fourier trans­
form techniques. The electrostatic energy can thus be re-written:222
-^Ewald =  ^ re a l “I" •^reciprocal ”1“ E s e if  T  -EsUrfa ce , ( 3 . 7 7 )
where E reai is the real space or direct sum, irreciprocal is the reciprocal, imaginary
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or Fourier sum, Ese\f is the self term and Efface term. The real sum is given by:
^  =  j E E E u erfcfK ° l  (3.78)
z  1=1 j = 1 n = o  r i i ’n
where q is a positive parameter that determines the width of the induced Gaus­
sian distribution and erfc is the complementary error function, given by:
2 f xerfc (x)  = 1 — erf (x)  =  1 -----■= / exp (—u2) du, (3.79)
V *  Jo
which rapidly falls to zero as interatomic separation increases. The reciprocal 
space term is given by:
i exp ( — (— ) 2)
^ reciprocal =  ~  77  Y ]  ---------"-----------  S  ^  S  ( _ m ) ’ ( 3 < 8 0 )Z7T V < m zm^ O
where V  is the volume of the simulation box, m is a reciprocal space vector and
S  (m) is the structure factor, defined as:218
N
S  (m) — y ;  qk exp (27rim • r ^ ) . (3.81)
k = 1
The self term corrects for the interactions of each of the induced charges with 
itself and is given by;
N
E„v = - ^ = Y . < i 2 i- <3-82)
The surface term arises due to the interaction of a dipole on the (roughly spher­
ical) surface of the array of periodic boxes and the surrounding medium.224 For
an infinite dielectric constant in the surrounding medium, this term is zero and 
tin-foil boundary conditions are said to be employed. For a surrounding vacuum 
with a dielectric constant of 1, the surface term is given by:72
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In PME,223 the real space sum is calculated using cutoffs while the reciprocal 
sum is approximated using fast Fourier transforms (FFT) on a grid where charges 
are interpolated to grid points.218 The parameter a  is chosen to be large enough 
that a fixed cutoff can be used for the direct sum, reducing its formal scaling 
from N 2 to N.  The scaling of the FFT approach used is formally \og(N) giving 
PME a scaling of N  \og(N ) . 2 1 8 , 2 2 3
Ewald approaches employ a neutralising background plasma for systems with 
a non-zero net charge. This can lead to artificial behaviour, particularly where 
the volume of the box changes, such as in constant pressure MD.225 This can 
be avoided by the use of counterions to neutralise the system electronically. Al­
ternatively, a correction term such as that proposed by Bogusz et a l 22 5 can be 
introduced to reduce any artificial effects.
3.6.5 C onstraints
3.6.5.1 G eom etric Constraints
It is often desirable to constrain one or more of the degrees of freedom within 
an MD simulation. In particular, constraint of high frequency motions such as 
bond vibrations can allow the use of a longer time step. The use of longer time 
steps without constraining these high frequency motions can lead to problems as 
these motions occur on a similar timescale to the time step. This is particularly 
pronounced for bonds involving hydrogen atoms.1
A general approach to constraining bond lengths in MD simulations226 involves 
artificially introducing forces acting along the bonds. A normal MD time step
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is calculated without the constraints and the magnitude of the constraint forces
are determined such that they correct the atomic positions and keep the bond
lengths constant. The equation of motion, equation 3.49, becomes:
Tfiid ii — F{ 4- Gj ~  Ft -f* G“, (3.84)
where Gj are the constraint forces acting on each atom i and the other terms 
are as before. In practice, since the equations of motion are integrated numeri­
cally, the constraint forces are generally evaluated to ensure that the constraints 
are satisfied for each time step.72 Thus, approximate restraint forces, G “, are 
calculated for each atom.226
This method can be illustrated by considering the example of restraining the 
bond lengths in water, H2O, where the oxygen atom is labelled atom 2 and the 
hydrogens are labelled atoms 1 and 3, respectively.72 The equations of motion 
for the three atoms in the water molecule are:
where =  |r  ^ — r^ | and d \ 2 and d23 are the bond lengths. Within the context 
of the Verlet algorithm,214 the propagation of the positions can be written as:
raiai — F 1 G i ~  F^ +  G^ (3.85)
77T.2&2 — F 2 +  G 2 ~  F 2 +  G 2 (3.86)
n i 3 a 3  —  F 3  G 3  ~  F 3  +  G 3 , (3.87)
and the constraint forces, G,, maintain the following constraints:
X 12 =  r 12 ( 0  -  d ? 2 =  0  
X 23 =  1*23 W  — ^23  = (3.89)
(3.88)
(3.90)
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where r ' (t +  t i t )  represents the position that would have been reached after an 
unrestrained time step. For the example of water, the approximations of the 
restraint forces are:
G “ =  Ai2 r i 2 (3.91)
GjJ =  A23r23 — Ai2 r i 2  (3.92)
G 3  =  —A23r23, (3.93)
where A12 and A23 are the multipliers that are yet to be determined. These forces 
act along the directions of the bonds and obey Newton’s third law.72 Writing the 
Verlet positions explicitly gives:
Fi (t +  t i t )  =  Fj (t +  8t) +  ^ ^  Ai2 Fj2 (t ) (3.94)
r 2 ( t  +  t i t )  =  t '2 ( t  +  t i t ) +  ( — ^ A23r23 — f — 1  Ai2r i2 ( t )  (3.95)
\ m 2 /  \ m 2 J
1*3 (t +  tit) =  r'3 (t +  tit) — f — ^ A23r23 ( t ) . (3.96)
\ r r i 3 J
Therefore, we can also write:
ri 2 ( t  +  t i t )  =  r i 2 ( t  +  t i t )  +  f  —-----^ Ai2 Fi2 (t )  —  ( — ^ A23 r 2 3  (t )  (3.97)
\ m 1+ m 2/  \ m 2)
f23 ( t  + t i t )  =  ( t  + t i t )  —  f — ^ Ai2r i2 (t )  +  ( ---------1 \  A23r23 ( t ) . (3.98)
\ m 2J \ m 2 + m 3J
The next step is to take the square modulus of both sides and apply the con­
straints:
Ir i2 ( t  +  t i t ) | 2 =  |ri2 (t) |2 =  d \ 2 (3.99)
| r 2 3  (t + <5^ ) | 2 =  |r23(t)|2 =  4 5 (3-100)
which yields a pair of quadratic equations in A12 and A23. These equations are 
solved iteratively to determine the multipliers, which are then used to correct
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the atomic positions. This method can also be extended to include bond angle 
constraints, for example by fixing the H-H separation in the water molecule.72
For large molecules such as proteins, the number of constraints is significant 
and these constraints have to be evaluated cyclically. Each constraint is calcu­
lated individually for one iteration and the process is repeated until all of the 
constraints are satisfied, to within some designated level of tolerance. This ap­
proach is referred to as the SHAKE algorithm226,227 and is most easily applied to 
the Verlet integration method,72 although it has been implemented in other inte­
gration schemes.228 A similar algorithm, implemented in explicit-velocity schemes 
such as the velocity Verlet or Beeman algorithms, is called R A T T L E .229 For ex­
ample, in the velocity Verlet scheme, as described in section 3.6.3.3, the first 
stage of the integration involves calculating the positions at time t +  St and the 
half-step velocities with the constraint forces:
r, (f +  St) =  r ' (( +  St) + i f — )  G “ (t) (3.101)
2 y 771, J
v, ( t  +  1 f t )  = y [ ( t  + 1 f t )  +  1 ( ~ - ^ )  G “ ( t ) , (3.102)
and the second stage involves completing the velocity propagation using:
Vj (t +  St) = (t +  St) +  — f — ^ G “ (t +  S t ) . (3.103)
1 \ r r i i j
R A T T L E 229 is the algorithm used in this work to constrain the bond lengths 
during the MD simulations.
3.6.5.2 Tem perature and Pressure Constraints
Berendsen et al. 2 3 0 described a method for performing MD with coupling to an 
external bath at constant temperature and pressure. The temperature coupling
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essentially involves scaling the atomic velocities at each time step from v to Av, 
where A is given by:
where Tp is the temperature coupling parameter, with dimensions of time, T  is 
the instantaneous temperature and To is the desired reference temperature. The
The temperature coupling parameter, t t ,  controls the strength of the coupling. 
If t t  is large, the coupling is weak and the temperature is perturbed slowly by 
the velocity scaling and vice versa. This perturbation acts like a frictional force, 
reducing the temperature if the system temperature is too high. Similarly, if the 
system temperature is too low, the coupling scales the velocities such that the 
temperature increases towards the reference temperature.68
A similar approach is used to maintain constant pressure by coupling to an 
external bath. The scaling is performed on the coordinates and the dimensions, 
L, of the simulation box: r scales to fir and L is scaled to //L, where fi is given
where (3 is the isothermal compressibility, rp is the pressure coupling parameter, 
P  is the instantaneous pressure and Po is the desired reference pressure. The 
coupling parameter rp again has dimensions of time and controls the strength of 
the pressure coupling in the same way as t t  controls the temperature coupling.68
(3.104)
change in temperature per time step can be set as (T° T)<5t, which gives:
(3.105)
by:
(3.106)
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An equivalent expression for fj, is:.230
l - ^ ( F o - P )
Tp
(3.107)
This method of coupling to an external bath is the basis of the temperature and 
pressure controls used in the MD simulations described in this work. This method 
can be used in conjunction with geometric constraint methods such as SHAKE 
or R A T TL E.230
Chapter 4
M ethods
4.1 Mdm2 with p53-derived peptides
4.1.1 A m ino A cid Sequences
The atomic coordinates of the complex formed between X. Laevis Mdm2 
(xMdm2) and an 11-residue peptide derived from p535 were obtained in Protein 
Data Bank (PDB) format from the Research Collaboratory for Structural Bioin­
formatics (RCSB) database.2 The atomic coordinates were also obtained for the 
complex formed between human Mdm2 (hMdm2) and a 13-residue p53-derived 
peptide.5 These PDB files were converted to T IN K E R 211 Cartesian coordinate 
files. Any histidine residues were uncharged to reflect the most likely protonation 
state at physiological pH. The amino acid sequences for xMdm2, hMdm2 and the 
p53-derived peptides are given in Table 4.1. The A M BER force field was used 
with the parm94 parameters of Cornell et al.74
91
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x M d m 2 — p53
P ro te in EKLVQPTPLLLSLLKSAGAQKETFTMKEVIYHLGQYIMAKQLYDEKQQHIVHCSNDPLGELFGVQEFSVKEPRRLYAMISRNLVSANV
P ep tid e ETFSDLWKLLP
h M d m 2 — p5 3
P ro te in ETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLW
Pep tide ETFSDLWKLLPEN
Table 4.1: Amino acid sequences for X. Laevis and human Mdm2 and the p53-derived 
peptides used in this work.5
Throughout this work, the term peptide is used to describe the smaller of the 
interacting polypeptides. In this case, the p53-derived peptides consist of the
11-residue (17-27) stretch and the 13-residue (17-29) stretch of human p53, re­
spectively. The term protein is used to describe the larger of the two interacting 
biomolecules, with xMdm2 consisting of residues 21-108 of the X. Laevis enzyme 
and hMdm2 consisting of residues 25-109 of the human enzyme. The term com­
plex refers to the complex formed between the protein and the peptide in each 
case. The structure of the xMdm2-p53 complex used in this work is given in 
Figure 4.1.
4.1.2 Com parison w ith  O ther Studies
The Mdm2-p53 system was chosen to test the methodology in its present 
implementation as an ideal previous study was available for comparison. Massova 
and Kollman3 inserted a 12-residue peptide, consisting of residues 16-27 of human 
p53, into the binding sites of both xMdm2 and hMdm2. The proteins consisted
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Figure 4.1: Structure of the complex formed between X. Laevis Mdm2 and a stretch 
of the tumour suppressor peptide p53.
of the same residues as those described in this work. The peptide sequence 
(QETFSDLWKLLP) is similar to those used in this work. The differences in the 
number of residues and net charge of each of the complex, protein and peptide 
structures are summarised in Table 4.2.
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x M d m 2 —p 5 3
C om plex P ro te in P ep tide
T h is  W ork M /K T h is W ork M /K T his W ork M /K
R esidues 99 100 88 88 11 12
C harge /  e 0 0 +  1 +  1 - 1 - 1
h M d m 2 —p 5 3
C om plex P ro te in P ep tide
T h is  W ork M /K T h is W ork M /K T h is W ork M /K
R esidues 98 97 85 85 13 12
C harge  /  e + 3 + 4 + 5 + 5 - 2 - 1
Table 4.2: Comparison of the number of residues and net charge of each of the complex, 
protein and peptide structures for the X. Laevis and human Mdm2-p53 systems as used 
here and in the work of Massova and Kollman.3
4.2 IQN17 with D- and C-peptides
4.2.1 A m ino A cid Sequences
The atomic coordinates of the complex formed between IQN17 and DIO-pl 
were obtained in PDB format, as before. Due to the unnatural, mirror image 
nature of the D-peptide, it was not possible to convert the PDB file directly 
into a T IN K E R  Cartesian coordinate file. The PDB file was edited in such a 
way that the D-amino acids were changed to L-amino acids and the coordinates 
were inverted through the origin. Thus the conversion to T IN K E R  Cartesian 
coordinates could be carried out to give an L-peptide version of the desired pep­
tide with coordinates that were inverted from the desired D-peptide. Another 
inversion through the origin was performed on the T I N K E R  file to give the orig-
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IQN17 RMKGIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARIL
DIO-pl GACEARHREVAVLCAA
C12 (MT)WEEWDREIENYT
Table 4.3: Amino acid sequences for IQN17, D10-pl21 and C12.40 The residues in 
brackets are those that complete the C14 sequence.
inal complex, retaining the recognition of the amino acid types and hence the 
appropriate atom types. The A M BER force field was used with the parm94 
parameters of Cornell et al.74 The structure of the IQN17-D10-pl complex used 
in this work is given in Figure 4.2.
The atomic coordinates of the complex formed between IQN17 and Cl41inkmid 
(Cl41m) were also obtained in PDB format, as before. A twelve residue stretch 
of C14 is used throughout this work and referred to as C12. C121m is bridged 
at the same residues as C141m. T IN K E R  could not assign appropriate atom 
types to the non-peptide diaminoalkane bridging atoms of the IQN17-Cl21m 
and IQN17-C12unlm complexes meaning that no partial charge parameters were 
available for those atoms. These parameters were assigned by hand by considering 
similar functional groups that were already parameterised within the T IN K E R  
implementation of the A M B ER 74 force field and making adjustments based on 
the electronegativity of each of the atoms. The formal net charge for the peptide 
was maintained throughout. The assigned partial charges and the atom types 
that were used as the basis of these assignments are given in Table 4.4. Although 
these partial charges may differ from their “correct” values to a certain extent, 
they are not expected to significantly affect the outcome of the simulations, since
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Atom Electronegativity Partial Charge /  e Atom Partial Charge /  e
N-bound C 2.55 0.3309 Glutam ine HE2 0.4251
H of N-bound C 2.20 0.0236 Isoleucine HG1 0.0236
sp 2 bridge C 2.55 -0 .0 4 3 0 Isoleucine CGI -0 .0 4 3 0
H of sp 2 bridge C 2.20 0.0236 Isoleucine HG1 0.0236
G lutam ine N 3.07 -0 .9 0 0 0 Glutam ine NE2 -0 .9 4 0 7
sp 2 broken bridge C 2.55 -0 .0 3 6 7 Isoleucine CGI -0 .0 4 3 0
H of sp2 broken bridge C 2.20 0.0236 Isoleucine HG1 0.0236
sp3 broken bridge C 2.55 -0 .0 6 0 0 Isoleucine CD1 -0 .0 6 6 0
H of sp 3 broken bridge C 2.20 0.0186 Isoleucine H D l 0.0186
Table 4.4: Partial charges for non-peptide bridging atoms in C121inkmid and
C 1 2 unlinkmid. The peptide atom types that were used as the basis of the assign­
ment of these partial carges are also given. The electronegativity values are given 
according to the Pauling scale. 2 3 1
the bridging atoms are not directly involved in the binding interface. Clearly, 
such a method of assigning partial charges by hand should only be used for a 
small number of atoms in a system. The total number of atoms, residues and 
the net charge of each of the complex, protein and peptide systems are given in 
Table 4.5. The structure of the IQN17-C121m complex is given in Figure 4.3.
4.2.2 The IQ N 17 H ydrophobic Pocket
As discussed in Chapter 1, the fusogenic conformation of gp41 consists of C- 
terminal helices bound to the trimeric N-terminal core along hydrophobic grooves 
with hydrophobic pockets at one end.12,21,25,35 Each of the three hydrophobic
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Figure 4.2: Structure of the complex formed between one helix of IQN17 and DIO-pl.
Figure 4.3: Structure of the complex formed between one IQN17 helix and C121inkmid 
(C 121m) . 4 0  The diaminoalkane linker is shown in red.
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IQ N 17/D 10-p l
Complex Protein Peptide
Atoms 1050 808 242
Residues 61 45 16
Charge /  e + 4 + 4 0
IQN17/C121m
Complex Protein Peptide
Atoms 1040 808 232
Residues 57 45 12
Charge /  e + 2 + 4 - 2
IQ N 17/C 12unlm
Complex Protein Peptide
Atoms 1045 808 237
Residues 57 45 12
Charge /  e + 2 + 4 - 2
Table 4.5: Numbers of atoms and residues and net charge of the complex, protein and 
peptide in the complexes between IQN17 and the D- and C-peptides used in this work.
pockets on the surface of the N-terminal core consists of residues from two ad­
jacent N36 helices, meaning that not all of the eleven pocket-forming residues 
are present in the monomeric IQN17 systems studied in this work. The residues 
Leu-565, Leu-568, Thr-569, Trp-571, Gly-572, Ile-573 and Leu-576 are all part of 
the IQN17 helix studied here, while the residues Leu-566, Val-570, Lys-574 and 
Gln-577 are all contributed by the adjacent helix. The hydrophobic pocket region 
of the IQN17-D10-pl complex is shown in detail in Figure 4.4, illustrating the 
positions of the missing pocket residues. The pocket region of the IQN17-C121m 
complex is given in Figure 4.5, which also demonstrates the different binding
4.2 IQ N 17 w ith  D- and C -peptides
Figure 4.4: Structure of the hydrophobic pocket region in the complex formed between 
IQN17 and DIO-pl. The residues of DIO-pl that make intimate contact with the full 
hydrophobic pocket are shown in red, illustrating where the missing pocket residues 
would be foUnd.
modes of the D-peptide and C-peptide to the hydrophobic pocket.
Clearly, it would be desirable to study the trimeric core bound to three D- 
peptide or C-peptide inhibitors but valuable insights can still be gained by study­
ing the interactions present in a monomer-inhibitor system. Scaling the system 
up to the trirner would not only increase the number of polypeptide atoms three­
fold, it would also necessitate the use of significantly larger solvent boxes. Since 
a large percentage of the simulation time is already spent calculating trajectories 
of solvent molecules, the computational cost of such calculations is prohibitive 
here.
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Figure 4.5: Structure of the hydrophobic pocket region in the complex formed between 
IQN17 and C121m. The residues of C121m that make intimate contact with the full 
hydrophobic pocket are shown in red.
4 .3  M o l e c u l a r  D y n a m i c s  S i m u l a t i o n s
4 .3 .1  P rep arin g  th e  In itia l S ystem
The first stage in preparing the molecular system for the MD simulation was 
to create a minimised box of T IP 3 P 81 water molecules into which the protein- 
peptide system could be solvated. The size of the water box was chosen to ensure 
that the whole complex was well solvated but care was taken to use the smallest 
number of water molecules possible, in order to limit the computational cost. The 
complex was solvated in the water box and any water molecules that overlapped
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System Dimensions of Solvent Molecules Number of Total Number
Solvent Box Before After protein atoms of Atoms
xM dm 2-p53 50A x 50A x 50A 2600 2251 1626 8379
hM dm2-p53 50A x 50A x 50A 2600 2238 1670 8384
IQ N 17-D 10-pl 70A x 33A x 33A 2400 2083 1050 7299
IQN 17-C121inkmid 75A x 33A x 33A 2600 2293 1040 7919
IQN17-C12unlinkm id 75A x 33A x 33A 2600 2287 1045 7906
Table 4.6: Dimensions of solvent boxes used in the MD simulations described in this 
work, total number of solvent molecules before and after insertion of the complex and 
total number of atoms in the simulations.
with polypeptide atoms were removed. The solvated complex was then partially 
minimised (to a root mean square (RMS) gradient of 1.0 kcal mol- 1/A) using 
a conjugate gradient minimisation algorithm within the T IN K E R  package, in 
order to relieve any unfavourable atomic overlaps within the system that were 
still present. The dimensions of the solvent box used, as well as the number of 
atoms before and after insertion of the complex, are given in Table 4.6.
4.3.2 Sim ulation C onditions
Each of the MD simulations was carried out using a modified Beeman algo­
rithm217 with time steps of 2.0 fs. Bond lengths were constrained to ideal values 
by default using R A TTL E 229 for all bonds involving hydrogen atoms. A cutoff 
with a polynomial switching function was used for van der Waals interactions, 
gradually reducing the interactions to zero between the inner and outer cutoffs:
7.2 A and 8.0 A, respectively. Periodic boundary conditions (PBC) 1 were used
4.3 M olecular Dynam ics Sim ulations 102
Molecular System Data-gathering Phase /  ps
xM dm 2-p53 400
hM dm2-p53 400
IQ N 17/D 10-p l 600
IQN17/C121inkmid 400
IQ N17/C12unlinkm id 350
Table 4.7: Duration /  ps of each of the data-gathering phases for the different molecular 
systems studied in this work.
throughout the simulation. Particle mesh Ewald summation223 was used for ef­
ficient treatment of long-range electrostatic interactions. Constant pressure and 
temperature of 1.0 atm and 300 K, respectively, were maintained by coupling to 
external baths using the method of Berendsen et al. 2 3 0  Both the pressure and 
temperature coupling parameters were 0.2 ps. The system was gradually heated 
to 300 K over 15 ps, allowing 5 ps per 100 K temperature increase. The system 
was then allowed to equilibrate at 300 K for a further 25 ps before the data- 
gathering phase of the simulation commenced. During the data-gathering phase 
the atomic structure of the complex was saved after every 1.0 ps of simulation 
time. The length of the data-gathering phase for each molecular system is given 
in Table 4.7.
4.3.3 A nalysing the Trajectory
The code MDANAL was developed in this laboratory to analyse the MD 
trajectory. The code takes each of the saved complex structures from the data- 
gathering phase of the trajectory, removes the explicit T IP 3 P 81 water molecules
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and calculates the molecular mechanical (MM) and continuum solvation (GBSA) 
energy for each of the complex, protein and peptide systems in the conforma­
tion found in that particular snapshot. This is repeated for all of the snapshots 
and average MM-GBSA energies and their components for each species are de­
termined for the data-gathering phase of the simulation. These absolute energy 
values are then used to determine the binding energy, A G s u b t o t a i -  The data are 
also analysed to yield standard deviations for the energy components in order to 
estimate the reliability of the data and to give insights into the stability of the 
MD simulation.
The program M DANAL also systematically mutates each of the peptide 
residues to alanine, except for those residues for which mutation is not desirable 
or appropriate. The sidechain atoms of the residue to be mutated are removed, 
with the exception of C7, C@ and its hydrogen atoms. C7 is then changed to 
a third /3-hydrogen and all of the remaining atoms of the residue are changed 
into their alanine equivalent. In general, this leaves the C/3-H bond distance too 
long, which has an effect when calculating the absolute energy and components 
for the complex or peptide system in question. However, since the effect on the 
binding energy due to changes in internal energy are defined as zero if the com­
plex, protein and peptide structures are taken from the same snapshot of the MD 
trajectory, as they are in this work, the only effect observed is in the non-bonded 
van der Waals and electrostatic contributions to the binding energy. The differ­
ence in energy for the peptide is balanced by a corresponding difference in the 
complex energy and it is therefore reasonable to neglect the effect on the binding 
energy caused by this single bond length change. This also makes the reasonable
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assumption that the continuum solvation energy is not significantly affected by 
this minor bond length difference.
4.4 Estim ation of Entropy
4.4.1 M inim isation o f the System
In order to perform the normal mode analysis of the complex, protein and 
peptide structures for each molecular system, it is necessary to perform an en­
ergy minimisation. It is desirable to find minima that are as close as possible to 
the observed X-ray structure. This can be achieved by performing the minimisa­
tion using a distance-dependent dielectric constant to mimic the effect of solvent 
screening.3,174 In this work, this effect is achieved by minimising the required 
structure with the continuum solvation energy term activated. For comparison 
purposes, the minimisations are also performed without the solvent term. The 
root mean square (RMS) deviations in the positions of the a-carbons relative 
to the X-ray structure for minimisations performed both with and without the 
continuum solvation term applied are given in Table 4.8. These were calculated 
using the code CA LPH A , developed in this laboratory to identify and list the a- 
carbons, and the S U P E R P O S E  program in T IN K ER , which superimpose two 
molecular structures and calculates the RMSD in the positions of the specified 
atoms for the best fit. This method is also used later for analysing the stability 
of the MD trajectories.
The calculations are expensive and it is important to ensure that there are
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System
C o m p le x P r o te in P e p t id e
No Solvent Solvent No Solvent Solvent No Solvent Solvent
xM dm 2-p53 1.79 1.73 2.33 1.75 3.83 0.57
hM dm2-p53 0.93 0.50 1.44 0.73 3.87 0.86
IQ N 17-D 10-pl 3.61 1.58 4.46 1.39 2.16 0.61
IQN17-C121m 3.38 1.56 4.46 1.39 1.11 0.55
IQN17-C12unlm 4.03 1.65 4.46 1.39 1.44 0.66
Table 4.8: CQ RMSD /  A, relative to the X-ray crystal structure, for each of the 
complex, protein and peptide of each molecular system following minimisation. The 
minimisations were carried out both without and with the continuum solvation energy 
term activated to mimic the effect of solvent screening.
six zero frequencies and no imaginary frequencies as problems arise in the calcu­
lation of the vibrational partition function and the contribution to the entropy 
from each mode. Since there are already significant approximations inherent 
in the method used here in estimating the entropy, the minimisation and nor­
mal mode analysis are performed once for IQN17 and the same data used for 
its complex with DIO-pl, Cl21inkmid and C l2unlinkmid. As can be seen, the 
structures minimised with the continuum solvation term applied are significantly 
closer to the X-ray configurations than those obtained without solvation. This is 
particularly pronounced for those systems that are not electronically neutral.
4.4.2 Entropy Codes: V IB E N T  and R O T R A N SE N T
The program V IB EN T was developed in this laboratory to calculate the vi­
brational component of the entropy of a molecular system. Existing algorithms
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within the T IN K E R 211 distribution are used to construct and diagonalise the 
Hessian matrix. The vibrational contribution to the entropy is determined us­
ing the vibrational frequencies, given by the non-zero eigenvalues of the Hessian 
matrix, as in Equation 3.34.
The program R O TR A N SEN T was developed in this laboratory to calculate 
the translational and rotational components of the entropy of a molecular system. 
Again, existing algorithms within T IN K E R 211 are used to determine the total 
mass of the molecule and the moments of inertia about its principal axes. These 
are used to determine the translational and rotational partition functions of the 
molecule, as shown in Equations 3.27 and 3.31. These are then used to determine 
the contributions to the entropy due to translation and rotation using Equations 
3.29 and 3.33, respectively. The FO RTRA N  codes for R O T R A N SE N T and 
V IB E N T  are given in Appendix B.
4.4.3 Testing the Codes: Propane
The codes developed to determine the entropy of the polypeptides were tested 
on the propane molecule. The translational and rotational components of the 
entropy only depend on the total mass of the molecule and its moments of 
inertia about the principal axes, and are calculated here using the code RO­
TR A N SEN T. The most difficult contribution to evaluate is the vibrational com­
ponent of the entropy, as all of the vibrational frequencies must be known. Table 
4.9 gives the vibrational frequencies in cm-1 as assigned by Herzberg232 based 
on the infrared spectrum of Wu and Barker.235 Only twenty-five frequencies are 
given by Herzberg232 and the two lowest frequency vibrations, the internal tor-
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Herzberg232 Pitzer233 T his Work
Ui /  cm -1 i>i /  cm -1 Ui /  cm 1 Contribution /  kcal mol 1
180 K 231 K 300 K
2980 2980 2969
2968 2970 2968
2968 2968 2967
2967 2968 2966
2967 2966 2944
2960 2960 2896
2903 2942 2875
2885 2914 2870
1470 1470 1472 0.0005 0.0041
1468 1468 1460 0.0005 0.0043
1465 1460 1459 0.0005 0.0044
1451 1450 1453 0.0005 0.0045
1451 1450 1450 0.0006 0.0045
1375 1375 1439 0.0006 0.0047
1370 1370 1395 0.0001 0.0007 0.0057
1278 1338 1355 0.0001 0.0009 0.0067
1179 1278 1220 0.0002 0.0020 0.0118
1152 1179 1066 0.0007 0.0046 0.0220
1152 1155 1061 0.0007 0.0047 0.0225
1053 1053 1037 0.0008 0.0054 0.0248
922 940 961 0.0014 0.0081 0.0336
870 922 938 0.0017 0.0091 0.0368
748 868 851 0.0031 0.0145 0.0520
375 748 803 0.0043 0.0186 0.0627
333 375 379 0.0726 0.1581 0.3152
283 251 0.1635 0.2984 0.5210
202 208 0.2141 0.3706 0.6212
Table 4.9: Vibrational frequencies /  cm - 1  of propane as assigned by Herzberg2 3 2  and 
Pitzer , 2 3 3  and as determined by the code VIBENT in this work. The contribution of 
each frequency to the entropy, T S V,b /  kcal mol- 1  is also given at various temperatures.
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Figure 4.6: A stick representation of the three-dimensional structure of the propane 
molecule. Carbon atoms are shown in white and hydrogen atoms in blue. The two 
torsional modes referred to in the text involve rotations of the CH3  groups about the 
C-C bonds. In one mode, the CH3  groups both rotate in the same direction and in the 
other mode they rotate in opposite directions.
siona! motions of the molecule, are not included. Pitzer233 gives largely similar 
vibrational frequencies and uses the experimental entropy measurements of Kemp 
and Egan234 to derive the torsional frequencies at 202 and 283 cm-1. The struc­
ture of propane and a description of the torsional motions are given in Figure 
4.6. The contribution to the vibrational entropy due to each normal mode are 
given at 180 K, 231 K and 300 K, as determined by the code VIBENT.
Table 4.10 gives the contributions to the total entropy of propane. The code
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Contribution
This Work Pitzer233 Kemp234
180 K 231 K 180 K 231 K 180 K 231 K
T Strans +  TSrot 9.83 13.07 9.82 13.07
TSVjb excl. torsions0 0.09 0.24 0.09 0.24
TSV^  incl. torsions** 0.45 0.87 0.44 0.90
T S vib incl. torsions0 0.46 0.87
TStot 10.30 13.98 10.27 13.97
Table 4.10: Entropic contributions /  kcal mol- 1  of propane due to translation, rota­
tion and vibrations based on various vibrational frequencies. All contributions to the 
entropy were determined here using the program VIBENT based on the vibrational 
frequencies as follows. a Vibrational frequencies as assigned by Pitzer . 2 3 3  The two 
lowest frequency torsional vibrations are not included. b Vibrational frequencies as 
assigned by Pitzer2 3 3  but including the derived torsional frequencies at 202 and 283 
cm-1 . c Vibrational frequencies determined in this work by the program VIBENT.
V IB E N T was tested using the vibrational frequencies given by Pitzer233 to cal­
culate the vibrational entropy. Excellent agreement is seen between the two sets 
of values, as would be expected. The code V IB EN T was also used to determine 
the vibrational frequencies and excellent agreement is seen with experiment for 
the total entropy of propane. Pitzer233 derived the torsional frequencies from 
the entropy difference between the experimental value234 and his total entropy 
excluding internal rotations. The contribution to the vibrational entropy, T S Vjb 
due to the two torsional modes was 0.36 kcal mol-1 at 180 K and 0.67 kcal mol-1 
at 231 K. In this work, the contribution due to the torsional modes was found 
to be 0.38 kcal mol-1 at 180 K and 0.67 kcal mol-1 at 231 K. This shows excel-
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lent agreement for the determination of the vibrational frequencies of the vital 
torsional modes and their contributions to the vibrational entropy.
Part III 
R esults and Discussion
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Chapter 5
M dm2—p53
As discussed in Chapter 1, the interactions between the oncoprotein Mdm2 and 
the tumour suppressor peptide p53 are of significant interest in cancer research. 
The interactions between X. Laevis and human Mdm2 (referred to as xMdm2 
and hMdm2, respectively) have been investigated in this work and the results are 
given below.
5.1 X .  L a e v i s  M dm2—p53 Interaction
5.1.1 B inding Energy
Figure 5.1 shows a plot of the root mean square deviation (RMSD) in the po­
sitions of the a-carbons in the xMdm2-p53 complex, relative to the X-ray crystal 
structure, over the course of the data-gathering phase of the MD simulation. The 
observed RMS deviations do not fluctuate greatly, suggesting that the MD sim­
ulation is stable over the timescale of interest here. The average value for Ca
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Figure 5.1: Root mean square deviation (RMSD) of the a-carbons in the xMdm2-p53 
complex, relative to the X-ray crystal structure, during the data-gathering phase of the 
molecular dynamics trajectory.
RMSD is 0.78 A and the standard deviation is 0.1 A.
The absolute energy values and components for each of the complex, protein 
and peptide systems are given in Table 5.1. The term ( 7 subtotai is simply the sum 
of Egas and Gsoivation and is used throughout this work as the main criterion for 
calculating changes in binding energy. This relies on the reasonable assumption 
that the entropic contribution to the binding energy is the same for mutated 
and wild type (unmutated) peptides. The entropy and its components are given 
in Table 5.2 for complex, protein and peptide structures minimised both with
5.1 X. Laevis M dm 2-p53 Interaction 114
Contribution
C o m p le x P r o te in P e p t id e
Mean S.D. M /K Mean S.D. M /K Mean S.D. M /K
^ 'e le c t r o s ta t i c -2 8 1 5 .9 43.8 -2 9 5 1 .6 -2 5 1 2 .5 33.3 -2 5 8 4 .8 -1 4 4 .6 9.8 -2 6 5 .5
Ev dW -4 0 0 .3 10.9 -3 9 9 .0 -3 3 2 .9 10.1 -3 3 1 .0 -1 4 .5 3.0 -1 2 .8
^ in t e r n a l 1920.5 31.8 1721.3 1708.6 29.6 1502.0 211.9 10.4 219.3
i ig a s -1 2 9 5 .7 46.8 -1 6 2 9 .3 -1 1 3 6 .8 42.5 -1 4 1 3 .8 52.8 14.1 -5 9 .0
O ’p o la r -1 4 6 8 .8 44.3 -1 6 5 3 .6 -1 3 0 7 .8 30.8 -1 5 0 9 .3 -3 5 1 .3 9.2 -2 7 5 .3
O n o n  —p o la r 46.1 0.8 35.5 43.1 0.7 32.7 11.7 0.4 10.2
^ s u b t o t a l -2 7 1 8 .3 35.6 -3 2 4 7 .3 -2 4 0 1 .5 33.7 -2 8 9 0 .4 -2 8 6 .8 10.1 -3 2 4 .1
Table 5.1: Absolute energy and components /  kcal mol- 1  for the xMdm2-p53 complex. 
Structures have been minimised with and without the application of the continuum 
solvation term. The columns marked M/K refer to the work of Massova and Kollman. 3
and without the continuum solvation term applied. The binding free energy, 
AGbinding, and its components are given in Table 5.3. The given entropic contri­
bution to the binding free energy, —TAS, is for structures minimised with the 
implicit solvent term applied. Where possible, the corresponding values from the 
work of Massova and Kollman3 are given for comparison.
There are differences between the absolute energy values determined here for 
the complex, protein and peptide systems and those given by Massova and Koll­
man.3 However, it is interesting to note that despite these differences, the cal­
culated binding energy is very similar for the two studies. In particular, there 
are differences between the absolute internal energy values, External, for the two 
studies but, since the complex, protein and peptide structures come from the 
same snapshot of the MD trajectory, A-External is zero by definition. The stan­
dard deviations in the absolute energy components are comparable for the two
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C o m p le x P r o te in P e p t id e
No Solvent Solvent M /K No Solvent Solvent M /K No Solvent Solvent M /K
T S vib 1066.9 1142.1 951.0 1013.0 122.3 134.6
T  S r o t 15.6 15.6 15.5 15.5 12.4 12.4
T  S t r a n s 16.2 16.2 16.1 16.1 14.3 14.3
r s t o t 1098.7 1173.9 1198.5 982.5 1044.5 1041.9 148.9 161.3 185.0
Table 5.2: Entropy and components /  kcal mol 1 for the xMdm2-p53 complex. The 
columns marked M/K refer to the work of Massova and Kollman . 3
Contribution Mean S.D. M /K
^ • ^ e le c t r o s ta t i c -1 5 8 .7 25.9 -1 0 1 .3
A E vdw -5 2 .9 3.6 -5 5 .2
A E g n s -2 1 1 .6 27.3 -1 5 5 .6
A ^ p o l a r 190.2 26.1 131.0
^ - ^ e l e c t r o s t a t i c  4" A G  p o la r 31.5 3.5 29.7
A G  n o n  —p o la r - 8 .6 0.4 - 7 .8
A C » s u b to ta l -3 0 .0 3.5 -3 2 .9
— T A S  (solvent) 31.9 n /a 28.4
A ^ b i n d i n g 1.9 n /a - 4 .5
Table 5.3: Binding free energy and components /  kcal mol 1 for the xMdm2-p53 
complex. The column marked M/K refers to the work of Massova and Kollman. 3
studies.
There are also differences between the absolute values of Electrostatic and Gpdar 
for the two studies. In this work, the Eelectrostatic values are less negative for each 
of the complex, protein and peptide systems. This has the effect that for E gas, 
the value determined here is of opposite sign to the literature value, although the
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zero in energy is effectively arbitrary and the discrepancy in sign has no particular 
physical significance. It is worth noting that the molecular systems studied here 
and by Massova and Kollman3 differ in the number of amino acid residues in 
the p53-derived peptide. These differences have been described in Chapter 4 and 
are illustrated in Table 4.2. There is a corresponding decrease in the magnitude 
of the Gpdar values for the protein and peptide systems in this study compared 
to the work of Massova and Kollman.3 However, the value of Gpoiar for the p53- 
derived peptide is determined to be more negative than that reported by Massova 
and Kollman.3 This may be partly due to the fact that the N-terminal residue 
of the p53-derived peptide used here, Glu-1 (Glu-17 as labelled by Massova and 
Kollman3), is a charged residue that will be highly exposed to the continuum 
solvent giving a large Gpoiar- This compares with the polar but uncharged N- 
terminal glutamine of the 12-residue p53-derived peptide used by Massova and 
Kollman.3 Also, the two studies use different methods to evaluate the polar 
contribution to the solvation free energy. This study uses the Generalized Born 
method while Massova and Kollman3 use the Poisson-Boltzmann method.
Massova and Kollman3 estimated the entropy of each of the complex, protein 
and peptide systems using normal mode analysis. The structures were min­
imised using a distance-dependent dielectric constant to mimic the effect of sol­
vent screening and obtain minimum energy structures similar to those seen in the 
X-ray crystallographic structure. In this work this was achieved by minimising 
the structures both with and without the continuum solvation energy term ap­
plied. When minimised with the application of the solvent term, the structure is 
found to deviate from the crystal structure by significantly less, as shown previ­
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ously in Table 4.8. The differences in CQ RMSD for the unsolvated and solvated 
structures are more pronounced for the charged protein and peptide systems, 
whereas the difference is small for the electronically neutral complex. The ab­
solute entropy values for the solvent-minimised structure show good agreement 
with the values given by Massova and Kollman.3
The entropic contribution to the binding free energy, —T A S ,  is 32.8 kcal 
mol-1 for the unsolvated structure and 31.9 kcal mol-1 for the solvated structure 
at 300K. This compares with a value of 28-36 kcal mol-1 given by Massova and 
Kollman.3 This value depended on how well the structure was minimised before 
the normal mode analysis was performed. In their determination of the binding 
free energy, A  G r in d in g , they used a value of 28.4 kcal mol-1.
Despite the differences in the absolute energy values for the complex, protein 
and peptide structures, the calculated binding energy, excluding entropic effects, 
AGsubtotai, is very similar for the two studies considering the differences in the 
p53-derived peptides used in each case. The changes in electrostatic energy and 
polar solvation energy upon binding, A £ ’eiectrostatic and A G poiar, are both found 
to be larger in magnitude here than the values determined by Massova and Koll­
man.3 These two contributions to the binding energy have opposing effects, with 
A  ^ electrosta tic  favouring binding and A G poiar opposing complex formation as polar 
residues are shielded from the continuum solvent in the protein-peptide interface. 
Both of these energy contributions fluctuate considerably over the timescale of 
the MD simulation, as indicated by their large standard deviations. However, 
these fluctuations tend to cancel each other out and the sum of the two terms 
remains reasonably constant. This is reflected by the much smaller standard de-
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Figure 5.2: Contributions to the binding energy of the xMdm2-p53 complex due to 
electrostatic energy, polar solvation energy and the net effect of these two terms during 
the data-gathering phase of the molecular dynamics trajectory.
viation for the net term and is also illustrated in Figure 5.2. This relationship is 
further illustrated in Figure 5.3, a plot of F’eiectroetatic against Gpoiar, which shows 
the strong correlation between the two contributions. The calculated correlation 
coefficient is —0.99, confirming the linear relationship.
The difference between A(7subtotai for this work and that of Massova and Koll­
man3 is 2.9 kcal mol-1. This compares with a difference of 2.3 kcal mol-1 in 
AEydw for the two studies. In this work there is one less residue in contact with 
the binding site and the corresponding reduction in the number of hydrophobic
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Figure 5.3: Plot of A .E eiectrostatiC against A G p o ia ,. for the xMdm2-p53 complex. The 
correlation coefficient is —0.99.
van der Waals interactions leads to this difference in A Evdw-
The calculated value of 1.9 kcal mol-1 for the free energy of binding, AGbinding, 
compares to the value of —4.5 kcal mol-1 determined by Massova and Kollman.3 
The experimentally determined binding free energy of —6.6 to —7.8 kcal mol-1 
is based on the reported IC50 value of 2-14 ^M .6 Although the small, positive 
value for AGbinding is of some concern, it is not overly surprising given the ap­
proximations inherent in the determination of the entropic contribution. There is 
good agreement between this work and the previous study3 for AGsubtotai, which 
will be used as the main criterion for determination of changes in binding energy 
upon mutation of the peptide residues to alanine.
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5.1.2 C om putational A lanine Scanning
Each of the residues in the p53-derived peptide, apart from Pro-11 (Pro-27), 
has been systematically mutated to alanine and the resulting changes in the 
mean binding energy and its components are given in Table 5.4. The changes 
in binding energy, A A G su b to ta i , are shown for the mutation of each residue in 
Figure 5.4. This method relies on the assumption that only local conformational 
change result from each mutation. This assumption was examined by Massova 
and Kollman3 by carrying out a separate simulation with the Trp23Ala mutation 
in the p53-derived peptide. They found that the binding energies, A G su b to ta i ,  were 
nearly identical for the mutated and modified wild-type trajectories, justifying 
the assumption. Clearly, this assumption is not reasonable for the proline to 
alanine mutation. A negative value of AAGsubtotai indicates a mutation leading 
to less favourable binding of the p53-derived peptide to Mdm2, whereas a positive 
A A G Su b to ta i indicates a preference for alanine at that position.
Amino acid replacement experiments6 have identified the residues Phe-3, Trp- 
7 and Leu-10 (Phe-19, Trp-23 and Leu-26) as key to the binding between p53 
and Mdm2. The experiments, carried out on human Mdm2 with a 12-residue 
p53-derived peptide, found that no other amino acid could be substituted at 
these positions without increasing the IC50 at least threefold. The residue Leu-6 
(Leu-22) was also found to be highly selective, with only two other amino acids 
allowed without a threefold increase in I C 5 0 . The calculations of Massova and 
Kollman3 identified these residues as having large, negative values of A A G su b to ta i 
upon mutation to alanine, confirming them as key to the binding of p53 and 
Mdm2. These four residues are also found to have large, negative changes in
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M u ta t io n
G lu lA la T h r 2 A la P h e 3 A la
Contribution Mean SD M /K Mean SD M /K Mean SD M /K
A Aj£e]ectrostatic -3 8 .5 24.4 -6 6 .3 - 1 .4 1.0 - 1 .7 - 1 .4 0.6 - 0 .8
AAEvdW - 0 .5 0.6 - 0 .7 - 0 .4 0.2 - 0 .7 - 9 .0 0.9 1 00 00
AA iigas -3 8 .9 24.2 -6 7 .0 - 1 .8 1.2 - 2 .4 - 1 0 .4 1.0 - 9 .6
A A G po)ar 39.7 23.7 68.2 1.3 0.8 2.2 6.8 0.6 6.2
A A G non _ polar - 0 .1 0.1 -0 .1 0.01 0.0 0.0 - 0 .5 0.1 - 0 .3
A A G gubtotal 0.6 1.0 1.1 - 0 .5 0.5 - 0 .2 -4 .1 1.0 - 3 .7
S e r 4 A la A s p 5 A la L e u 6 A la
Contribution Mean SD M /K Mean SD M /K Mean SD M /K
A A £ electrostatic -0 .1 1.3 - 0 .2 -2 6 .1 3.6 -2 4 .2 -0 .1 0.3 0.1
AAJSvdw - 0 .4 0.2 - 0 .3 -0 .1 0.0 -0 .1 -3 .1 0.6 - 3 .8
A A £gas - 0 .5 1.3 - 0 .5 -2 6 .2 3.7 -2 4 .5 - 3 .2 0.7 - 3 .7
AAGpoUr 1.4 1.3 0.9 26.5 3.6 24.2 0.9 0.4 2.2
A A G non_ polar 0.0 0.0 -0 .1 0.0 0.0 0.0 - 0 .3 0.1 - 0 .2
A A G subtotal 0.9 0.4 0.3 0.3 0.1 - 0 .3 - 2 .6 0.6 - 1 .7
T r p 7 A la L y s8 A la L e u 9 A la
Contribution Mean SD M /K Mean SD M /K Mean SD M /K
AAEeiectrostatic - 4 .6 1.4 - 4 .8 24.0 3.4 33.1 -0 .1 0.1 -0 .1
A A E vdw -1 2 .1 1.3 -1 1 .7 - 0 .3 0.1 -0 .1 - 0 .3 0.4 - 0 .2
AAEgas -1 6 .7 1.4 -1 6 .5 23.7 3.4 33.0 - 0 .4 0.4 - 0 .4
A A G p0|ar 13.9 1.1 10.8 -2 3 .2 3.4 -33 .0 0.3 0.1 0.1
A A G non_ p0iar - 1 .0 0.1 - 0 .6 -0 .1 0.1 0.0 0.0 0.0 0.0
A A G subtotal - 3 .8 1.3 - 6 .3 0.4 0.1 0.0 - 0 .2 0.4 - 0 .3
L e u lO A la
Contribution Mean SD M /K
A A i?c)cctrostatic - 0 .3 0.2 - 0 .3
AAEydW -5 .4 0.7 - 3 .9
AAEgaa - 5 .7 0.8 - 4 .2
A AGpolar 4.0 0.5 2.7
A A G non —polar - 0 .3 0.1 0.0
A A G subtotal - 2 .0 0.8 - 1 .5
Table 5.4: Computational alanine scanning mutagenesis energy changes /  kcal mol-1 
for the xMdm2-p53 complex. The columns marked M/K refer to the work of Massova 
and Kollman.3
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Mutated Residue
Q 0.0
S - 1 .0
Figure 5.4: AAGsubtotal /  kcal mol-1 for the systematic mutation to alanine of each 
p53-derived peptide residue in the xMdm2-p53 complex. Residues marked in blue indi­
cate favourable mutations and residues marked in red indicate unfavourable mutations.
binding energy in the present work, as shown in Table 5.4 and Figure 5.4.
The bulky sidechains of each of these four residues are involved in hydrophobic 
van der Waals interactions with residues in the binding site of Mdm2 that are lost 
when the residue is mutated to alanine. This results in a large, negative A A £ vdW  
and opposes the mutation to alanine. There is also a gain in AGpoiar upon muta­
tion, favouring the smaller alanine residue. For Phe-3, Leu-6 and Leu-10 (Phe-19, 
Leu-22 and Leu-26), the loss of van der Waals interactions upon mutation is not 
balanced by the gain in polar solvation energy and a large, negative A A G SUbtotai
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results.
For Trp-7, there is also a contribution of —4.6 kcal mol-1 from A A £ ,eiectrostatic- 
In the case of p53 binding to Mdm2, a hydrogen bond is formed between the 
nitrogen-bound hydrogen of the tryptophan indole ring and the backbone car­
bonyl oxygen of lie-50 of xMdm2. This hydrogen bond is lost upon mutation 
of tryptophan to alanine, leading to the unfavourable change in the electrostatic 
contribution to the binding energy. This effect was also observed by Massova and 
Kollman3 as the main contribution to A A G subtotai-
Qualitative agreement between this work, that of Massova and Kollman3 and 
the replacement experiments6 is seen for all of the mutations considered here. 
Both Glu-1 and Ser-4 (Glu-17 and Ser-20) were found to give positive A A G subtotai, 
indicating a slight preference for alanine at those positions. This is caused by 
replacing a polar residue with a hydrophobic alanine and, in fact, the best binding 
sequence determined by Bottger et al.6 had a more hydrophobic residue (proline 
and methionine, respectively) at each of these positions. Small, almost negligible, 
positive A A G Subtotai were observed for the mutations of Asp-5 and Lys-8 (Asp-21 
and Lys-24). The mutations of Thr-2 and Leu-9 (Thr-18 and Leu-25) gave rise to 
small, almost negligible negative A A G subtotai> as also observed by Massova and 
Kollman.3
In general, the energy terms can be considered in the context of their physi­
cal origin. Thus, terms of an electrostatic origin, A A -E g ie c tr o s ta t ic  and A A G poiar, 
can be considered as a single contribution. For residues with a large, negative 
A A G SUbtotai the main contribution is due to the unfavourable AA-EVaw not be­
ing balanced by the net electrostatic contribution, A A ^ e ie c tr o s ta t ic  + A A G poiar-
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The effect of A A G non-p o ia r  was found to be negligible for most of the mutations 
considered here, although a small, unfavourable contribution was found for the 
Trp7Ala mutation.
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5.2.1 Binding Energy
Figure 5.5 shows a plot of the root mean square deviation (RMSD) in the 
positions of the a-carbons in the hMdm2-p53 complex, relative to the X-ray 
crystal structure, over the course of the data-gathering phase of the MD simula­
tion. The RMSD values are higher than for the xMdm2-p53 complex and some 
instability is seen, as also observed by Massova and Kollman.3 The net charge 
of +3e may contribute to this as systems with a net charge can exhibit artificial 
behaviour when PME is used, particularly under constant pressure conditions.225 
The average value for Ca RMSD is 1.01 A and the standard deviation is 0.1 A.
The absolute energy values and components for each of the complex, protein 
and peptide systems are given in Table 5.5. The entropy and its components 
are given in Table 5.6 for complex, protein and peptide structures minimised 
both with and without the continuum solvation term applied. The binding free 
energy, AGbinding, and its components are given in Table 5.7. The given entropic 
contribution to the binding free energy, —T A S ,  is for structures minimised with 
the implicit solvent term applied. Where possible, the corresponding values from 
the work of Massova and Kollman3 are given for comparison. Once again, the
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Figure 5.5: Root mean square deviation (RMSD) of the a-carbons in the hMdm2-p53 
complex, relative to the X-ray crystal structure, during the data-gathering phase of the 
molecular dynamics trajectory.
main criterion used in determining changes in binding energy is A G SUbtotai- 
There are differences between the p53-derived peptide used in this work and 
that used by Massova and Kollman.3 These are summarised in Table 4.2. There 
are extra residues in the peptide used in this study and the net charge of the 
complex is +3e compared to +4e for the work of Massova and Kollman.3 Hence, 
it is not surprising to see discrepancies between the two studies for the terms 
of electrostatic origin, -Electrostatic and GPoiar- The standard deviations for these 
terms are also larger for the human Mdm2-p53 system than for the electronically
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Contribution
C o m p le x P r o te in P e p t id e
Mean S.D. M /K Mean S.D. M /K Mean S.D. M /K
■ ^ 'e lec trosta tic -3 0 4 0 .5 61.6 -2 8 7 5 .4 -2 4 6 1 .5 38.6 -2 5 1 7 .7 -2 1 5 .9 23.4 -2 5 5 .1
Ev d W -3 9 3 .1 12.1 -3 8 5 .5 -3 0 7 .5 10.8 -3 1 3 .1 -1 1 .7 3.2 -1 4 .6
^ in t e r n a l 1935.8 28.5 1688.1 1689.4 26.4 1466.6 246.4 10.8 2 2 1 .6
Egaa -1 4 9 7 .9 63.3 -1 5 7 2 .8 -1 0 7 9 .6 44.2 -1 3 6 4 .2 18.7 25.0 -4 8 .2
^■ po lar -1 4 1 2 .2 57.0 -1 7 3 1 .6 -1 3 6 9 .0 36.7 -1 5 7 7 .7 -4 4 1 .8 22.0 -2 8 7 .7
^ n o n  —p o la r 45.7 0.8 35.6 43.6 0.7 32.8 13.7 0.4 10.3
^ s u b t o t a l -2 8 9 4 .4 27.9 -3 2 6 8 .9 -240 5 .1 25.5 -2 9 0 9 .2 -4 0 9 .5 10.2 -3 2 5 .6
Table 5.5: Absolute energy and components /  kcal mol 1 for the hMdm2-p53 complex. 
The columns marked M/K refer to the work of Massova and Kollman.3
neutral xMdm2-p53 system studied in this work.
As seen for the xMdm2-p53 system, -Electrostatic is smaller for the peptide and 
protein systems compared to the work of Massova and Kollman.3 However, the 
corresponding value for the complex is larger in this work than that given by 
Massova and Kollman.3 This is a reflection of the fact that the p53-derived 
peptide has a charge of +2e in this study compared to +e and that there will 
be stronger electrostatic interactions between the protein and peptide. As also 
seen for the xMdm2-p53 system, G poiar is smaller for the complex and protein 
systems compared to the work of Massova and Kollman.3 Gpoiar is larger for the 
peptide in this study, which is again due to the fact that the p53-derived peptide 
used here has a larger net charge.
As for the xMdm2-p53 system, the entropic contribution to the binding free 
energy has been estimated using normal mode analysis of complex, protein and 
peptide systems minimised both with and without the continuum solvation en-
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C o m p le x P r o te in P e p t id e
No Solvent Solvent No Solvent Solvent No Solvent Solvent
TSy ,b 1074.7 1160.0 942.7 1004.6 149.6 164.1
TSrot 15.6 15.6 15.4 15.5 12.7 12.9
T Straus 16.2 16.2 16.1 16.1 14.4 14.4
TS tot 1106.5 1191.8 974.2 1036.1 176.7 191.4
Table 5.6: Entropy and components /  kcal mol-1 for the hMdm2-p53 complex. Struc­
tures have been minimised with and without application of the continuum solvation 
term.
ergy term switched on. Once again, the structure minimised with the solvent 
term applied deviated considerably less from the X-ray crystal structure. For the 
unsolvated structure, —T A S  is 44.4 kcal mol-1 and for the solvated structure, 
—T A S  is 35.7 kcal mol-1. The difference between the entropic contributions for 
the two minimised structures is much more pronounced than for the xMdm2-p53 
system. Once again, this could be due to the charged nature of the complex. 
Minimising the structure without the continuum solvent applied leads to a struc­
ture that deviates from the X-ray crystallographic structure by much more than 
with the solvent term applied, as shown previously in Table 4.8. The xMdm2- 
p53 and hMdm2-p53 systems would be expected to have roughly similar entropic 
contributions to the binding energy and much better agreement is seen here be­
tween the structures minimised with the continuum solvation term than for the 
unsolvated minimised structures.
The value determined here for the binding energy, A ( 7 subtota i, is much larger 
(i.e. more negative) than that determined by Massova and Kollman.3 Once again,
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Contribution Mean S.D. M /K
A -E e le c t ro s ta t i c -3 6 3 .1 26.8 -1 0 2 .6
A E y d W -7 3 .9 4.2 -5 7 .9
A Z Jg a s -4 3 7 .0 26.0 -1 6 0 .4
A G p 0 ia r 398.6 25.4 133.8
A  ^ e l e c t r o s ta t i c  "i" A G  p o la r 35.6 4.52 31.2
A G n o n _  p o la r -1 1 .6 0.4 - 7 .5
A G s u b to ta l -4 9 .9 3.9 -3 4 .1
— T A S  (solvent) 35.7 n /a
A G b jn d in g -1 4 .2 n /a
Table 5.7: Binding free energy and components /  kcal mol 1 for the hMdm2-p53 
complex. The column marked M/K refers to the work of Massova and Kollman.3
this is likely to be due to the differences in the p53-derived peptide used in each 
study. As seen for the xMdm2-p53 system, the difference between AGsubtotai for 
the two studies, 15.8 kcal mol-1, is very similar to the difference between A-EVdw 
for the two studies, 16.1 kcal mol-1. Clearly, the larger 13-residue p53-derived 
peptide used in this study is involved in more van der Waals interactions with 
residues in the protein-peptide binding interface, leading to this stabilising effect.
As seen for the xMdm2-p53 system, A Electrostatic and AGpoiar are both larger 
in magnitude than the values determined by Massova and Kollman,3 although 
the effect is much more pronounced here, possibly due to the presence of the 
extra charged residue in the p53-derived peptide used here. Despite the larger 
standard deviations seen for the absolute electrostatic and polar solvation terms, 
the standard deviations for the corresponding energy changes upon binding are 
comparable for the X. Laevis and human systems. The fluctuations tend to
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Figure 5.6: Contributions /  kcal mol-1 to the binding energy of the hMdm2-p53 
complex due to electrostatic energy, polar solvation energy and the net effect of these 
two terms during the data-gathering phase of the molecular dynamics trajectory.
cancel each other out, as before, and the sum of the two terms remains reasonably 
constant. This is supported by the relatively small standard deviation for the net 
term, AF i^ectrostatic + A(7polar, and is illustrated in Figure 5.6. This relationship 
is further illustrated in Figure 5.7, a plot of e^lectrostatic against G poiar, which 
shows the strong correlation between the two contributions. As for the xMdm2- 
p53 system, the calculated correlation coefficient is —0.99, confirming the linear 
relationship.
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Figure 5.7: Plot of A F eiec tro sta tic  against AG^ia,. for the hMdm2-p53 complex. The 
correlation coefficient is —0.99.
5.2.2 Com putational A lanine Scanning
As before, each of the residues of the p53-derived peptide, apart from Pro-11 
(Pro-27), has been systematically mutated to alanine and the changes in the mean 
binding energy and its components are given in Table 5.8. The changes in the 
binding energy, A A G subtotai, are shown for the mutation of each residue in Figure 
5.8. As before, a negative value for A A G subtotai indicates less favourable binding 
for the alanine mutant, whereas a positive A A G subtotai indicates a preference for 
alanine at that position in the p53-derived peptide.
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M utation
G lu lA la T h r 2 A la P h e 3 A la
C ontribu tion M ean SD M /K M ean SD M /K M ean SD M /K
A  ^ ^ 'e l e c t r o s t a t i c -1 1 2 .5 21.3 -7 6 .3 -1 .1 0.7 - 1 .5 - 1 .5 0.6 - 1 .2
A A £ vdw - 0 .9 0.8 -0 .9 - 0 .7 0.3 - 0 .4 -9 .1 0.9 - 9 .2
A A E g a g -1 1 3 .4 21.2 -7 7 .2 - 1 .8 0.8 - 1 .9 -1 0 .7 0.9 -1 0 .4
A A G p o ia r 113.1 20.5 77.2 0.5 0.7 1.8 7.4 0.7 7.9
A  A G n o n _  p o la r -0 .1 0.1 -0 .1 0.00 0.0 0.0 - 0 .5 0.1 -0 .1
A A G aubtotal -0 .4 1.2 -0 .1 - 1 .3 0.5 -0 .0 - 3 .8 1.0 - 2 .7
S e r 4 A la A s p 5 A la L e u 6 A la
C on tribu tion M ean SD M /K M ean SD M /K M ean SD M /K
A A - E e le c tr o s ta t ic - 0 .3 0.7 - 0 .2 -8 2 .1 4.0 -6 8 .5 -0 .1 0.3 0.3
A A E v<iw - 0 .3 0.2 - 0 .4 -0 .1 0.0 -0 .1 - 4 .2 0.9 -4 .1
A A -E g a s - 0 .6 0.7 - 0 .6 -8 2 .2 4.0 -6 8 .6 - 4 .4 0.9 - 3 .8
A A G p o i a r 1.8 0.6 1.3 81.7 4.1 68.1 1.0 0.4 2.5
A  A G n o n  —p o la r 0.0 0.0 0.0 0.0 0.0 0.0 - 0 .3 0.1 - 0 .2
A A G g Ub to ta l 1.2 0.5 0.7 - 0 .5 0.2 - 0 .5 -3 .6 4 0.9 - 1 .5
T rp 7 A la L y s 8 A la L e u 9 A la
C on tribu tion M ean SD M /K M ean SD M /K M ean SD M /K
A  A E e |e c t ro a ta t ic -5 .2 1.4 - 5 .2 86.7 6.6 76.8 0.0 0.2 -0 .1
A A E v d w -1 2 .0 1.2 -1 1 .0 - 0 .3 0.1 - 0 .2 - 2 .1 0.8 - 0 .6
A A E g a a -1 7 .3 1.5 -1 6 .3 86.4 6.6 76.7 -2 .1 1.0 - 0 .7
A A G p o i a r 14.3 1.4 11.4 -8 5 .1 6.5 -7 6 .4 0.6 0.3 0.7
A A G n o n —p o la r - 0 .9 0.1 -0 .7 -0 .1 0.2 - 0 .0 - 0 .2 0.1 -0 .1
A A G Su b to ta l - 3 .9 1.1 - 5 .5 1.2 0.2 0.3 - 1 .7 0.8 - 0 .0
L e u lO A la G lu l 2 A l a A s n l3 A la
C ontribu tion M ean SD M /K M ean SD M /K M ean SD M /K
A A E e ie c t r o s ta t i c -0 .1 0.2 0.2 -1 5 8 .0 20.3 -1 5 .2 5.9
A A E Vd w -5 .6 0.8 -5 .1 - 0 .4 1.3 - 1 .3 1.1
A A E g a s - 5 .7 0.8 - 4 .9 -1 5 8 .4 19.9 -1 6 .6 5.7
A A G p 0 ]ar 3.9 0.4 3.3 156.6 19.0 13.3 3.6
A A G n o n _  p o la r -0 .2 0.1 -0 .1 - 0 .2 0.1 - 0 .3 0.1
A A G s u b t o t a l - 2 .0 0.8 - 1 .7 -2 .1 1.5 - 3 .6 2.7
Table 5.8: Computational alanine scanning mutagenesis energy changes and compo­
nents /  kcal mol-1 for the hMdm2-p53 complex. Columns marked M/K refer to the 
work of Massova and Kollman.3
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Figure 5.8: A A G s u b to ta i  /  kcal mol-1 for the systematic mutation to alanine of each 
p53-derived peptide residue in the hMdm2-p53 complex. Residues marked in blue indi­
cate favourable mutations and residues marked in red indicate unfavourable mutations.
As discussed previously, amino acid replacement experiments6 on human Mdm2 
bound to a 12-residue p53-derived peptide have identified several residues, Phe-3, 
Leu-6, Trp-7 and Leu-10 (Phe-19, Leu-22, Trp-23 and Leu-26), as being key to 
the interaction. These residues were also identified by Massova and Kollman3 as 
giving large, negative values for A A ( 7 s u b to ta i  upon mutation to alanine. As for 
the X. Laevis system, the present work found large, negative AAGsubtotai values 
for these residues, as shown in Table 5.8 and Figure 5.8.
As also discussed previously, these residues all have bulky sidechains that
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participate in hydrophobic van der Waals interactions with residues in the binding 
site of Mdm2. These interactions are lost upon mutation to alanine resulting in 
a large, negative AA-EVdW, opposing the mutation to alanine. For Phe-3, Leu-6 
and Leu-10 (Phe-19, Leu-22 and Leu-26), the loss of these interactions is not 
balanced by the positive AAGpoiar that favours the smaller alanine residue.
For Trp-7 (Trp-23), there is a significant contribution of —5.2 kcal mol-1 from 
A  A  ^ e l e c t r o s t a t i c  • As seen for the X. Laevis system, this is caused by the mutation 
to alanine resulting in the loss of a hydrogen bond between the nitrogen-bound 
hydrogen of the tryptophan indole ring and the backbone carbonyl oxygen of 
Leu-54 in hMdm2. This effect was also observed by Massova and Kollman3 to be 
the main contribution to the large, negative A A G s u b t o t a i -
Unlike for the xMdm2-p53 system, a signifcant change in binding energy is ob­
served for the mutation of Leu-9 (Leu-25). The main contribution to A A G s u b to ta i  
is AAE'vdw- No such loss of van der Waals interactions is observed in the X. 
Laevis system, probably due to the presence of the two extra residues, Glu-12 
and Asn-13 (Glu-28 and Asn-29), not present in the system studied by Massova 
and Kollman.3 A plot of AA-EVdw against time for the human and X. Laevis 
systems is given in Figure 5.9. For the xMdm2-p53 system, the loss of van der 
Waals interactions is small and fairly constant throughout the simulation. For the 
hMdm2-p53 system, AA-EVdw behaves similarly at the start of the simulation but 
then increases and fluctuates significantly as time increases. The standard devi­
ation is twice as large for the human system. This suggests that the p53-derived 
peptide behaves slightly differently in the binding site of Mdm2 during the course 
of the MD simulation, bringing the leucine sidechain into greater contact with
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Figure 5.9: Comparison of AAEV(\w for the Leu9Ala mutation in each of the xMdm2- 
p53 and hMdm2-p53 systems over the data-gathering phase of the molecular dynamics 
trajectory.
the binding site.
Both of the extra residues, Glu-12 and Asn-13 (Glu-28 and Asn-29), are highly 
polar and give large, negative A A G s u b to ta i  upon mutation to alanine. In both 
cases, the net electrostatic term, A  A  ^ e le c t r o s ta t i c  +  A A G p o ia r ,  is negative and op­
poses the mutation to alanine. These combine with small losses of van der Waals 
interaction energy to give the negative A A G SUb to ta i-  There are two hydrogen 
bonds present between Asn-13 (Asn-29) and Mdm2. One such bond is formed 
between the hydroxyl hydrogen of Thr-26 in hMdm2 and the backbone carbonyl
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oxygen atom of Asn-13 (Asn-29) in the p53-derived peptide. The second hy­
drogen bond is formed betwen one of the amide hydrogen atoms in the Asn-13 
sidechain and the backbone carbonyl oxygen atom of Glu-25 in hMdm2 and is 
lost upon mutation to alanine. This is partly responsible for the large, negative 
AAEeiectrostatic observed.
The residues Glu-1, Thr-2 and Asp-5 (Glu-17, Thr-18 and Asp-21) all have 
small, negative values for A A G su btotai although the value determined here for the 
mutation of Thr-2 (Thr-18) is larger than that given by Massova and Kollman.3 
The replacement experiments6 allowed 13 possible amino acids at this position 
with a larger, charged arginine residue selected in the best binding sequence.
The mutation of both Ser-4 and Lys-8 (Ser-20 and Lys-24) to alanine leads to a 
small, positive A A ( 7 subtotai, as also predicted by Massova and Kollman.3 Neither 
residue has a large loss in van der Waals interaction energy upon mutation as they 
do not participate strongly in such interactions with residues in the binding site 
of Mdm2. The net positive change in the electrostatic terms, A A .E 'e iec tr o sta tic  +  
AAGpoiar, leads to the slight preference for alanine at these positions. In the 
replacement experiments,6 the polar serine residue is replaced by a hydrophobic 
methionine and the positively charged lysine residue is replaced by a negatively 
charged glutamic acid. Therefore, it is not surprising to see a slight preference 
for alanine at these positions.
Chapter 6
IQN17
As discussed in Chapter 1, IQN17 is a synthetic peptide designed to represent 
a potential drug target in the gp41-mediated HIV cellular fusion process. The 
hydrophobic pocket region is of particular interest as it is essentially conserved 
in the vast majority of strains of HIV-1.21 The interactions between IQN17 
and a D-peptide, DIO-pl, which has been shown to inhibit the cellular fusion 
process have been investigated in this work and the results are given below. 
The interactions between IQN17 and two C-peptides, Cl21inkmid (Cl21m) and 
C12unlinkmid (C12unlm), have also been investigated.
6.1 IQ N 17-D 10-p l Interaction
6.1.1 Binding Energy
Figure 6.1 shows a plot of the root mean square deviation (RMSD) in the 
positions of the a-carbons in the IQN17-D10-pl complex, relative to the X-ray
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crystal structure,21 over the course of the data-gathering phase of the MD tra­
jectory. Clearly, the deviations from the crystal structure are significantly larger 
than for either of the Mdm2-p53 systems. The net charge of +4e may con­
tribute to this as systems with a net charge can exhibit artificial behaviour when 
PME is used, particularly under constant pressure conditions.225 Furthermore, 
the attempts to limit the system size by using the smallest possible solvent box 
may also have contributed to the observed instability. It is likely that more sta­
ble simulations would have been achieved using counterions to make the system 
electronically neutral and using a larger solvent box to ensure that the entire 
system was surrounded by a more significant amount of solvent at all times. The 
shape of the protein IQN17, a long a-helix, made it difficult to completely solvate 
the whole molecule without using a very large solvent box. Therefore, although 
the complex was smaller than the Mdm2-p53 complexes discussed previously in 
terms of the number of atoms, more solvent molecules would have been needed 
to achieve the same depth of solvent around the complex. The average value for 
CQ RMSD is 1.64 A and the standard deviation is 0.4 A.
The absolute energy values and components for each of the complex, protein 
and peptide systems are given in Table 6.1. The entropy and its components 
are given in Table 6.2 for complex, protein and peptide structures minimised 
with and without the continuum solvation energy term applied. The binding free 
energy, AGbinding, and its components are given in Table 6.3. The given entropic 
contribution to the binding free energy, —T A S ,  is for structures minimised with 
the implicit solvent term applied.
The complex formed between IQN17 and DIO-pl is considerably smaller than
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Figure 6.1: Root mean square deviation (RMSD) of the a-carbons in the IQN17-D10- 
pl complex, relative to the X-ray crystal structure, during the data-gathering phase of 
the molecular dynamics trajectory.
the Mdm2-p53 systems considered in Chapter 5, as can be seen from a comparison 
of Tables 4.2 and 4.5. Unsurprisingly, the absolute energy values for the complex 
and protein systems are smaller than those determined for the Mdm2-p53 systems 
but the 16-residue D-peptide has larger absolute energy values than either the 
11-residue or 13-residue p53-derived peptide. The standard deviations in the 
absolute energy terms are comparable for the different systems.
The entropic contribution to the binding free energy, —T A S ,  is estimated to 
be 21.0 kcal mol-1 for the structures minimised without the continuum solva-
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Contribution
C o m p le x P r o te in P e p t id e
Mean S.D. Mean S.D. Mean S.D.
^ e l e c t r o s ta t i c -1 7 5 0 .0 48.9 -1 1 7 6 .5 48.0 -4 7 3 .5 12.0
E v  d W -1 7 9 .5 7.9 -1 1 4 .2 6.9 -3 4 .5 3.9
^ 'i n t e r n a l 1192.3 26.1 908.4 22.8 283.8 12.7
•^sgas -7 3 7 .1 51.2 -3 8 2 .3 48.8 -2 2 4 .2 16.0
^ p o l a r -1 6 4 3 .8 46.9 -1 3 8 2 .5 47.6 -3 7 9 .1 10.3
n o n  — p o la r 45.5 0.7 37.9 0.6 13.4 0.4
^ s u b t o t a l -2335 .41 24.8 -1726 .92 21.3 -5 8 9 .8 8 12.0
Table 6.1: Absolute energy and components /  kcal mol 1 for the IQN17-D10-pl 
complex.
C o m p le x P r o te in P e p t id e
No Solvent Solvent No Solvent Solvent No Solvent Solvent
T S V ib 701.9 762.9 539.4 580.1 156.9 172.6
T ’S r o t 15.6 15.6 15.3 15.2 12.7 12.9
T S t m n a 15.8 15.8 15.5 15.5 14.5 14.5
T  S t o t 733.3 794.3 570.2 610.8 184.1 199.9
Table 6.2: Entropy and components /  kcal mol-1 for the IQN17-D10-pl complex. 
Structures have been minimised with and without application of the continuum solva­
tion term.
tion term and 16.5 kcal mol-1 for the solvated minimised structures at 300 K. 
The experimentally determined value for the formation of the complex between 
IQN17 and D10-pl-2K is 9.7 kcal mol-1 at 298 K.236 The peptide D10-pl-2K 
has the same sequence as DIO-pl but with two lysine residues added to increase 
solubility.21 The agreement with experiment for the structures minimised with
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Contribution Mean S D
A £ / e |e c t r o s ta t lc -1 0 0 .0 24.6
AEV dW -3 0 .7 2.9
A -E g a s -1 3 0 .6 23.7
A G p 0 la r 117.8 23.1
A f i 'e le c t r o s ta t i c  "b A G p 0 lar 17.9 3.1
A G n o n  _  p o la r - 5 .8 3.1
A G s u b to ta l -1 8 .6 3.2
—TAS (solvent) 16.5 n /a
A G b i n d in g -2.1 n /a
Table 6.3: Binding energy and components /  kcal mol 1 for the IQN17-D10-pl com­
plex.
the implicit solvent present is reasonable considering the approximations inherent 
in the method.
As seen for the Mdm2-p53 systems, the contributions to the binding energy 
arising from terms of electrostatic origin, A £ leiectrostatic and A G poiar fluctuate con­
siderably throughout the course of the MD trajectory, as suggested by their large 
standard deviations. However, as before, these fluctuations tend to cancel one 
another out and the net effect of the two terms remains reasonably constant. This 
is reflected by the smaller standard deviation for the net term and is also illus­
trated in Figure 6.2. This relationship is further illustrated in Figure 6.3, a plot 
of e^lectrostatic against Gpoian which shows the strong correlation between the two 
contributions. The calculated correlation coefficient is —0.99, again confirming 
the linear relationship.
The experimentally determined enthalpy change, A H 0, for the formation of
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Figure 6.2: Contributions to the binding energy of the IQN17-D10-pl complex due to 
electrostatic energy, polar solvation energy and the net effect of these two terms during 
the data-gathering phase of the molecular dynamics trajectory.
the IQN17-D10-pl-2K complex is -16.6 kcal mol-1 at 298 K.236 Although this 
quantity does not have exactly the same physical meaning as A G 'subtotai, the sig­
nificance is similar and good agreement is seen between this work and experiment. 
The calculated binding free energy, AGbindmg, is -2.1 kcal mol-1, which is in fair 
agreement with the experimental value236 of —6.9 kcal mol-1, particularly given 
the differences between the molecular system considered here and that studied 
experimentally.
As described in Section 4.2.2, not all of the hydrophobic pocket region of IQN17
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Figure 6.3: Plot of A£’eiectrostatic against AGpdar f°r the IQNl7-D10-pl complex. The 
correlation coefficient is —0.99.
is represented in the system used in this study, as some of the pocket residues 
come from the adjacent IQN17 helix. The effect of these missing residues on 
the binding energy must also be considered. The charged Lys-574 residue is 
the type of residue normally found on the surfaces of proteins but forms a salt 
bridge with Asp-632 in the C34 helix of the HIV-1 gp41 complex. No such salt 
bridge is formed in the IQN17-D10-pl system. The presence of an intermolecular 
hydrogen bond between Gln-577 of the adjacent helix and Trp-12 of DIO-pl in the 
full trimeric system would lead to an increase in the magnitude of the binding 
energy compared to the system studied here. This will be discussed in more 
detail in the following section. The hydrophobic Leu-566 and Val-570 are typical
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residues found in protein-protein interfaces and would increase the favourable 
intermolecular hydrophobic interactions, again increasing the magnitude of the 
binding energy. Therefore, it is reasonable to expect that the addition of the 
missing residues would lead to an increase in binding energy, in agreement with 
experimental observations.
6.1.2 C om putational A lanine Scanning
Eight of the 16 residues of DIO-pl were mutated to alanine, as before, and the 
effect on the binding energy and its components are given in Table 6.4. These 
results are represented graphically in Figure 6.4. For obvious reasons, the five 
alanine residues were not mutated. The glycine residue was not mutated as the 
mutagenesis technique used here requires that, unlike glycine, the sidechain of 
the amino acid residue has both (3- and 7-carbons. This represents one of the 
drawbacks of this method, as mutations to larger sidechains would be desirable 
for examining potential drugs. In this case, however, very little information 
would be gained from a mutation of the glycine residue to alanine. The two 
cysteine residues of DIO-pl were also not mutated due to their essential function 
in determining the circular nature of this class of D-peptide inhibitor.21
The residues Trp-10 and Leu-13 showed large, negative A A G subtotai upon mu­
tation to alanine, indicating a highly unfavourable change in binding. The two 
glutamine residues, Glu-4 and Glu-9, showed small, negative A A G subtotai- The 
residues Arg-6, His-7, Arg-8 and Trp-12 showed small, positive A A G su btotai, in­
dicating a slight preference for the alanine residue at these positions.
Alanine scanning experiments on the interhelical interactions in the HIV-1
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M u ta tio n
G lu 4 A la A r g 6 A la H is7 A la A r g 8 A la
Contribution Mean SD Mean SD Mean SD Mean SD
A A E e le c t ro s ts t ic -8 7 .0 10.3 57.2 3.7 - 3 .3 1.9 49.8 2.2
A A E v d W - 0 .3 0.1 0.0 0.0 - 0 .8 0.7 0.0 0.0
A  A Eg a s -8 7 .3 10.3 57.2 0.0 -4 .1 2.4 49.8 2.2
A A G p0iar 86.2 10.3 -5 6 .4 3.6 4.5 2.5 -4 9 .1 2.1
A  A G n o n _  p o la r 0.0 0.0 0.0 0.0 -0 .1 0.1 -0 .0 1 0.0
A A G s u b t o t a l - 1 .1 0.2 0.7 0.1 0.3 0.3 0.64 0.0
G lu 9 A la T r p lO A la T r p l2 A la L e u l3 A la
Contribution Mean SD Mean SD Mean SD Mean SD
A  A E e ie c t r o s t s t i c -9 4 .7 18.6 - 0 .2 2.1
o1 0.5 0.1 0.1
A A E v d w 0.0 1.3 - 8 .0 1.0 - 0 .9 0.3 - 4 .7 0.7
A  A  E g  as -9 4 .7 18.0 - 8 .2 2.3
o1 0.6 - 4 .7 0.7
A  A G p 0 ia r 93.8 16.8 4.5 2.0 1.4 0.5 1.2 0.2
A A G n0n_p0]ar -0 .2 0.1 - 0 .9 0.1 0.0 0.1 - 0 .4 0.1
A A G s u b to ta l - 1 .0 2.0 - 4 .6 1.0 0.3 0.3 - 3 .9 0.7
Table 6.4: Computational alanine scanning mutagenesis energy changes and compo­
nents /  kcal mol-1 for the IQNl7-D10-pl system.
gp41 core by Wang et al. 2 3 7  have identified several key residues in the C34 helix 
that bind to the hydrophobic pocket region of N36. The residues Trp-628, Trp-631 
and Ile-635 of the C-terminal helix all triggered a significant reduction in binding 
upon mutation to alanine. This consequently resulted in a reduction of the ability 
of gp41 to mediate cellular fusion. These key residues in the C34 helix of gp41 
correspond in position to the residues Trp-10, Trp-12 and Leu-13, respectively, of 
DIO-pl in the complex with IQN17. However, due to the opposite chirality of the 
mirror image D-peptide, the orientations of the sidechains are different for Trp-12
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Figure 6.4: AAGsubtotai /  kcal mol-1 for the systematic mutation to alanine of each 
D-peptide residue in the IQN17-D10-pl complex. Residues marked in blue indicate 
favourable mutations and residues marked in red indicate unfavourable mutations.
and Leu-13. The residue Trp-10 closely overlaps with the position of Trp-628 in 
the gp41 complex.
For Trp-10 and Leu-13, the calculated values of AAGsubtotai are in agreement 
with the experimental observations.237 These residues have bulky sidechains that 
participate in hydrophobic van der Waals interactions with the IQN 17 pocket 
residues. These interactions are lost upon mutation to alanine and a large, nega­
tive AA£Vdw results that is not compensated for by the gain in A A G poiar. The 
mutation of Trp-12 to alanine would also be expected to result in a similarly
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large, negative A A G subtotai- However, in this case, both A A E V d w  and A A G p o ia r  
are small. This is due to the fact that the pocket residues that make closest con­
tact with Trp-12 are among those not included in this simulation, as described 
previously in Chapter 4. Furthermore, Eckert et a l21 reported a hydrogen bond 
between the nitrogen-bound hydrogen atom of the tryptophan indole ring and 
the sidechain oxygen atom of Gln-577 of the adjacent IQN17 helix. This is one 
of the missing residues and the presence of such a hydrogen bond would lead to 
a highly unfavourable A A £’eiectrostatic when the bond is lost upon mutation to 
alanine.
The residue Glu-9 was conserved in all of the series of D-peptide inhibitors 
identified by the experiments of Eckert et al.21 The mutation to alanine re­
sults in a large, negative A A E eiectrostatic that is slightly larger than the opposing 
A A G p o ia r ,  leading to the observed small, negative A A G Subtotai- The same effect 
is also observed for the mutation of Glu-4 to alanine. The opposite effect is seen 
for mutation of the positively charged arginine residues, Arg-6 and Arg-8, as 
the favourable A A E eiectrostatic slightly larger than the unfavourable A A G Poiar- 
The positive AAGsubtotai for the mutation of His-7 to alanine is negligible and is 
comparable to the standard deviation.
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6.2 IQN 17—C12 Interactions
6.2.1 Binding Energy
Figure 6.5 shows a plot of the RMSD in the positions of the c*-carbons, relative 
to the X-ray crystal structure, for the data-gathering phase of the MD simulation 
of the IQN17-C121m system. Figure 6.6 shows the same for the IQN17-Cl2unlm 
system. The Ca RMSD values are initially higher for the IQN17-C12unlm system 
than for the IQN17-C121m system. This is likely to be related to the fact that 
the X-ray structure used for comparison is the IQN17-Cl21m structure. Since the 
structure is less constrained, it is likely that the initial minimisation before the 
equilibration phase would lead to a greater deviation from the crystal structure 
than that seen for the cross-linked peptide. However, the standard deviations 
do not increase as the simulation takes its course and the simulations have sim­
ilar Ca RMSD profiles to that seen for the IQN17-D10-pl system. Once again, 
the net charge of +2e is the likely cause of these fluctuations. The net charge 
of +2e may contribute to this instability as systems with a net charge can ex­
hibit artificial behaviour when PME is used, particularly under constant pressure 
conditions.225 Furthermore, the attempts to limit the system size by using the 
smallest possible solvent box may also have contributed to the observed insta­
bility. As for the IQN17-D10-pl system discussed previously, t t  is likely that 
more stable simulations would have been achieved using counterions to make the 
system electronically neutral and using a larger solvent box to ensure that the 
entire system was surrounded by a significant amount of solvent at all times. 
The average values for Ca RMSD are 1.94 A and 2.29 A for the linked and un-
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Figure 6.5: Root mean square deviation (RMSD) of the cv-carbons in the IQN17- 
C121m complex, relative to the X-ray crystal structure, during the data-gathering phase 
of the molecular dynamics trajectory.
linked systems, respectively. The respective standard deviations are 0.5 A and 
0.4 A. These values are higher than for the relatively stable Mdm2-p53 systems 
discussed previously.
The absolute values for the energy and its components for each of the complex, 
protein and peptide systems are given in Table 6.5 for both IQN17-Cl21m and 
IQN17-C12unlm. The entropy and its components are given in Table 6.6. As 
before, the structures have been minimised both with and without the application 
of the continuum solvation energy term. The binding free energy, A Grinding, and
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Figure 6.6: Root mean square deviation (RMSD) of the a-carbons in the IQN17- 
C12unlm complex, relative to the X-ray crystal structure, during the data-gathering 
phase of the molecular dynamics trajectory.
its components are given in Table 6.7. The given entropic contributions are given 
for structures minimised with the implicit solvent term applied.
The entropic contributions to the binding free energy, —T A S ,  are estimated 
to be 26.8 and 29.1 kcal mol-1 for the linked and unlinked peptides, respectively, 
when the solvation term is not applied to the minimisation. For the solvated 
minimised structures, the values of —T A S  are estimated to be 25.6 and 22.4 
kcal mol-1, respectively. As before, the structure minimised with the implicit 
solvation energy term was closer to the observed X-ray crystal structure than the
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IQN 17-C  121m
Contribution
C o m p le x P r o te in P e p t id e
Mean S.D. Mean S.D. Mean S.D.
^ e l e c t r o s ta t i c -1815 .1 61.5 -1 1 6 6 .0 50.0 -4 6 6 .4 20.2
E v  d W -1 7 6 .3 6.5 -1 0 8 .2 6.0 -3 0 .6 3.0
•^ 'in te rn a l 1161.2 22.8 907.7 21.7 253.5 10.8
£<gas -8 3 0 .3 62.6 -3 6 6 .6 53.7 -2 4 3 .4 21.9
^ p o l a r -166 5 .1 52.1 -1 3 9 5 .5 41.1 -4 6 9 .4 18.8
^ n o n - p o l a r 44.8 0.7 39.1 0.6 12.2 0.4
^ - 's u b to ta l -2 4 5 0 .5 24.4 -1 7 2 2 .9 23.5 -7 0 0 .6 10.4
IQ N17—C12unlm
Contribution
C o m p le x P r o te in P e p t id e
Mean S.D. Mean S.D. Mean S.D.
^ e l e c t r o s ta t i c -181 6 .1 51.1 -1 1 4 5 .8 42.7 -4 7 4 .6 17.4
E v  d W -1 7 9 .8 6.8 -1 0 7 .9 6.1 -3 1 .9 3.0
■ ^in tern al 1168.9 23.6 913.5 19.8 255.5 12.0
E g a s -8 2 7 .1 52.4 -3 4 0 .2 42.2 -2 5 1 .1 19.0
^ p o l a r -1 6 5 5 .8 45.6 -1 4 1 2 .6 38.1 -4 5 6 .9 16.4
^ n o n - p o l a r 45.3 0.8 39.2 0.6 13.0 0.5
^ s u b t o t a l -2 4 3 7 .6 25.0 -1 7 1 3 .6 20.4 -6 9 4 .9 12.2
Table 6.5: Absolute energy and components /  kcal mol 1 for the IQN17-C121m and 
IQN17~C12unlm complexes.
structure obtained by minimisation without the solvation term. Unsurprisingly, 
the IQN17-Cl21m complex and peptide structures have Ca RMSD values that 
are smaller than for IQN17-Cl2unlm, given that the reference structure used 
is that of IQN17-Cl21m. These Ca RMSD values have already been given in 
Chapter 4, in Table 4.8.
The experimentally determined values for —T A S  are 6.2 and approximately 7
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IQ N 1 7 —C 121m
C o m p le x P r o te in P e p t id e
No Solvent Solvent No Solvent Solvent No Solvent Solvent
T S vib 694.0 745.9 539.4 580.1 154.7 164.7
TSVot 15.6 15.6 15.3 15.2 12.8 12.8
TSx.ra.na 15.8 15.8 15.5 15.5 1*4.5 14.5
T S t o t 725.3 777.2 570.2 610.8 182.0 192.0
I Q N 1 7 —C 1 2 u n lm
C o m p le x P r o te in P e p t id e
No Solvent Solvent No Solvent Solvent No Solvent Solvent
T S v ib 693.3 756.0 539.4 580.1 156.2 171.6
T S ro t 15.5 15.6 15.3 15.2 12.8 12.8
T  S t r a u s 15.8 15.8 15.5 15.5 14.5 14.5
T S t o t 724.6 787.4 570.2 610.8 183.5 198.9
Table 6.6: Entropy and components /  kcal mol-1 for the IQN17-C121m and IQN17- 
C12unlm complexes. Structures have been minimised with and without application of 
the continuum solvation term.
kcal mol-1 for the linked and unlinked peptides, respectively.40 The calculations 
presented here overestimate the loss of entropy upon binding of the protein and 
peptide. Furthermore, the loss of entropy is expected to be less for the linked 
peptide, Cl21m, as observed experimentally, yet this is not seen here for the 
solvent-minimised structures, although it is the case for the unsolvated minimised 
structures. Clearly, the method used here for estimating the entropy cannot 
adequately describe the conformational entropy of the C-peptide. This is perhaps 
not surprising given the assumptions inherent in the method. However, as stated 
previously, the loss of entropy upon binding is the most difficult contribution to
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IQ N 1 7 —C 121m IQ N 1 7 —C 1 2 u n lm
Contribution Mean S.D. Mean S.D.
^ ^ e l e c t r o s t a t i c -1 8 2 .8 20.2 -1 9 5 .7 14.2
AEV dw -3 7 .5 3.0 -4 0 .1 3.4
-2 2 0 .3 20.8 -2 3 5 .8 15.4
A ^ p o l a r 199.8 20.1 213.6 14.0
^ ■ ^ 'e le c tr o s ta t ic  "t" A ^ - 'p o la r 17.0 2.0 17.9 2.1
A G n 0 n  — p o la r - 6 .5 0.3 - 6 .9 0.4
^ ^ s u b t o t a l -2 7 .1 2.7 -2 9 .1 3.1
—T A S  (solvent) 25.7 n /a 22.4 n /a
A C ? b in d in g - 1 .4 n /a - 6 .7 n /a
Table 6.7: Binding energy and components /  kcal mol 1 for the IQN17-C121m and 
IQN17-C12unlm complexes.
quantify and it is not critical to do so for the computational alanine scanning 
studies. This relies on the assumption that the entropy change upon binding is 
essentially the same for two very similar mutants such as those studied here.
As seen for the systems studied previously, the contributions to the binding 
free energy arising from terms of electrostatic origin, A  E l e c t r o s t a t i c  and A G p o i a n  
fluctuate considerably throughout the simulations for both linked and unlinked 
C-peptides. As before, the fluctuations tend to cancel one another out and the 
net effect, A Electrostatic +  AGpoian has a much smaller standard deviation than 
either of the individual energy terms. This is illustrated graphically in Figures 
6.7 and 6.9. This relationship is further illustrated in Figures 6.8 and 6.10, plots 
of Electrostatic against Gpoiar, which show the strong correlation between the two 
contributions. The calculated correlation coefficients were both —0.99, once again
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Figure 6.7: Contributions to the binding energy of the IQN17-C121m complex due to 
electrostatic energy, polar solvation energy and the net effect of these two terms during 
the data-gathering phase of the molecular dynamics trajectory.
confirming the linear relationship.
The experimentally determined enthalpy change, A H , for the formation of 
both IQN17-C141m and IQN17-C14unlm complexes is approximately —15 kcal 
mol-1 at 310 K.40 The peptides used in this work would be expected to have sim­
ilar values for A G subtotai but the predicted values of —27 and -29  kcal mol-1 are 
somewhat larger than experiment. The predicted binding free energies, AG binding? 
of —1.4 and —6.7 kcal mol-1 for the linked and unlinked peptide, respectively, 
compare with experimental values of -8 .4  and approximately - 7  kcal mol-1.40
6.2 IQ N17-C12 Interactions 154
300
- 250
200
150
100
-250 -200 -100-150
AE*toctro*«ic I kcal mol'1
Figure 6.8: Plot of A F e ie c t r o s t a t i c  against AGp0iar for the IQN17-C121m complex. The 
correlation coefficient is —0.99.
The good agreement observed for the binding free energy of the IQN17-Cl2unlm 
complex arises from the overestimation of both the entropy and enthalpy of bind­
ing by similar amounts.
As for the IQN17-D10-pl complex, the effect of the missing residues of the 
IQN17 hydrophobic pocket must be considered. Unlike for the D-peptide system, 
there are no hydrogen bonds between the missing residues and the C-peptides. 
This led to an underestimation of A G s u b to ta i  for the D-peptide and partly accounts 
for the apparent overestimation of A G s u b to ta i  seen here. As before, there would 
be a greater number of stabilising van der Waals interactions in the pocket region 
if all of the residues were included in the calculation. Furthermore, only 12 of
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Figure 6.9: Contributions to the binding energy of the IQN17-C12unlm complex due 
to electrostatic energy, polar solvation energy and the net effect of these two terms 
during the data-gathering phase of the molecular dynamics trajectory.
the residues of the C14 sequence are included in the Cl2-peptides studied here.
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Figure 6.10: Plot of e^lectrostatic against Gpoiar for the IQN17-C12unlm complex. The 
correlation coefficient is —0.99.
6.2.2 Com putational A lanine Scanning
Each residue of both Cl21m and Cl2unlm has been mutated to alanine, with 
the exception of the two bridging glutamine residues, Gln-2 and Gln-9 (Gln-629 
and Gln-646). The numbers in brackets correspond to the equivalent residue in 
gp41 taken from the HXB2 strain of HIV-1. The resulting effects on the binding 
energy and its components are given in Tables 6.8 and 6.9 for the IQN17-Cl21m 
and IQN17-Cl2unlm complexes, respectively. The change in binding energy, 
A AGsubtotai, is shown for each residue in Figures 6.11 and 6.12, respectively, 
where a large, negative AAGsubtotai indicates a highly unfavourable mutation, as
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M u ta tio n
T r p lA la G lu 3 A la T r p 4 A la A s p 5 A la A r g 6 A la
Contribution Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D.
A A f f e l e c t r o s t a t i c 1.0 1.7 -6 0 .8 3.2 - 4 .2 1.3 -6 5 .7 2.7 60.4 2.5
AAEydw - 5 .9 1.0 -0 .1 0.0 - 6 .2 1.1 -0 .1 0.0 0.0 0.0
A A Eggs - 4 .9 2.1 -6 0 .8 3.2 -1 0 .4 1.2 -6 5 .8 2.7 60.4 2.5
A A G p o l a r 2.3 1.7 60.4 3.2 5.5 0.9 65.4 2.7 -5 9 .7 2.5
A A G n o n _  p o la r - 1 .0 0.2 0.0 0.0 - 0 .5 0.1 0.0 0.0 0.00 0.0
A  A G s u b to ta l - 3 .7 1.0 - 0 .5 0.1 - 5 .5 0.9 - 0 .3 0.1 0.7 0.0
G lu 7 A la I le 8 A la A sn lO A la T y r l l A l a T h r l2 A la
Contribution Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D.
A A E e le c t r o s t a t i c -9 4 .0 11.2 - 0 .3 0.1 1.3 3.3 - 2 .9 2.5 0.6 0.4
A A E v d W - 0 .8 0.4 - 3 .2 0.6 - 0 .3 0.1 - 6 .5 1.0 - 0 .5 0.3
A  A  E g o # -9 4 .8 11.5 - 3 .5 0.6 - 0 .3 0.1 - 9 .5 2.4 0.1 0.5
A  A G p o la r 94.1 11.4 0.8 0.1 -1 .1 3.4 4.7 2.1 0.4 0.7
A A G n o n —p o la r 0.0 0.0 -0 .2 0.1 0.01 0.0 - 0 .1 0.1 0.0 0.0
A  A G Su b to ta l - 0 .7 0.3 - 2 .8 0.6 -0 .1 0.2 - 5 .4 1.0 0.4 0.4
Table 6.8: Computational alanine scanning mutagenesis energy changes and compo­
nents /  kcal mol-1 for the IQN17-Cl21m system.
before.
The amino acid residues comprising the C l 2-peptides used in this work corre­
spond to the stretch of residues from Trp-628 to Thr-639 of gp41 taken from the 
HXB2 strain of HIV-1.40 Alanine scanning experiments on this stretch of residues 
identified four residues that contribute to the stability of the six-helical bundle, 
which is the fusion-active conformation of gp41.237 Mutating the residues Trp- 
628, Trp-631 and Ile-635 to alanine led to a reduction in gp41-mediated fusion. 
The residue Tyr-638 also played a role in stabilising the six-helical bundle.237
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Mutated Residue
Figure 6.11: AAGsubtotai /  kcal mol- 1  for the systematic mutation to alanine of each 
C-peptide residue in the IQN17-C121m complex. Residues marked in blue indicate 
favourable mutations and residues marked in red indicate unfavourable mutations.
These residues correspond to Trp-1, Trp-4, Ile-8 and Tyr-11 of C12 as described 
in this work. Both numbering schemes are given for ease of comparison. X-ray 
crystallography studies have confirmed that these residues adopt positions similar 
to those seen for the corresponding residues of the C34 helix in the gp41 core.40
As would be expected, both IQN17-C121m and IQN17-C12unlm complexes 
exhibit similar changes in binding energy upon systematic mutation of the pep­
tide residues to alanine. All four residues identified by the alanine scanning ex­
periments of Wang et al.237 showed large, negative AAGgubtotai here, indicating
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M u t a t i o n
T r p l A l a G lu 3 A la T rp 4 A la A s p 5 A la A rg 6 A la
C ontribu tion M ean S.D. M ean S.D. M ean S.D. M ean S.D. M ean S.D.
A  ^  ^ e l e c t r o s ta t ic - 1 .9 1.7 -6 3 .0 4.1 - 3 .9 1.4 -6 6 .6 2.3 59.7 2.3
A A E v d W - 6 .6 1.9 -0 .1 0.0 - 6 .5 1.1 -0 .1 0.0 0.0 0.0
A AEgas - 8 .5 2.8 -6 3 .1 4.1 -1 0 .4 1.2 -6 6 .6 2.3 59.6 2.2
A A G p0]ar 5.0 1.8 62.7 4.0 5.1 0.9 66.3 2.3 -5 9 .0 2.3
A A G n o n _ p 0 ]a r - 1 .2 0.2 0.0 0.0 - 0 .6 0.1 0.0 0.0 0.0 0.0
A A G s u b to ta l - 4 .7 1.9 - 0 .4 0.1 -5 .9 1.0 - 0 .3 0.1 0.7 0.0
G lu 7 A la I le 8 A la A s n lO A la T y r l l A l a T h r l 2 A l a
C o n tribu tion M ean S.D. M ean S.D. M ean S.D. M ean S.D. M ean S.D.
A  A  £ e [ect ro s t  a t  ic -9 2 .3 8.3 - 0 .3 0.1 -4 .6 1.6 - 2 .6 2.0 0.8 0.4
A A E v d w - 0 .7 0.2 -3 .1 0.6 - 0 .2 0.1 - 6 .6 0.8 - 0 .6 0.2
A A E g a s -9 3 .1 8.4 - 3 .4 0.6 -4 .9 1.7 - 9 .2 2.1 0.2 0.5
A A G p o | a r 92.4 8.4 0.8 0.1 5.2 1.7 4.8 1.7 0.1 0.8
A A G n o n _ p o |a r 0.0 0.0 - 0 .2 0.0 0.0 0.0 - 0 .7 0.1 0.0 0.0
A A G s u b to ta ] - 0 .7 0.2 - 2 .7 0.6 0.3 0.2 -5 .1 0.8 0.3 0.4
Table 6.9: Computational alanine scanning mutagenesis energy changes and compo­
nents /  kcal mol-1 for the IQN17-C12unlm system.
highly unfavourable substitutions. The remaining residues showed small changes 
in binding energy upon mutation, with Arg-6 (Arg-633) showing the greatest 
preference for alanine at any of the peptide positions.
In the cases of the mutation of Ala-1 (Ala-628), Ile-8 (Ile-635) and Tyr-11 
(Tyr-638) to alanine the main contribution to the observed negative AA(2subtotai 
arises from the loss of stabilising van der Waals interactions between the bulky 
sidechains and the binding site following the mutation. This results in a large, 
negative AAE'vdw that is not balanced by the net effect of the terms of electro-
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Mutated Residue
Figure 6.1 2 :  A A G 'subtota] /  kcal mol-1 for the systematic mutation to alanine of each 
C-peptide residue in the IQN17-C12unlm complex. Residues marked in blue indicate 
favourable mutations and residues marked in red indicate unfavourable mutations.
static origin, A A Electrostatic+ AAGPoiar- In the case of the TyrllA la (Tyr638Ala) 
mutation there is an electrostatic contribution of approximately —3 kcal mol-1 
opposing the mutation. This is not strong enough to suggest a lost hydrogen 
bond upon mutation and no such bond is observed in the X-ray crystal structure 
of IQN17-Cl21m.
For the IYp-4 (Trp-631) mutation to alanine there is a very large, negative 
AAGgubtotai- In part, this can be accounted for in a similar fashion to the pre­
vious mutations. However, there is also a contribution of —4.2 kcal mol-1 from
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AAE'eiectrostatic due to the loss of an intermolecular hydrogen bond, between the 
backbone carbonyl oxygen of Leu-568 of IQN17 and the nitrogen-bound hydrogen 
of the indole ring of Trp-4 (Trp-631), upon mutation to alanine. It is interesting 
to note that no intermolecular hydrogen bond was observed for Trp-12 in the 
IQN17-D10-pl complex, which occupies a similar position to Trp-4 (Trp-631) 
but with the indole ring in a different orientation, although such a bond would 
be present in the IQN17-D10-pl complex if the entire hydrophobic pocket were 
modelled. The different binding modes of DIO-pl and Cl21m to the hydrophobic 
pocket of IQN17 are illustrated by Figures 4.4 and 4.5 and are largely related to 
the opposite chirality of the two peptides.
For the negatively charged residues, Glu-3 (Glu-630), Asp-5 (Asp-632) and 
Glu-7 (Glu-634), the large, negative AAF'eiectrostatic opposing the mutation is 
balanced by the large, positive A A G p o ia r  and the net effect is small. Conversely, 
the positively charged residue Arg-6 (Arg-633) has a positive A A £ ’eiec tro s ta t ic  and 
a negative AAGPoiar upon mutation to alanine but the net effect is still small. 
These sidechains are also relatively small or are situated far from the hydrophobic 
binding site and the resulting loss of van der Waals interactions is small for each 
mutation.
Part IV  
Conclusions and Further Work
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Chapter 7
Conclusions
The computational alanine scanning technique first implemented by Massova 
and Kollman3,174 has been confirmed as a valuable tool for the investigation of 
protein-peptide binding interfaces. This technique has the advantage that impor­
tant information on the key factors in the binding of two polypeptide molecules 
can be obtained without having to calculate the entropic contributions to the 
binding free energy. Treating the entropy using classical ideal gas thermody­
namics has been shown to give entropic contributions of the correct order of 
magnitude.
The technique has been applied to the previously studied interaction between 
the oncoprotein Mdm2 and the transcription regulator and tumour suppressor 
peptide p53, both for Xenopus Laevis and human systems. Qualitative agreement 
has been observed between this work and previous theoretical and experimental 
investigations. The key residues in the binding interface have been identified 
in agreement with amino acid replacement studies and quantitative information
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regarding the contributions to the binding energy of each of these residues has 
been obtained. In most cases, van der Waals interactions in the binding interface 
have been found to be of greater importance than any net electrostatic effects, 
although an intermolecular hydrogen bond has been identified between a trypto­
phan residue and the largely hydrophobic binding site.
The technique has also been extended to the interactions of several potential 
inhibitors of the gp41-mediated viral fusion process in HIV-1 infection. Compu­
tational alanine scanning mutagenesis has been used to identify the key residues 
in the binding of a D-peptide and two similar C-peptides to IQN17, a model of a 
transiently exposed potential drug target in the fusion process. Good agreement 
with experimental alanine scanning studies on the HIV gp41 core was seen for 
most of the key residues in the D-peptide and the only discrepancy has been 
attributed to the incompleteness of the protein structure used, necessitated by 
the computational expense of modelling the complete trimeric system. Good 
agreement with the alanine scanning experiments has been observed for all of the 
key residues of the C-peptide inhibitors. Once again, van der Waals interactions 
have been found to play a key role in the binding interface and an intermolecular 
hydrogen bond that contributes to the stability of the complex has also been 
identified.
This technique allows the contributions of the key residues to the binding free 
energy to be decomposed according to their physical origin, an advantage over 
the analogous experimental methods. The agreement with experiments for all of 
the systems studied is encouraging, suggesting that the systematic mutation of 
residues, as implemented here, is a useful tool for predicting the relative activity
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of peptides as drug candidates. The main computational cost of such studies 
is invested in determining the molecular dynamics trajectories and with the ad­
vances in algorithms, increasing parallelisation and computational power, this 
method could provide a fast and effective way of screening proteins and peptides 
for such inhibitory activity.
Chapter 8
Future Work
The computational alanine scanning technique utilised in this work is com­
pletely general and could readily be applied to any non-covalent protein-peptide 
interaction for which a suitable molecular mechanical force field was available, 
with the only limits being those of computational resources. For example, en­
veloped viruses with similar cellular fusion mechanisms to HIV-1, such as in­
fluenza, could be studied using the method in order to identify the key binding 
residues. It would be relatively simple to alter the MDANAL code developed 
during this work to allow mutation of residues in the binding site of the target 
protein, giving further insights into the factors affecting protein-peptide binding.
As computational resources and the use of efficient parallelisation techniques 
increase, larger systems will be accessible using similar approaches. For example, 
this would allow simulation of the entire trimeric core of HIV-1 gp41, allowing 
the entire hydrophobic pocket region to be modelled. It would be of interest to 
study a range of D-peptide inhibitors in order to study the link between binding
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free energy and strength of inhibitory activity. It would also be of interest to 
study larger C-peptides such as C34 in complex with the N36 trimeric core in 
order to investigate the interactions along the hydrophobic groove on the surface 
of the trimer, as well as the more highly-conserved pocket region.
The most approximate part of this work is the treatment of entropy using 
classical ideal gas thermodynamics in the evaluation of the binding free energy. 
It would be desirable to improve the treatment, possibly by explicitly considering 
the conformational entropy of the backbone and sidechain groups.
Appendix A  
Amino Acids
A .l Identification Codes
Name Sidechain
Alanine Ala A - c h 3
Valine Val V -C H (C H 3) 2
Leucine Leu L -C H 2CH(CH3)2
Isoleucine lie I -C H (C H 3)CH 2CH3
Table A.l: The hydrophobic aliphatic amino acid sidechains and identification codes.
Name Sidechain Notes
Phenylalanine Phe F - c h 2c 6h 5
Tryptophan Trp W - c h 2i n d IND =  indole ring
Tyrosine Tyr Y - c h 2c 6h 4o h phenyl ring is 1,4 substituted
Table A.2: The hydrophobic aromatic amino acid sidechains and identification codes.
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Name Sidechain Notes
Aspartic Acid Asp D - c h 2c o o -
Glutamic Acid Glu E - c h 2c h 2c o o -
Lysine Lys K - c h 2c h 2c h 2c h 2n h +
Arginine Arg R -C H 2CH2CH2NHC(NH2) =  NH+
Histidine His H -C H 2C  =  CHN =  CHNH ring; uncharged at physiological pH
Table A.3: The charged amino acid sidechains and identification codes.
Name Sidechain Notes
Serine Ser S -C H 2OH
Threonine Thr T -C H (O H )C H 3
Cysteine Cys C - c h 2s h largely non-polar; can form disulphide bridges
Methionine Met M - c h 2c h 2s c h 3 largely non-polar
Asparagine Asn N - c h 2c o n h 2
Glutamine Gin Q - c h 2c h 2c o n h 2
Table A.4: The neutral polar amino acid sidechains and identification codes.
Name Sidechain Notes
Glycine Gly G -H achiral
Proline Pro P -C H 2CH2C H 2 C  bound to backbone N to form ring
Table A.5: The conformationally important amino acid sidechains and identification 
codes.
Appendix B
Entropy Codes
B .l  ROTRANSENT
C
C
c ###################################################################
C # #  # #
c ## program rotran sen t — r o ta t io n a l and tr a n s la t io n a l  entropy ##
c ## ##
c ###################################################################
c
c
c "rotransent" c a lc u la te s  th e  t o t a l  mass and p r in c ip a l moments of
c in e r t ia  of th e m olecule and subsequ en tly  c a lc u la te s  th e  r o ta t io n a l
c and tr a n s la t io n a l entropy of th e system
c
c NB: The code fo r  c a lc u la t in g  th e  moments o f in e r t ia  were taken
c from th e TINKER package
c
c L itera tu re  R eference :
c
c D. A. McQuarrie, " S t a t is t ic a l  Mechanics", Harper and Row,
c New York, 1976
program rotran sen t
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im p lic it  none 
include ’s i z e s . i ’ 
includ e ’atom s. i ’ 
include ’atm typ. i ’ 
includ e ’ io u n i t . i ’ 
includ e ’m a th .i’ 
in c lu d e ’u n i t s . i ’ 
in te g e r  i , j , k
rea l* 8  t s t r a n s , t s r o t ,z t r a n s ,z r o t
rea l* 8  k b ,p l,n a
rea l* 8  tem p,pres
rea l* 8  i a , i b , i c
rea l* 8  w e ig h ,to ta l , dot
rea l* 8  xcm,ycm,zcm
rea l* 8  x x ,x y ,x z ,y y ,y z ,z z
rea l* 8  xterm ,yterm ,zterm
rea l* 8  moment( 3 ) ,v e c (3 ,3 )
rea l* 8  w orkl( 3 ) ,work2(3)
rea l* 8  te n s o r ( 3 ,3 ) , a ( 3 ,3)
c
c
c s e t  up th e s tru ctu re  and mechanics c a lc u la t io n  
c
c a l l  i n i t i a l  
c a l l  getxyz  
c a l l  mechanic
c
c c a lc u la te  th e p o s it io n  of th e cen tre  o f mass
c
to t a l  = O.OdO 
xcm = O.OdO 
ycm = O.OdO 
zcm * O.OdO 
do i  = 1, n
weigh = m ass(i) 
t o t a l  = t o t a l  + weigh  
xcm = xcm + x (i)* w e ig h  
ycm = ycm + y (i)* w e ig h  
zcm = zcm + z ( i)* w e ig h  
end do
xcm = xcm /  t o t a l  
ycm = ycm /  t o t a l  
zcm = zcm /  t o t a l
c
c p r in t out the t o t a l  mass
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w rite  ( io u t ,5 )  t o t a l  
5 format ( / , ’ T ota l Mass (amu) : ’ ,1 1 6 .2 )
c
c compute and then  d ia g o n a lize  the in e r t ia l  ten so r
c
xx * O.OdO 
xy = O.OdO 
xz = O.OdO 
yy = O.OdO 
yz = O.OdO 
zz = O.OdO 
do i  * 1, n
weigh = m ass(i)  
xterm = x ( i )  -  xcm 
yterm = y ( i )  -  ycm 
zterm = z ( i )  -  zcm 
xx = xx + xterm*xterm*weigh 
xy = xy + xterm*yterm*weigh  
xz = xz + xterm*zterm*weigh  
yy = yy + yterm*yterm*weigh 
yz = yz + yterm*zterm*weigh 
zz  = zz  + zterm*zterm*weigh  
end do
te n s o r (1 ,1 )  = yy + zz  
te n s o r (2 ,1 )  = -xy  
te n s o r (3 ,1 ) = -x z  
te n so r (1 ,2 ) = -xy  
te n so r (2 ,2 ) = xx + zz  
te n so r (3 ,2 ) = -y z  
te n so r (1 ,3 ) = -x z  
te n so r (2 ,3 ) = -y z  
te n so r (3 ,3 ) = xx + yy
c a l l  jacob i ( 3 ,3 , tensor,m om ent,vec,w orkl,w ork2)
c
c s e le c t  the d ir e c t io n  fo r  each p r in c ip a l moment a x is  
c
do i  = 1, 2 
do j = 1, n
xterm = v e c ( l , i )  *  (x (j)-x cm )  
yterm = v e c ( 2 , i )  * (y (j)-y cm )  
zterm = v e c ( 3 , i )  * (z (j)-zcm )  
dot = xterm + yterm + zterm  
i f  (dot . I t .  O.OdO) then  
do k = 1, 3
B .l  RO TRANSENT 173
v e c ( k , i )  * - v e c ( k , i )  
end do 
end i f
i f  (dot .n e . O.OdO) goto  10 
end do 
10 continue  
end do
c
c moment axes must g iv e  a righ t-handed  coord in ate system  
c
xterm * v e c ( l , l )  * (v e c (2 ,2 )* v e c (3 ,3 ) -v e c (2 ,3 )* v e c (3 ,2 ) )  
yterm = v e c ( 2 , l )  * ( v e c ( l ,3 ) * v e c ( 3 ,2 ) - v e c ( l ,2 ) * v e c ( 3 ,3 ) )  
zterm * v e c ( 3 , l )  * ( v e c ( l ,2 ) * v e c ( 2 ,3 ) - v e c ( l ,3 ) * v e c ( 2 ,2 ) )  
dot = xterm + yterm + zterm  
i f  (dot . I t .  O.OdO) then  
do j = 1, 3
v e c ( j ,3 )  = - v e c ( j ,3 )  
end do 
end i f
c
c p r in t th e moments o f in e r t ia  and th e p r in c ip a l axes
c
w rite  ( io u t ,2 0 )
20 format ( / ,  ’ Moments o f I n e r t ia  and P r in c ip a l Axes
& //,9 x ,'M o m en t’ ,1 5 x ,'X - , Y- and Z-Components o f A x is ')
w r ite  ( io u t ,3 0 )  ( m o m e n t ( i ) , v e c ( l , i ) , v e c ( 2 , i ) , v e c ( 3 , i ) , i= l ,3 )  
30 format ( 3 ( / , f 16 .4 ,9 x ,3 f 1 2 .6 ))
c
c s e t  some SI con stan ts
c
kb = 1.38066d-23  
p i = 6 . 62608d-34 
na -  6.02214d+23 
temp * 3 0 0 .OdO 
pres = 1 .Od+5
c
c zero th e p a r t it io n  fu n ctio n  and entropy va lu es
c
zro t = 0 . OdO
ztran s = 0 .OdO
ts r o t  = O.OdO
ts tr a n s  = O.OdO
c
c c a lc u la te  the tr a n s la t io n a l  p a r t it io n  fu n ctio n
c
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t o t a l  = t o t a l  * 1.66054d-27
ztran s = s q r t ( (2*p i*tota l*k b*tem p /p l**2)**3) * (kb*tem p/pres) 
w rite  ( io u t ,4 0 )  ztran s  
40 format ( / , ’ T ra n sla tio n a l P a r t it io n  Function = ’ ,e l6 .6 )
c
c c a lc u la te  th e  r o ta t io n a l  p a r t i t io n  fu n c tio n , assuming th a t sigm a,
c the symmetry number, i s  always u n ity  fo r  b iom olecu les
c
ia  * moment(1) * 1 .66054d-47  
ib  = moment(2) * 1.66054d-47  
i c  = moment(3) * 1.66054d-47
zro t = s q r t (p i* ia * ib * ic )  * s q r t ( (8*(p i**2)*k b *tem p /(p l**2))**3) 
zro t * 0 .5 * zro t  
w rite  ( io u t ,5 0 )  zro t  
50 format ( / , ’ R o ta tio n a l P a r t it io n  Function = J,e l6 .6 )
c
c c a lc u la te  th e t r a n s la t io n a l  entropy (TS) from th e  t r a n s la t io n a l
c p a r t it io n  fu n ctio n
c
ts tr a n s  = (2 .5  + log(ztrans))*na*kb*tem p  
t s tr a n s  * ts tr a n s  /  4184
c
c c a lc u la te  th e r o ta t io n a l entropy (TS) from th e r o ta t io n a l
c p a r t i t io n  fu n ctio n
c
t s r o t  * (1 .5  + log(zrot))*na*kb*tem p  
t s r o t  * t s r o t  /  4184
c
c p r in t out th e va lu es fo r  tr a n s la t io n a l  and r o ta t io n a l  entropy (TS)
c
w rite  ( io u t ,6 0 )  ts tr a n s  
60 format ( / , ’ T ra n sla tio n a l Entropy (k ca l/m ol) = ’ , f l 6 .6 )  
w rite  ( io u t ,7 0 )  t s r o t  
70 format ( / , ’ R ota tion a l Entropy (k ca l/m ol) = ’ , f l 6 .6 )
c
c end th e program
c
end
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B.2 VIBENT
c
c
C ###############################################################
c ## ##
c ## program v ib en t — normal modes and v ib r a tio n a l entropy ##
c ## ##
c ###############################################################
c
c
c "vibent" performs a v ib r a t io n a l normal mode a n a ly s is  as in  the
c program "vib rate" , fo llo w ed  by a c a lc u la t io n  of th e  v ib r a tio n a l
c entropy of th e  system
c
c NB: th e code fo r  th e normal mode a n a ly s is  was taken from th e
c TINKER package
program v ibent  
im p lic it  none 
in c lu d e ’s i z e s . i ’ 
in c lu d e ’atm typ. i ’ 
in c lu d e ’a to m s .i’ 
in c lu d e ’f i l e s . i ’ 
inc lud e ’hes c u t . i ’ 
includ e ’ i o u n i t . i ’ 
include ’m a th .i’ 
include ’u n i t s . i ’
in teg er  i , j ,k ,m , i x y z , ih e s s , l e x t , f r e e u n i t  
in teg er  nfreq.ndum m y,nvib ,iv ib ,nview
in teg er  h in it(3 ,m axatm ),hstop(3,m axatm ),h index(m axhess)
rea l*8  p i,k b ,n a ,te m p ,lig h t
rea l*8  t s v i b l , t s v ib 2 , t s v ib 3 , t s v i b , t s v ib t o t
rea l*8  h(m axhess),hdiag(3,m axatm )
rea l*8  xref(m axatm ), yref(m axatm ), zref(maxatm)
rea l*8  m ass2(m axatm ).factor,vnorm ,ratio
rea l*8  m atrix((m axvib+l)*m axvib/2)
rea l* 8  eigen(m axvib ),vects(m axvib ,m axvib )
rea l*8  a(m axvib+l),b(m axvib+ l),p (m axvib+l),w (m axvib+l)
rea l*8  ta(maxvib+l) ,tb(maxvib+l) ,ty(meLXvib+1)
chsiracter*l eigu n its(m axv ib )
character*7 ext
ch2u:acter*6 0  c o o r d f i le , s tr in g
lo g ic a l  e x is t ,q u e r y
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c
c
c s e t  up th e s tru c tu re  and mechanics c a lc u la t io n
c
c a l l  i n i t i a l  
c a l l  getxyz  
c a l l  mechanic
c
c i n i t i a l i z e  variou s th in g s  needed fo r  v ib r a tio n s
c
n freq  = 3 * n 
ndummy = 0
i f  (n freq .g t.m axv ib  .o r . n freq**2.gt.m axhess) then  
w rite  ( io u t ,1 0 )
10 format ( / , ’ VIBRATE — Too many Atoms in  th e M olecu le’ ) 
c a l l  f a t a l  
end i f  
do i  = 1, n
i f  (a to m ic (i)  .eq . 0) then  
ndummy = ndummy + 1 
m ass(i) = O.OOldO 
end i f
m ass2(i) = sq r t(m a ss (i))  
end do
nvib = n freq  -  3*ndummy
c
c c a lc u la te  th e H essian m atrix o f second d e r iv a t iv e s
c
hesscu t = O.OdO
c a l l  h essia n  (h .h in it ,h s to p ,h in d e x ,h d ia g )
c
c s to re  upper tr ia n g le  of th e  H essian  in  "matrix"
c
ih e ss  = 0 
do i  = 1, n 
do j = 1, 3
ih e s s  = ih e s s  + 1 
m a tr ix (ih e ss )  = h d ia g ( j , i )  
do k = h i n i t ( j , i ) ,  h s t o p ( j , i )  
ih e s s  = ih e s s  + 1 
m a tr ix (ih e ss )  = h(k) 
end do 
end do 
end do
c
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c perform d ia g o n a liza tio n  to  g e t H essian e ig en v a lu es  
c
c a l l  d iagq (n fr e q ,m a x v ib ,n fr eq ,m a tr ix ,e ig e n .v ec ts ,
& a ,b ,p ,w ,t a ,t b , t y )
w rite  ( io u t ,2 0 )
20 format ( / , ’ E igenvalues of th e H essian Matrix : ’ , / )  
w rite  ( io u t ,3 0 )  ( i , e i g e n ( i ) , i= l ,n v ib )
30 format ( 5 ( i 5 , f 9 . 3 , l x ) )  
w rite  ( io u t ,4 0 )
40 format ()
c
c s to r e  upper tr ia n g le  of th e m ass-w eighted H essian m atrix  
c
ih e s s  = 0 
do i  = 1, n 
do j = 1, 3
ih e s s  = ih e s s  + 1
m a tr ix (ih e ss )  = h d ia g ( j , i )  /  m ass(i) 
do k = h i n i t ( j , i ) ,  h s t o p ( j , i )  
m = (h index(k)+2) /  3 
ih e s s  = ih e ss  + 1
m a tr ix (ih ess) = h(k) /  (m ass2(i)*m ass2(m )) 
end do 
end do 
end do
c
c d ia g o n a lize  to  get v ib r a tio n a l fr eq u en c ie s  and normal modes 
c
c a l l  d iagq (n fr eq ,m a x v ib ,n fr eq ,m a tr ix ,e ig e n ,v ec ts ,
& a ,b ,p ,w ,t a ,t b , t y )
fa c to r  = sq rt(co n v ert) /  (2 .0 d 0 * p i* lig h tsp d )  
do i  = 1, nvib
i f  ( e ig e n ( i)  . I t .  0) then  
e ig u n i t s ( i )  = ’I* 
e ls e
e ig u n i t s ( i )  = > } 
end i f
e ig e n ( i)  = fa c to r  * s q r t (a b s ( e ig e n ( i ) ) )  
end do
w rite  ( io u t ,5 0 )
50 format ( / , ’ V ib ration a l F requencies (cm-1) : ’ , / )  
w rite  ( io u t ,6 0 )  ( i , e i g e n ( i ) , e i g r m i t s ( i ) , i = l ,n v i b )
60 format ( 5 ( i 5 , f 9 . 3 , a l ) )
c
c TEST FOR PROPANE FREQUENCIES
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c
c e ig e n ( l) = O.OdO
c e ig en (2 ) = O.OdO
c e ig en (3 ) « O.OdO
c eig en (4 ) = O.OdO
c e ig en (5 ) = O.OdO
c e ig en (6 ) = O.OdO
c e ig en (7 ) = 3 7 5 .OdO
c eig en (8 ) = 7 4 8 .OdO
c eig en (9 ) = 8 6 8 .OdO
c eigen (lO ) = 9 2 2 .OdO
c e ig e n ( l l ) = 9 4 0 .OdO
c eig en (1 2 ) = 1053.OdO
c eig en (1 3 ) = 1155.OdO
c eig en (1 4 ) = 1179 .OdO
c eig en (1 5 ) = 1278.OdO
c eig en (1 6 ) - 1338.OdO
c eig en (1 7 ) = 1370.OdO
c eig en (1 8 ) = 1375.OdO
c eigen (19) = 1450.OdO
c eig en (2 0 ) * 1450.OdO
c eig en (2 1 ) = 1460.OdO
c eig en (2 2 ) - 1468.OdO
c eig en (2 3 ) = 1470.OdO
c eig en (2 4 ) = 2914 .OdO
c eigen (25) = 2 942 .OdO
c eigen (26) = 2 960 .OdO
c eigen (27) - 2 9 6 6 .OdO
c eigen (28) = 2 968 .OdO
c eigen (29) = 2 968 .OdO
c eigen (30) = 2 970 .OdO
c eigen (31) = 2 9 8 0 .OdO
c eigen (32) = 2 0 2 .OdO
c eigen (33) = 2 8 3 .OdO
c
c s e t  some SI con stan ts  
c
c kb = boltzmann
c p i = planck
c na = avogadro
c temp = 300.0
kb = 1 .38066d-23
p i = 6.62608d-34
na = 6.02214d+23
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l ig h t  = 2.99792d+8 
temp = 3 . 00d+2
c
c c a lc u la te  th e v ib r a tio n a l entropy (TS) in  kcal/m ol
c
c note th a t th e fa c to r  of 100 in  t s v ib l  converts e ig e n ( j )  from
c cnT-1 to  dT -1
c
t s v ib to t  ■ O.OdO 
t s v ib  = O.OdO 
do j = 7 , nvib
t s v ib l  = 1 0 0 * p l* lig h t* e ig en (j)/(k b * tem p )  
ts v ib 2  = e x p (t s v ib l)  -  1 
tsv ib 3  = 1 -  e x p ( - t s v ib l)
ts v ib  = ( ( t s v ib l / t s v ib 2 )  -  (log(tsv ib 3)))*na*k b *tem p  
t s v ib  = t s v ib  /  4184 
t s v ib to t  = t s v ib to t  + t s v ib  
w rite  ( io u t ,7 0 )  j , e i g e n ( j ) , t s v ib  
70 format ( / , i 4 , f 1 6 . 6 , f 16.6)
end do
w rite  ( io u t ,* )  
w rite  ( i o u t ,80) t s v ib to t  
80 format ( / , ’ T otal V ib ra tio n a l Entropy (k cal/m ol) : * ^ 1 6 . 6 )
c
c perform any f in a l  ta sk s  b efo re  program e x it  
c
c a l l  f in a l  
end
Appendix C 
List of Abbreviations
ABP arabinose binding protein
AIDS acquired immunodeficiency syndrome
AspRS aspartyl tRNA synthetase
ATP adenosine triphosphate
BPTI bovine pancreatic trypsin inhibitor
CQ, etc. a-carbon, /3-carbon etc.
CK2 casein kinase 2
CMC/MD chemical Monte Carlo/molecular dynamics
cyto cytoplasmic
D dextrorotatory
DNA deoxyribonucleic acid
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181
eq equilibrium
ER estrogen receptor
(US) FDA (US) Food and Drug Administration
FEP free energy perturbation
FFT fast fourier transform
fp fusion peptide
GB(SA) generalised Born (surface area)
GTP guanine triphosphate
HCV hepatitis C virus
HDAC histone deacetylase
HEI hydroxyethylene inhibitor
HGH human growth hormone
HIV-1 human immunodefiency virus type 1
HRSV human respiratory syncytial virus
IC50 inhibitory concentration to reduce activity by 50%
IDV Indinavir
IR infrared
LIE linear interaction energy
182
M molar, mol dm-3
MBP mannose binding protein
MC Monte Carlo
MD molecular dynamics
MM molecular mechanics, molecular mechanical
MMLV Moloney murine leukaemia virus
NMR nuclear magnetic resonance
OWFEG one-window free energy grid
PB(SA) Poisson-Boltzmann (surface area)
PBC periodic boundary conditions
PDB protein data bank
PES potential energy surface
PME particle mesh Ewald
PI path integral, predictive index
(HIV-)PR (HIV) protease
PROFEC pictorial representation of free energy components
QM quantum mechanics, quantum mechanical
183
RCSB Research Collaboratory for Structural Bioinformatics
RMS(D) root mean square (deviation)
RNA ribonucleic acid
(HIV-)RT (HIV) reverse transcriptase
(SA)SA (solvent accessible) surface area
SQV Saquinavir
T thymine
TI thermodynamic integration
tm transmembrane
TS thymidylate synthetase
TyrRS tyrosyl tRNA synthetase
U deoxyuracil
UV ultraviolet
vdW van der Waals
WHAM weighted histogram analysis method
WNDR weighted non-polar desolvation ratio
X. Laevis Xenopus Laevis, African clawed frog
Appendix D  
List of Symbols
A Helmholtz free energy
a acceleration
a electrostatic coefficient in LIE
a effective Born radius
a constant governing width of Gaussian in PME
P hydrophobic coefficient in LIE
A change in
St time step
E energy
erfc(a;) complementary error function of x
€ permittivity, dielectric constant
184
185
F force
/ g b generalised Born function
G Gibbs free energy
G constraint force
g gradient vector
H enthalpy
Hamiltonian
H Hessian matrix
h Planck constant
h h/27T
I moment of inertia
K kinetic energy
K equilibrium constant
Kr, Ke stretching, bending force constants
K Debye-Hiickel parameter
k Boltzmann constant
L length of a cubic simulation box
A coupling parameter in FEP/TI
A multiplier used in geometric constraints
A multiplier used for velocity scaling in constant temperature MD
186
M number of simulation steps
m mass
m reciprocal space vector in PME
V multiplier used for length scaling in constant pressure MD
N number of particles
n coordinate space vector in PME
V normal mode frequency
V nabla, differential operator
P pressure
P momentum
$ electrostatic potential
0 torsional angle
total wavefunction
4> electronic wavefunction
$ torsional angle
Q mass-wieghted displacement coordinates
Q charge
187
R molar gas constant
R position vector of atomic nuclei
r position vector of atoms or electrons, dependent on context
r bond length
P charge density
P probability density
S entropy
S(r) truncation function
S ( m ) structure factor in PME
a atomic solvation parameter
a symmetry number
T temperature
t time
Tp coupling parameter in constant pressure MD
rT coupling parameter in constant temperature MD
V potential energy
V volume
Vn torsional force constant
V velocity
X position in one dimension, unit cell vector
y unit cell vector
z total partition function
z component of total partition function
z unit cell vector
0 ensemble average
[] concentration
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